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ABSTRACT 
Raquel Burger-Calderon: The BK virus and HIV-associated Salivary Gland Disease: 
Corroborating the Link 
(Under the direction of J. Webster-Cyriaque, DDS/PhD) 
 
BK polyomavirus (BKPyV) is the most common viral pathogen among allograft patients 
and is known to adversely affect immune suppressed individuals since the discovery of the virus 
in 1971. Increasing evidence links BKPyV to the human oral compartment and to HIV-
associated salivary gland disease (HIVSGD). To date, few studies have analyzed oral-derived 
BKPyV. The studies described in this manuscript, aimed to characterize BKPyV isolated from 
throatwash (TW) samples of HIVSGD patients. The BKPyV non-coding control region (NCCR) 
is the main determinant of viral replication and rearranges readily in vivo and in vitro. Further, 
NCCR rearrangements have been associated with functional differences. This study analyzed 36 
clinical samples, of which 29 were BKPyV positive. One hundred percent of TW samples from 
HIVSGD patients and urine samples from transplant patients yielded BKPyV NCCR sequences. 
Importantly, 94% of the BKPyV HIVSGD NCCRs carried the rearranged OPQPQQS block 
arrangement, suggesting a distinctive architecture among this sample set. Of interest, in the 22% 
of BKPyV positive oral samples from individuals without HIVSGD, the BKPyV substrains were 
distinct from OPQPQQS. The studies also assessed the replication potential and NCCR promoter 
strength of HIVSGD-derived clinical isolates in vitro. The majority of HIVSGD-derived BKPyV 
isolates underwent productive infection and had active promoters in an oral cell culture system. 
iv  
Quantitation of infectious virus suggested that HIVSGD BKPyV had preferential tropism for 
salivary gland cells over kidney cells. Evidence of HIVSGD-derived BKPyV oral tropism and 
adept viral replication in human salivary gland cells corroborated the potential link between 
HIVSGD pathogenesis and BKPyV. 
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CHAPTER 1: INTRODUCTION 
Opportunistic Infections - An HIV/AIDS Public Health Challenge  
HIV/AIDS has become one of the world’s main public health challenges since its first 
reported case in 1981 (1). According to the UNAIDS Report 2013 an estimate of 35.3 (32.2–
38.8) million people were living with HIV globally in 2012. The report further quotes that an 
estimate of 1.6 million people died of AIDS in 2012 alone. AIDS-related deaths have declined in 
the past years (2), thanks to increased interdisciplinary humanitarian efforts. Opportunistic 
infections and cancer however are still the primary cause of death among HIV positive 
individuals. Despite AIDS-associated opportunistic pathogens being prevalent among AIDS 
patients, they remain poorly understood. Cytomegalovirus (CMV), herpes simplex virus (HSV) 
and paramyxovirus infections are reported frequently among AIDS patients, while the BK 
polyomavirus (BKPyV) has been emerging as a new opportunistic pathogen within that group, 
possibly carrying harmful implications (3).  
AIDS-related Salivary Lymphadenopathy 
AIDS-related salivary lymphadenopathy was first described in 1983, shortly after the 
initial AIDS case (4). The salivary gland lymph nodes often become the primary site of 
lymphadenopathy (disease affecting the lymph nodes) associated with HIV infection and 
opportunistic pathogens (5). Salivary glands are intimately associated with the lymph nodes in 
the oral cavity (5). Lymph nodes are embedded in the parotid gland and 
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found adjacent to the submaxillary gland (5). Salivary gland structures, such as acini and ducts 
are frequently present in oral cervical lymph nodes (5). One can therefore refer to this 
intertwined system as the salivary gland lymph nodes. Visually lymphadenopathy is commonly 
identified by enlarged lymph nodes and can lead to dry mouth or xerostomia. Histological 
analysis reveals frequent salivary gland duct obstruction and inflammation of saliva producing 
tissue (lymphadenitis).  
Persistent lymphadenopathies were reported in homosexual men in New York and 
considered a possible early symptom of AIDS in 1987 (4). Only two years later, 
lymphadenopathies in the neck and head region were found to precede opportunistic infections 
and neoplasia in a similar patient cohort (6). Similar symptoms, salivary gland enlargement due 
lymphocytic infiltration, xerostomia and predisposition to lymphoma formation, are also known 
as Sjogren's Syndrome-like illness (4), AIDS-associated Persistent Generalized 
Lymphadenopathy (6) and Diffuse Infiltrative Lymphocytosis Syndrome (DILS) (7). The 
resemblance to Sjogren's syndrome was determined to be superficial from the start, since neither 
the clinical nor the pathologic criteria were satisfied. None of the AIDS-related salivary 
lymphadenopathy cases displayed autoimmune phenomena or tested positively for the presence 
of autoantibodies (8). Schiodt et al. were the first to coin the term HIV-associated salivary gland 
disease (HIVSGD) in 1989 (9), a disease encompassing clinical indicators described for all the 
AIDS-related salivary lymphadenopathies mentioned above. The group defined HIVSGD as 
disease encompassing symptoms linked to AIDS-related salivary lymphadenopathy such as, 
enlargement of the major salivary glands and/or xerostomia (dry mouth) and localized 
lymphocytic infiltration.   
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HIV-associated Salivary Gland Disease  
Today, HIV-associated salivary gland disease (HIVSGD) is among the most common 
salivary gland presentations in HIV + individuals (10). Incidence is as high as 48% among HIV-
infected patients in developing countries (11). HIVSGD is more commonly diagnosed among the 
pediatric population, considered AIDS-defining among children, but affects adults as well. 
Importantly, HIVSGD is considered a pre-malignant lesion and its diagnosis is associated with 
increased lymphoma incidence (5, 8, 12, 13).  
HIVSGD presents itself superficially as unilateral or bilateral salivary gland enlargement 
due parotitis. Histologically, the oral disease is characterized by hyperplastic, intraparotid lymph 
nodes and/ or lymphatic CD8 + infiltrates (10). Parotid gland enlargements are greater and more 
disfiguring in children than in adults (13). HIVSGD also affects the minor salivary glands, with 
labial salivary glands demonstrating features of sialadenitis (13). Patients diagnosed with 
HIVSGD commonly have reduced salivary flow rates of the parotid, submandibular, and 
sublingual glands (10). Saliva composition may be affected as well as saliva contains increased 
sodium, chloride, lysozyme, peroxidase, lactoferrin, and immunoglobulin A levels (10).  
Salivary gland disease impacts oral health. Maintenance of good oral health among 
HIV/AIDS patients is of outmost importance to protect the patients from secondary and 
opportunistic infections. Bacterial, viral and fungal infections that begin in the mouth may 
escalate to systemic infections and may in turn harm vital organs if left untreated (14). Moreover, 
the decline of oral health has shown to impact the patients quality of life by limiting career 
opportunities and social contact as result of facial appearance and odor (14). Poor oral health 
may also lead to complications with food intake, leading to general malnutrition and 
malabsorption of their medication (14). Poor oral health further predisposes the development of 
 4 
oral diseases such as dry mouth (xerostomia). Xerostomia leads to dental decay, periodontal 
disease and increases the patients likelihood to be affected by pathogenic opportunistic infections 
(14). Xerostomia indicates a dysfunction of the salivary glands and is commonly associated with 
AIDS-related salivary lymphadenopathy. 
HIVSGD Etiology 
Interestingly, there has been an increase in HIVSGD prevalence of among HIV + patients 
in the highly active antiretroviral therapy (HAART) era at the UNC hospitals (Fig. 1.1. Adapted 
from J. Webster-Cyriaque) (15, 16). Taking a combination of three or more anti-retroviral drugs 
is termed HAART and its application dramatically increase the life expectancy of HIV+ patients. 
HIVSGD has risen from 1.8% to 5% among HIV-infected adults from 1995 to 1999, even 
though the overall presence of oral lesions has decreased (15). Patton’s data implies that AIDS 
patients might be experiencing a higher risk of developing HIVSGD under HAART treatment. 
The group also determined that there has been a change in the occurrences of oral opportunistic 
infections in general from 1995/96, where the use of HIV protease inhibitor was less common, to 
1999, a period of greater protease inhibitor use, indicating the importance of understanding 
opportunistic pathogens (15). HAART hinders AIDS progression by reducing HIV RNA levels 
and increasing CD4+ cell counts, but it has been shown that opportunistic infectious agents can 
take advantage of the newly reconstituted immune system.  
Twenty-five to 35% of patients undergoing HAART develop a pathological inflammatory 
response called immune reconstitution inflammatory syndrome (IRIS) to previously treated or 
asymptomatic opportunistic infections. The majority of IRIS cases are reported within the first 
two months of HAART, even though IRIS development can take up to two years (17). Detecting 
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an increase in prevalence of HIVSGD among HIV + patients in the HAART era may therefore 
hint towards persistence of an opportunistic infectious agent as the cause of HIVSGD. 
Further evidence suggesting an infectious agent as HIVSGD etiological agent is data 
suggesting antigen-driven HIVSGD pathogenesis. A prospective study analyzing epidemiology, 
clinical presentation, and extra-glandular manifestations of HIVSGD suggests that this 
lymphadenopathy is an antigen (viral)- driven response (18). Further, an antigen-driven MHC-
determined host immune response recorded by Itescu et al. based on the infiltrating lymphoid 
cells characterizing HIVSGD, points to an antigen-driven response (19). Finding differential 
rates of HIVSGD in children (20-47%) and adults (3-7.8%) (12) may also elude to a viral 
infection as it indicates primary viral infection in children versus residual immunity in adults 
(13). Trials are ongoing in our group to address these questions. 
The reviewed literature suggests that the etiological agent of HIVSGD is an opportunistic 
infectious agent. Additionally there is published evidence suggesting the etiological agent of 
HIVSGD to be a virus.  
 
 
 
 
 
 
 
Figure 1.1. HIVSGD (red) has increased during the HAART era compared to all other 
HIV-associated oral lesions (blue) at the UNC Hospitals from 1995 to 2009.  
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Viral Salivary Gland Infection and Pathology  
AIDS-related salivary lymphadenopathy has previously been postulated to be caused by a 
viral agent (20). Furthermore, viral co-infections have been implicated in the pathogenesis of 
HIV-related salivary gland disease (SGD) (21) and opportunistic DNA viruses are often the 
etiologic agents of HIV-associated oral lesions. For example, Epstein-Barr virus (EBV) causes 
EBV-associated hairy leukoplakia, Human Herpesvirus 8 (HHV8) causes Kaposi’s sarcoma and 
polyomaviruses cause salivary gland pathology. It is of evolutionary advantage to an infectious 
agent to infect and replicate within the oral compartment and subsequently spread by oral fluids 
or contaminated objects. Various viral agents are known to have evolved to infect and replicate 
efficiently within oral tissues. It is of no surprise that various salivary gland diseases are 
consequently associated with viral infections. Viruses well known to infect human salivary 
glands include Paramyxovirus, EBV, and cytomegalovirus (CMV) among many others (22). For 
a more comprehensive review see Jeffers et al. (13) where the link between viral infections and 
salivary gland pathology are further explored. 
Mumps is the most prevalent virally induced salivary gland disease, despite its incidence 
being reduced significantly by the introduction of the mumps vaccine in 1967 (22). The mumps 
virus causes paramyxo-induced parotitis and symptoms are characterized by bilateral parotid 
swelling, although other salivary glands may be involved. Mumps is a highly infectious but self-
limiting disease (22). It is caused by a single-stranded RNA virus, member of the paramyxovirus 
family and infects exclusively humans. Transmission commonly occurs via the upper respiratory 
tract by droplets, aerosol, direct contact, or fomites (23). Previous to vaccinations mumps lead to 
meningitis and encephalitis in up to 36% of reported cases in the United States (24). 
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EBV is a DNA virus, member of the herpesviridae family and establishes persistent latent 
infection with sporadic reactivation (25). EBV has been shown to infect salivary glands, and 
viral particles are exclusive shed by saliva (22). EBV causes infectious mononucleosis (better 
known as mono), nasopharyngeal carcinoma and Burkitt’s lymphoma (26, 27). Rivera et al. 
analyzed biopsies of DILS patients and consistently detected EBV, but not CMV DNA (21). The 
connection between EBV and DILS pathogenesis could not further confirmed however.  
CMV, as all members of the herpesviridae family, also establishes persistent latent 
infection with sporadic reactivation (28). It is a ubiquitous virus that rarely shows clinical 
symptoms in the healthy host but can cause mononucleosis similar to EBV-associated 
mononucleosis (28). CMV affects mostly the immunocompromised and is one of the most 
common, significant, and difficult opportunistic pathogens among HIV + and transplant patients 
(28). 
Polyomavirus-induced Salivary Gland Pathology 
Polyomavirus-induced salivary gland pathology in animals is well described. 
Polyomavirus (PyV) infections have been shown to cause salivary gland enlargements and 
tumors in animal models (13). In 1984 Ward et al. showed that athymic nude rats infected with 
PyV develop a wasting disease that is accompanied by parotid sialoadenitis with intranuclear 
inclusion bodies. Importantly, the intranuclear inclusions of the parotid epithelium were found to 
express PyV antigens (29). Transgenic mice expressing BKPyV develop hepatocellular 
carcinoma and renal tumors (30, 31). Another transgenic mouse study shows that mice 
expressing PyV T antigen (Tag) undergo salivary gland tumorigenesis as the animals developed 
submandibular gland adenocarcinomas of intercalated duct origin by 1 year of age (32). Similar 
studies further corroborate the transforming potential of Tag in mice and show that conditional 
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expression of PyV Tag in transgenic mice induces ductal hyperplasia (33, 34). Hence, there is 
substantial evidence establishing an association between PyV and salivary gland pathology and 
carcinogenesis in animals. The carcinogenic potential of PyV products may explain the risk of 
increased lymphoma formation among HIVSGD patients. Interestingly, animal models also 
reflect the characteristic lymphocyte infiltration detected in HIVSGD pathology. Murine and 
guinea pig animal models reflected HIVSGD on a histological level as mouse PyV-induced 
salivary epitheliomas in neonatal mice were infiltrated with T lymphocytes (35). Similar 
infiltrates were characterized in tumors growing from newborn guinea pigs infected with SE 
polyomavirus that also develop salivary gland enlargements (36).  
Polyomavirus Family 
BK polyomavirus (BKPyV), JC polyomavirus (JCPyV), Merkel cell polyomavirus 
(MCPyV) and Simian Virus 40 (SV40) are the most recognized members of the human 
polyomavirus family (37). However several new members have been discovered in the past years 
from which all have been suggested to be ubiquitous and of opportunistic nature. The human 
polyomaviruses KI (KIPyV) (38) and WU (WUPyV) (39) were isolated and characterized in 
2007. Trichodysplasia spinulosa-associated polyomavirus (TSPyV) was discovered in skin 
lesions of immunosuppressed patients with Trichodysplasia spinulosa more recently (40). 
Human polyomavirus (HPyV) 6, 7, 9 and 10 were discovered most recently and are currently not 
associated with any disease. Wieland et al. evaluated cutaneous DNA prevalence and viral loads 
of the HPyV 6, 7, 9, 10 and TSPyV by real-time PCR in HIV + men and compared to healthy 
male controls. While they found HPyV6, HPyV7, TSPyV, and HPyV10 to be found more 
frequently among HIV + men as compared to HIV negative men (p < 0.05) they did not connect 
any of the viruses to a particular disease state (41). 
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Based on epidemiological, virological, and phylogenetic data it has been hypothesized 
that human polyomaviruses evolved with their hosts, leading to high prevalence, low morbidity 
and symptom-less latency (42). Yet, on a molecular level, the definition of latency is unclear 
among polyomavirus. It is not clear whether the virus maintains minimal replication levels or if 
the viruses undergo true latency. It is also unclear whether polyomavirus DNA is commonly 
integrated into the host genome. Human polyomaviruses tend to become latent post-primary 
infection and undergo reactivation among immune-compromised individuals. Their opportunistic 
nature and associated viral reactivation leads to serious complications, such as progressive 
multifocal leukoencephalopathy (PML), trichodysplasia spinulosa, Merkel cell carcinoma, and 
BKPyV-associated nephropathy (BKVN) (43). Individuals with suppressed or compromised 
immune systems include mainly HIV and organ transplant patients (43). Immunosuppressant 
conditions such as seen during pregnancy or chronic alcohol abuse may be sufficient however, to 
lead to polyomavirus reactivation (43). The specific factors of a dysfunctional host cellular 
immune system leading to reactivation however are yet to be defined. The identification of these 
factors is of increasing importance as the human polyomavirus family is rapidly expanding. 
BK Polyomavirus (BKPyV) 
BKPyV was first isolated from the urine of a British renal transplant patient in 1971 (44). 
BKPyV is a holoendemic member of the polyomavirus family and therefore found at high 
frequencies throughout most human populations. BKPyV transmission is not clear but thought to 
take place mainly via the respiratory route during infancy (45). Others have suggested BKPyV to 
be transmitted by a fecal-oral route (42), a urino-oral route (43) or vertically. Boldorini et al. 
analyzed blood and urine samples of 19 pregnant women and their newborns. Detected BKPyV 
DNA and seroprevalence suggested that BKPyV is likely to be transmitted during pregnancy or 
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soon after birth (46). While primary BKPyV infection commonly occurs without symptoms, in 
rare cases it can cause clinical complications such as urinary tract disease (47). Upon reactivation 
BKPyV is mainly associated with 3 major clinical syndromes: ureteral stenosis, hemorrhagic 
cystitis, and BKPyV-associated nephropathy (BKVN) (48).  
BKPyV-associated Diseases 
BKPyV has been studied mainly due the severe complications reactivation causes among 
transplant patient even though symptomatic BKPyV infection is also known to cause interstitial 
inflammations, renal tubular atrophy, pneumonia and meningoencephalitis in other settings (3, 
49). Ten percent of renal transplant patients with increased BKPyV viremia and viruria, 
compared to healthy individuals, will develop BKPyV-associated nephropathy (BKVN), which 
leads to graft loss in 90% of the cases (50). BKVN has developed into a new epidemic, 
becoming the most important infectious complication affecting kidney transplants over the past 
eight years. The worldwide BKVN incidence rate lies within 1% and 9% (6.5% at the University 
of North Carolina in Chapel Hill) among children and adults and has been increasing due the 
development of potent immunosuppressive drugs (51). Yet, effective antiviral treatments are not 
available and BKVN often results in chronic allograft dysfunction and failure (52). Clearly, the 
deleterious implications of BKPyV on public health are significant (48), emphasizing the 
importance of elucidating the pathological process leading to BKPyV-associated disease. Our 
work done in chapter 3 adds to the knowledge of BKPyV-associated pathogenesis in that we 
characterized and compared viral replication levels and tropisms of clinical BKPyV isolates in 
human salivary gland and kidney cells that are likely to have caused HIVSGD in vivo. Our work 
presented in the appendix advances the anti-BKPyV treatment options in that we characterized 
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the antiviral effects several drugs have on clinical and laboratory-derived BKPyV isolates in 
vitro.  
BKPyV Structure And Life Cycle 
BKPyV consists of a naked icosahedral virion with a diameter of about 45 nm (28). The 
capsid is constituted of 72 capsomers, made of the major structural protein VP1 and one copy of 
a minor structural protein VP2 or VP3, which also link the genome to the capsid structure (53). 
The viral genome is a circular, double-stranded 5 kb DNA molecule and is divided into three 
functional regions (Fig. 1.2), the early region, the late region and the promoter, termed non-
coding control region (NCCR). The early region encodes the regulatory proteins T antigen (Tag): 
large Tag (80.5 kDa), small tag (20.5 kDa) and the truncated Tag (17 kDa), which arise from 
three different mRNAs by alternative splicing of a single primary transcript (53). 
Polyomaviruses in general depend on the host cell for replication, as they do not encode for their 
own polymerase. Tag in particular carries numerous and indispensible functions and displays 
76% sequence similarity to the well-studied SV40 Tag (54). Tag acts as major regulatory protein 
and interacts with pRb and p53 through its domains in order to overcome the host cell cycle 
control and disrupt host apoptosis. Furthermore, Tag carries DNA unwinding/helicase activity 
and regulates viral DNA replication and gene expression by interacting with host-cell 
transcription factors and  the viral promoter region (NCCR) (42). The late region encodes the 
three structural proteins VP1 (40.1 kDa), VP2 (38.3 kDa) and VP3 (26.7 kDa) and the non-
structural agnoprotein (7.4 kDa). Proteins VP2 and VP3 are translated from the same transcript 
and the agnoprotein and protein VP1 are translated from a different open reading frame (ORF) 
(53). The agnoprotein is a small, non-immunogenic lipid-associated cytoplasmic protein with 
elusive functional nature even thought it has been thought to be important for capsid assembly 
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and egress. The late BKPyV genome region contains additional ORFs, which are not well 
studied but may encode a protein similar to the VP4 protein of SV40 (55).  
 
 
 
 
 
 
 
 
 
 
Figure 1.2. BKPyV Genome 
 
BKPyV Promoter Region 
The BKPyV promoter region, a.k.a. non-coding control region (NCCR), is of 
bidirectional nature and controls transcription of the early and late genes. The NCCR has been 
found to be the major determinant of in vitro replication (56, 57) and is divided into 5 block 
sequences. The O block contains 57 bp, the P block 68 bp, the Q block 39 bp, the R block 63 bp 
and the S block 63 bp. The O block contains the origin of DNA replication and each block 
carries a combination of transcription factor binding sites (TFBS) (28, 58). TFBS AP-1, CREB, 
NF-1, C/EBPβ, C/EBPδ, NF-kB, NF-kB1, p53, Sp1, Tag and p300 among others have been 
described within the polyomavirus NCCR (57, 59-62). The NCCR commonly undergoes block 
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deletions and/or duplications as compared to the archetype (Fig. 1.3). Promoter architectures that 
diverge from the original urine-derived archetypic OPQRS arrangement are referred to as 
rearranged (rr) and are readily detected in vitro and in vivo (63-70). It has been shown that 
NCCR block rearrangements bestow remarkable differences in transforming potential and host 
cell permissivity (57, 64, 69, 71-73). Clinical studies determined that the emergence of rr NCCR 
BKPyV variants in the plasma samples from immune suppressed kidney transplant recipients 
was correlated to increased replication efficiencies and pathogenesis (71). Furthermore, 
rearranged NCCRs have been reported to be more efficient replicators in vitro (56, 57, 66, 74, 
75).  
JCPyV, the closely related polyomavirus member mentioned above, has been studied in 
more detail than BKPyV. JCPyV exhibits tropism for oligodendrocytes in the brain and is the 
etiological agent of the neurodegenerative disease progressive multifocal leukoencephalopathy 
(PML) (76). Similar to BKPyV, the JCPyV promoter has been found to rearrange and 
rearrangements of following substrains isolated from brain, kidney, lymphocytes of PML 
patients, brain, cerebrospinal fluids (CSF), and lymphocytes of healthy individuals have been 
described (77-81). JCPyV promoter region includes binding sites for a variety of transcription 
factors, similar to the BKPyV NCCR. Interestingly, within JCPyV it is thought that these 
rearrangements lead to alterations of the TFBS and hence transcriptional patterns of the 
promoter, which are thought to increase the viral replication capacity in the brain and ultimately 
the viral disease potential (82). It is important to note that the correlation between promoter 
structure rearrangement and disease is not perfect in JCPyV as the same promoter architectures 
can be found within patients with extensive and patients without noticeable disease (45). It is 
known however that following TFBS Tst-1, NF-1, Sp1, GBPi, NF-kB, YB-1, Pura, and GF-1 
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determine the tropism of JCPyV to glial cells in the brain (45, 83-89). While host factors 
contribute to the viral pathogenic capacity and likely fluctuate between individuals and over time 
(45) both JCPyV and BKPyV promoter rearrangements are likely to drive viral replication and 
therefore pathogenicity in vivo.   
Whether BKPyV rr NCCR variants are more efficient at in vivo disease development is 
debated (90, 91) but not unlikely since JCPyV promoter rearrangements have also been 
suggested to drive neural tropism and bestow increased virulence as discussed above (92). It is 
important to conclusively determine whether BKPyV promoter rearrangements truly endow 
higher replication levels and increased virulence in order to understand BKPyV pathogenesis and 
prevent disease development effectively. This may be facilitated by either using certain BKPyV 
NCCR architectures as biomarkers or treatment targets. We therefore aimed to characterize the 
BKPyV promoter region of clinical isolates from HIVSGD patients. We asked whether there was 
a specific promoter architecture detected among HIVSGD patients. We further determined 
whether the promoter architecture potentially affects viral tropism. The promoter architecture 
from following samples have been described: bladder, brain, cerebrospinal fluid, eye, heart, 
kidney, lung, muscle, nasopharyngeal aspirates, ovarium, monocytes, placenta, prostate, ureter, 
urine and sewage (73). To our knowledge our group is the first to characterize the NCCR from 
oral-derived HIVSGD BKPyV. The work described in Chapter 2 detected a unique OPQPQQS 
BKPyV NCCR promoter sequence among 18 out of 19 analyzed HIVSGD TW samples. Chapter 
3 describes a study that corroborated the OPQPQQS promoter architecture in two clinical 
HIVSGD-derived BKPyV isolates (58).  
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Figure 1.3. BKPyV NCCR Block Architectures 
 
 
BKPyV Tropism 
Given the historic connection between BKPyV and the uroepithelial compartment and 
our novel connection between BKPyV and the oral malady we wanted to ensure that HIVSGD-
derived BKPyV isolates displayed oral tropism. Indeed, the work presented in Chapter 3 shows 
that HIVSGD-derived BKPyV isolates replicated well within human salivary gland cells and 
provided evidence of preferred oral tropism as HIVSGD-derived BKPyV isolates replicated 
more efficiently in human salivary gland (HSG) cells than in kidney cells (58). 
Interestingly, it is not clear which factors determine BKPyV tropism. Members of the 
polyomavirus family have a narrow species host range but infect a wide range of cell types 
within a host (48). BKPyV capsid proteins interact directly with the receptor molecules as 
infection is initiated, since it is a non-enveloped virus. This interaction is generally thought to be 
the major determinant of viral host and tissue tropism (93). BKPyV binds to cellular receptors 
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such as N-linked glycoproteins with a2,3-linked sialic acids and gangliosides GD1b and GT1b. 
BKPyV is subsequently internalized via caveolae-mediated endocytosis, and is transported 
towards the endoplasmic reticulum (ER) via the host cell cytoskeleton. Mutations in the major 
capsid protein VP1 may lead to differential host cell receptor binding. Neu et al. (94) described 
the structural requirements that underlie receptor switching and showed that the amino acid at 
position 68 in VP1 is a determinant of receptor specificity. The in vitro experiments show that a 
lysine to serine mutation of this residue switches the receptor specificity of BKPyV from GD3 to 
GM1. These findings emphasize the plasticity of viral receptor binding sites and potential host 
cell type retargeting mechanism.  
How does BKPyV infect human salivary gland cells? Jeffers et al. infected human 
parotid (HSY) and submandibular gland (HSG) cells with laboratory strain BKPyV (VR837), 
emphasizing the capability of BKPyV to replicate in human oral tissue. The study illustrates 
successful viral ganglioside-dependent entry, uncoating, gene expression, virion formation and 
release (95). Interestingly, there is evidence that downstream events such as endocytosis, virus-
induced signaling, intracellular trafficking and transcriptional regulation contributes significantly 
to viral tropism (93). We therefore wanted to ask what factors, beyond the initial receptor 
interaction is likely to allow BKPyV to infect and replicate within the oral compartment and 
subsequently cause HIVSGD? Could the promoter region be a major determinant, similar to 
JCPyV described earlier?  
During infection BKPyV undergoes uncoating once at the endoplasmic reticulum (ER) 
and nuclear localization signals (found on the minor capsid proteins VP2 and/or VP3) further 
direct viral genomes to the nucleus and are subsequently imported via the host’s nuclear import 
machinery (53). Maraldi et al. showed that this process may be completed within 12 hours (96). 
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Once in the nucleus, the early genes are expressed and the BKPyV genome is replicated before 
late gene expression starts and virions are assembled in the nucleus (42). Given the hypothesis 
that receptor interactions may be not be the only factors determining tropism and JCPyV tropism 
to be determined by its promoter, it may be important to consider the contribution of 
transactivating factors affecting BKPyV gene expression to tropism (57, 93). As mentioned 
earlier, the BKPyV NCCR promoter contains the origin of replication and the enhancer/promoter 
elements of the genome and is the main determinant of BKPyV replication in vitro (56). The 
NCCR is a hypervariable region and comparative studies have suggested that it may regulate 
host cell tropism mainly due to the rearrangement, duplication or deletion of TFBS (57, 93, 97). 
It is therefore plausible that the interplay of TFBS found within the NCCR sequence of a certain 
BKPyV substrain and transcription factors present within a certain cell type may allow for 
successful completion of a viral life cycle and therefore determine BKPyV tropism. We therefore 
analyzed the TFBS present within the signature OPQQPS NCCR architecture of the clinical 
HIVSGD BKPyV isolates in Chapter 2.    
BKPyV in vitro Cultivation  
In vitro cultivation of archetype BKPyV in kidney cells, a biologically relevant strain and 
cell culture model, is inefficient unless Tag is provided in trans by over-expression (74) and few 
studies have successfully cultivated clinical BKPyV isolates. Much of the BKPyV in vitro 
cultivation work has been done in cell types that do not represent the natural host, therefore 
unlikely to mimic natural infection. Archetypic BKPyV has been passaged and studied in skin 
fibroblasts (63), HT-1080 fibrosarcoma cell line (98), HeLa cervical cancer cells (60), HEL-299 
human lung fibroblast (99) and WI-38 human embryonic fibroblasts (100). Similarly, the bulk of 
BKPyV in vitro studies were performed with laboratory BKPyV substrains, equally unsuited to 
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represent a natural infection. The following laboratory BKPyV substrains have been used to 
elucidate the BKPyV life cycle: Dunlop (101), TU (99), Proto-2 (98), Gardner strain, VR837 
(100), MM (60). When the cell culture system was suited to represent natural infection, the focus 
was solely on kidney cells due the historic connection of BKPyV and the renal transplants. 
BKPyV infection and transfection experiments intended to represent the naturally infected renal 
compartment have been performed in human embryonic kidney cells (63), human primary renal 
proximal tubule epithelial cells RPTE cells (56, 98), Vero cells (75, 99), baby hamster kidney 
(BHK), newborn rat kidney (NRK) cells, monkey kidney (BSC and CV1) cells (101, 102) and 
primary human urothelial (HUCs) cells (103).  
The lack of an in vitro system that adequately represents the oral in vivo compartment 
and a system that allows for efficient cultivation of clinical BKPyV isolates hinders the complete 
elucidation of the BKPyV life cycle, potential pathogenic mechanism within the oral 
compartment or testing of HIVSGD treatment options. My work described in Chapter 2 and 
Chapter 3 will address this gap. A cell culture system that allows studying oral BKPyV 
replication, potential pathogenesis and anti-viral treatment options was established. Our group 
previously cultivated laboratory strain BKPyV in human salivary gland cells (95), and in Chapter 
2 and Chapter 3, for the first, time clinical BKPyV isolates were assessed in human salivary 
gland cells (58).  
BK Polyomavirus - HIVSGD Association 
BKPyV has been shown to display oral tropism in vivo and in vitro. BKPyV has been 
detected in tonsillar tissue from both pediatric and adult donors (45, 104, 105) and Jeffers et al. 
showed in 2009 that BKPyV is able to infect and reproduce in human salivary gland cells in vitro 
(95). Our group showed that laboratory strain BKPyV undergoes entry, transcribes, translates 
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and produces virions within human submandibular (HSG) and parotid (HSY) salivary gland 
cells. It is plausible therefore that the oral compartment represents an infectious reservoir in 
addition to the historically described renal/urinary compartment (51, 106). Previous studies have 
shown that the replication compartments of urine and plasma-derived BKPyV are distinct in vivo 
(71, 72), similarly, the salivary gland may embody a separate replication compartment in the 
HIVSGD setting (107). 
The Koch’s postulates, used as scientific standard since its publication over 100 years 
ago, established a guideline to identify a causal correlation between a microorganism and a 
disease. Fredricks and Relman re-formulated Koch's postulates in 1996 by integrating modern 
sequence-based identification of microbial pathogens (108). In short, sequences from a 
microorganism proposed to cause a disease need to be found in the majority of cases among 
diseased organisms, ideally at affected sites. Furthermore, fewer or no sequences from the 
microorganisms must be found within negative controls. Based on the re-formulated postulates 
we were able to corroborate that BKPyV contributes to HIVSGD. Jeffers et al. detected, for the 
first time, significantly higher BKPyV viral loads (VLs) in the saliva of patients diagnosed with 
HIVSGD as compared to HIV negative patients (95). The oral BKPyV VLs of HIVSGD patients 
(n=11) ranged from 10
1 
to 10
4 
copies/ml whereas the HIV negative control cohort (n=7) VLs 
ranged from 0 to 10
2
 copies/ml. Our group confirmed the high BKPyV levels shed in a HIVSGD 
cohort two years later (13). The study found highest BKPyV VLs in patients diagnosed with 
HIVSGD (n=11) as compared to patients who are HIV + without HIVSGD (n=46) and HIV 
negative individuals (n=12). Furthermore, our group found BKPyV products, but not herpesviral 
DNA, via PCR and immunofluorescence in HIVSGD patient salivary gland biopsies but not in 
biopsies from patients without HIVSGD (109). Hence, BKPyV sequences were detected among 
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most HIVSGD TW samples and biopsies. Furthermore, significantly lower BKPyV levels were 
detected among HIVSGD negative TW samples and no BKPyV sequence were found among 
biopsies from patients without HIVSGD. In summary, based on Fredricks and Relman’s 
postulates, we have provided evidence that BKPyV may be involved in HIVSGD pathogenesis. 
To further strengthen these assertions, Chapter 2 and Chapter 3 of this thesis will characterize in 
vitro replication and the promoter region and activity of HIVSGD-derived BKPyV and compared 
to those detected in transplant patients with BKPyV infection. We established a salivary gland 
cell culture system that allows the cultivation and study of clinical BKPyV isolates which is 
important because HIVSGD is associated with significant morbidity. Furthermore, Appendix 1 
describes how the salivary gland cell culture system was used to test antiviral treatment options 
potentially alleviating general BKPyV-associated ailments. 
Increased lymphoma incidence among HIVSGD patients is one of the most significant 
morbidities. In light of potential treatment options it is important to define whether the BKPyV 
DNA tumorvirus is the potential cause of it. As mentioned earlier, HIVSGD is considered a pre-
malignant lesion and its diagnosis is associated with increased lymphoma incidence (5, 8, 12, 
13). While evidence of BKPyV causing cancer in humans is less conclusive than in animal 
models (discussed earlier), there are numerous cases where BKPyV sequences were found in 
human tumors, including brain, pancreas, rhabdomyosarcoma, lung, liver, Kaposi's sarcoma, and 
urinary tract neoplasms (45, 110-119). The most definite evidence linking BKPyV to cancer 
focused on the urinary tract. Monini et al. PCR-amplified BKPyV sequences from both normal 
and tumor urinary tract tissue and found BKPyV in almost all samples, as would be expected due 
the holoendemic and renal/urinary tract-tropic nature of BKPyV (117). By Southern Blot 
analysis however they detected integrated BKPyV in tumor samples only. Moreover they found 
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the NCCR architecture of the tumor-derived BKPyV to be homologous (although not sequence 
homologous), rearranged and to represent a novel substrain they termed URO1. It is remarkable 
that the group found a novel and conserved BKPyV substrain, similar to our study described in 
Chapter 2, where we analyze the NCCR region of HIVSGD-derived patients and find a uniform 
OPQPQQS architecture in 18 out of 19 samples (see Chapter 2).  
BKPyV tumorigenic capability in experimental models, as mentioned above, is 
accredited to the presence of the oncoprotein Tag (101). Tag is a nuclear phosphoprotein that 
wields its transforming abilities by interacting and suppressing cellular tumor suppressor proteins 
p53 and members of the pRb family, which leads to unrestrained host cell proliferation (120). It 
transforms rodent cells and immortalizes human cell lines in vitro. The viral protein immortalizes 
human cell lines independently or in the presence of other oncogenes including ras, myc and 
adenovirus E1A (reviewed in (120)). Understanding the complete life cycle of the virus and the 
role Tag plays during infection will be critical in the development of possible therapeutic 
interventions of lymphoma formation during HIVSGD pathogenesis. Towards that goal we have 
completed a study analyzing the possible connection between the metastasis-associated lung 
adenocarcinoma-associated transcript 1 (MALAT-1) and PyV Tag described in Appendix 2.  
 
My Scientific Contributions To The Field 
As suggested by the reviewed literature, there is likely a connection between BKPyV and 
HIVSGD development. My first goal was to corroborate the BKPyV-HIVSGD connection by 
confirming elevated BKPyV VL levels in oral samples from HIVSGD patients (Chapter 2). 
Secondly, I aimed to characterize the BKPyV promoter region of the HIVSGD isolates due the 
importance of the NCCR for the viral life cycle and potentially its pathogenic potential and 
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tropism (Chapter 2). I aimed to study the in vitro replication levels and tropism of clinical 
HIVSGD-derived isolates in order to elucidate the role BKPyV may play during HIVSGD 
pathogenesis and to determine whether the virus could be inhibited in this system (Chapter 3, 
Appendix 1). Further, I aimed to determine downstream cellular effects associated with BKPyV 
salivary gland infection (Appendix 2). We have therefore pursued and completed following 
AIMS: 
 
AIM1: To determine BKPyV viral loads in HIVSGD throatwash (TW) in vivo, we screened TW 
samples from HIVSGD positive and negative patients for BKPyV. Concomitantly, we 
characterized the BKPyV promoter from HIVSGD positive and HIVSGD negative TW samples 
and urine samples from transplant patients (Chapter 2).  
 
AIM2: To determine BKPyV viral fitness in the human oral cavity, we explored the tropism and 
in vitro replication efficiency of HIVSGD TW-derived BKPyV in human salivary gland and 
kidney cells in vitro (Chapter 3).  
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CHAPTER 2: 
 
DISTINCT BK VIRUS NON-CODING CONTROL REGION (NCCR) VARIANTS IN 
ORAL FLUIDS OF HIV- ASSOCIATED SALIVARY GLAND DISEASE PATIENTS 
 
Overview 
BK polyomavirus (BKPyV) has been recognized as human pathogen, affecting immune 
suppressed individuals, since its discovery in 1971. Our group has recently linked the small DNA 
tumorvirus BKPyV to HIV-associated salivary gland disease (HIVSGD), a disease persisting 
throughout the era of highly active antiretroviral therapy (HAART). The BKPyV non-coding 
control region (NCCR) is the main determinant of viral replication and rearranges readily in vivo 
and in vitro. Further, NCCR rearrangements have been associated with functional differences. 
This study analyzed 36 clinical samples for BKPyV, of which 29 were BKPyV positive. One 
hundred percent of throatwash (TW) samples from HIVSGD patients and urine samples from 
transplant patients yielded BKPyV NCCR sequences. Importantly, 94% of the BKPyV HIVSGD 
NCCRs carried the rearranged OPQPQQS block arrangement, suggesting a distinctive 
architecture among this sample set. These findings confirm the HIVSGD-derived BKPyV NCCR 
architecture previously described by our group. Only 22% of TW samples from HIV positive 
individuals without HIVSGD were BKPyV positive and resulted in NCCR sequences distinct 
from OPQPQQS. Despite the block homology in HIVSGD NCCRs, analysis of the underlying 
nucleotide sequences revealed substantial polymorphisms. The NCCR nucleotide 
polymorphisms predicted differential sets of transcription factor binding sites (TFBS). 
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TFBS C/EBPβ in particular, was significantly associated with differences in the detected viral 
loads. Finally, cloned HIVSGD BKPyV isolates displayed active promoters and efficient 
replication capability in human salivary gland cells in vitro. The unique HIVSGD NCCR 
architecture may define a new BKPyV substrain that is of significance for HIVSGD and for oral 
BKPyV pathogenesis. 
 
Introduction 
HIV-associated Salivary Gland Disease (HIVSGD) has persisted through the era of 
highly active antiretroviral therapy (HAART) and is associated with salivary gland enlargement, 
irreversible salivary gland damage, xerostomia (1-4) and increased risk of lymphoma 
development (5). HIVSGD is among the most commonly diagnosed salivary gland-associated 
complications in HIV positive individuals (6). Still, current treatment options are few due to the 
lack of insight into disease etiology and progression. Our group has previously established a link 
between HIVSGD and BK polyomavirus (BKPyV) (7-9). BKPyV is commonly detected in the 
adult population (10, 11) where it is thought to undergo latency in the uroepithelium and 
reactivate upon immune-suppression. BKPyV is the major driver of renal dysfunction among 
kidney transplant patients where reactivation of BKPyV, marked by increased viremia and 
viruria, is linked to polyomavirus-associated nephropathy (BKVN) (12-17). BKPyV, a member 
of the small DNA tumorvirus family, carries a circular double-stranded 5 kb genome, which 
consists of three major elements: the bidirectional viral promoter, known as the non-coding 
control region (NCCR), the early and the late regions (18). The early region encodes for non-
structural viral proteins large, small and mini T antigen (Tag), which are associated with the 
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transforming ability of BKPyV. The late region encodes for the agnoprotein and the structural 
proteins VP1, VP2 and VP3 (18).  
Broekema et al. (19) determined that the BKPyV NCCR not only controls gene 
expression but is also the main driver of in vitro replication. The NCCR consists of five block 
sequences: O (142 bp), P (68 bp), Q (39 bp), R (63 bp) and S (63 bp) (20, 21), which contain the 
origin of DNA replication and transcription factor binding sites (TFBS) (22, 23). Archetypic 
BKPyV carries the originally described NCCR architecture OPQRS (24). TFBS AP-1, CREB, 
NF-1, C/EBPβ, C/EBPδ, NF-kB, NF-kB1, p53, Sp1, Tag and p300 among others have been 
described within the polyomavirus NCCR (20, 23, 25-27). According to mathematical models, 
95% of archetypic urine BKPyV result from urothelial replication (11, 28, 29), and are excreted 
in the urine. Hence, the archetypic NCCR may be considered as kidney-tropic substrain. The 
NCCR is a hyper variable region and commonly undergoes block deletions and/or duplications 
as compared to the archetype. NCCR architectures that differ from the archetypic OPQRS 
arrangement are referred to as rearranged (rr) and have been found in vitro and in vivo (24, 30-
36). Importantly, NCCR block rearrangements confer remarkable differences in transforming 
potential and host cell permissivity (24, 25, 28, 31, 37, 38). BKPyV carrying rr NCCRs are more 
efficient replicators both in vitro (19, 25, 33, 39, 40) and in vivo compared to the archetype (37). 
Gosert et al. determined that the emergence of rr NCCR BKPyV variants in the plasma samples 
from immune suppressed kidney transplant recipients in vivo was correlated to increased 
replication potential and pathogenesis (37). A connection between enhanced promoter efficiency 
of rr NCCR variants and in vivo disease development is debated (29, 41). Of interest, this 
rearrangement ability is conserved among the polyomaviruses. JC polyomavirus (JCPyV) is a 
closely related member of the polyomavirus family and an opportunistic pathogen that also 
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affects HIV positive individuals (18). Similar to the JCPyV promoter, BKPyV promoter 
reformation may be the main driver of tropism and increased virulence (42).  
The BKPyV NCCR architecture of a wide range of human samples has been analyzed, 
including bladder, brain, cerebrospinal fluid, eye, heart, kidney, lung, muscle, nasopharyngeal 
aspirates, ovarium, monocytes, placenta, prostate, ureter, urine and sewage (38). A recent study 
from our group analyzed the BKPyV NCCR architecture and replication potential of two clinical 
HIVSGD-derived BKPyV isolates (9). The study detected an OPQPQQS NCCR architecture 
among HIVSGD-derived BKPyV isolates and showed evidence of both HIVSGD-derived 
BKPyV oral tropism and adept viral replication in human salivary gland (HSG) cells. The 
present study screened an additional 17 HIVSGD TW samples for HIVSGD-derived BKPyV. To 
our knowledge, the present study is the first to characterize the NCCR of a comprehensive set of 
orally-derived BKPyV substrains. 
BKPyV NCCR block arrangement and activity were analyzed, along with the underlying 
sequence variations in the context of transcription factor binding sites (TFBS). We found that the 
majority of HIVSGD TW BKPyV carried the distinct OPQPQQS NCCR architecture, found in 
the previous study, suggesting that the analyzed HIVSGD patient cohort sheds a common 
BKPyV substrain. Furthermore, we found that nucleotide polymorphism underlying the NCCR 
block homology influenced predicted TFBS. Finally, in vitro viral replication capacities and 
promoter activity of the clinical isolates were assessed. 
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Materials and Methods 
Patient Information and Sample Collection 
Patient-derived samples described in this study were retrieved retrospectively from 
studies conducted at UNC Chapel Hill enrolling North Carolina residents. HIV positive 
individuals from the UNC Chapel Hill Hospital Dental Clinics and Infectious Disease Clinic 
were screened for HIVSGD and chosen for throat-wash (TW) collection under IRB approved 
studies (informed consent HRSA IRB study #: 07-1431). HIV + patients were part of a yearlong 
longitudinal study, where participants were screened for HIVSGD-defining lesions and 
symptoms at baseline, at 6 months and at 12 months. A patient diagnosed with HIVSGD at any 
of the three time points during the 12 months study was considered HIVSGD positive (Table 1). 
Throatwash (TW) samples from 28 HIV + individuals were collected at baseline, and BKPyV 
viral loads (VLs) and NCCR architecture was determined. 19 of these individuals had HIV-
associated Salivary Gland Disease (Table 1) and 9 were HIVSGD negative (Table 2). TW 
samples and clinical information pertaining to the patients HIV status was recorded at entry (1
st
 
time point) and for 5 HIVSGD patients at the end of the study (12 months, 2
nd
 time point; not 
shown). Demographic information (age, gender and county of residency) and clinical 
information pertaining to the patients HIV status (HIV VLs and CD4 counts) were collected and 
are reflected in each table. Of the 8 transplant patient-derived samples, 5 were isolated from 
individuals diagnosed with BKPyV-associated nephropathy (BKVN). Each gathered sample 
corresponded to a single patient and time point of collection with the exception of samples T4-1 
and T4-2, which belonged to the same transplant patient and were collected one year apart. 10 ml 
TW samples (saline solution washes) were collected, centrifuged and DNA was isolated via the 
QIAamp DNA Blood Mini Kit as described by manufacturer (Qiagen). Patient samples T1, 
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HIVSGD19 and HIVSGD21 were collected and analyzed in a previous study under the 
identifications U1, HIVSGD-1 and HIVSGD-2 respectively (9). The samples were renamed and 
included in this study in order to expand on previous results. Eight urine samples from UNC 
Chapel Hill Hospital kidney transplant patients were collected and kindly donated by Dr. V. 
Nickeleit. Urine samples were centrifuged and the DNA isolated via Qiagen DNeasy kit as done 
for the TW samples (Qiagen). 
Whole Genome BKPyV Cloning and Transfection 
BKPyV whole genomes were cloned from clinical samples via the naturally occurring 
BamH1 restriction site as described in (9). Whole genome clones HIVSGD19 and HIVSGD21 
were available from the previous study. Human submandibular salivary gland epithelial cells 
(HSG cells) were transfected with re-ligated BKPyV episomes or NCCR constructs as described 
in (9). Supernatant from transfected cells was collected over 15 days, DNA isolated and BKPyV 
VLs determined. 
BKPyV Viral Load Measurements 
Encapsidated BKPyV genomes contained in clinical samples and supernatant of BKPyV 
transfected HSG cells were quantified via quantitative real-time PCR (qPCR) analysis: Roche 
Light Cycler 480 Syber Green I Master Mix in the Roche Light Cycler 480 (9). A BKPyV 
plasmid, kindly donated by Dr. V. Nickeleit, was used to establish a standard curve.  
BKPyV NCCR Sequencing  
Clinical and laboratory strain BKPyV NCCR was genotyped by PCR amplification with 
Vent polymerase and primers BKPyVTT1F and BKPyVTT1R (9, 31). PCR products were 
purified with the QIAquick PCR Purification Kit by Qiagen (according to manufacturer) and 
sequenced by Genewiz (www.genewiz.com). PCR amplification and sequencing was repeated a 
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minimum of three times per patient sample. Resulting NCCR nucleotide sequences were 
analyzed and aligned by the Vector NTI Advance program. Vector NTI identified the BKPyV 
NCCR block motifs with minimum similarity of 70% to original block sequences (20, 21). A 
Vector NTI Guide Tree, which resembles a phylogenetic tree, was built using the Neighbor 
Joining method (NJ) of Saitou and Nei (43). The Guide Tree Pane was built based on matrix 
distance values (in parenthesis following the molecule name displayed on the tree) which relate 
to the degree of divergence between sequences (44). 
NCCR Promoter Activity 
Reporter constructs were used to perform the dual luciferase (luc) assay as previously 
described (9). HIVSGD19 and HIVSGD21 NCCR luc clones used were available from the 
previous study, while all the others were cloned for this study. Briefly, HSG cells were 
transfected with NCCR-pGL3 constructs, pGL3 Basic and pGL3 Control. Each of these plasmids 
were co-transfected with RFP plasmid DNA, for transfection efficiency which was consistently 
detected at over 50%, and with pGL3 control (SV40 promoter), which demonstrated activity 4 
times higher than the NCCR constructs. Resulting luciferase activity was normalized to pGL3 
Basic activity and reported as relative luciferase units (RLU). 
Transcription Factor Binding Site Analysis 
Transcription factor binding sites (TFBS) were predicted via ALGGEN PROMO 
(http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3.) with a 
similarity margin of greater than or equal to 95%. PROMO predicts putative eukaryotic TFBS 
from the TRANSFAC® database, which is based on experimentally proven binding sites and 
consensus binding sequences (positional weight matrices). Eleven human TFBS, previously 
described in the context of the BKPyV NCCR (21, 31, 45-47), were selected along with non-
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human T-Ag in order to analyze the NCCR O blocks of BKPyV HIVSGD and MM: AP-1 
[T00029], CREB [T00163], NF-1 [T00539], C/EBPβ [T00581], C/EBPδ [T00583], NF-kB 
[T00590], NF-kB(-like) [T00591], NF-kB1 [T00593], p53 [T00671], Sp1 [T00759], T-Ag 
[T00788], p300 [T01427]. For the TFBS analysis of the entire NCCR, the similarity margin was 
greater than or equal to 85% and the following TFBS were included: AP-1 [T00029], C/EBPα 
[T00105], c-Fos [T00123], c-Jun [T00133], CREB [T00163], NF-1 [T00539], NF-AT1 
[T00550], C/EBPβ [T00581], C/EBPδ [T00583], NF-kB [T00590], NF-kB(-like) [T00591], NF-
kB1 [T00593], p53 [T00671], Sp1 [T00759], T-Ag [T00788], p300 [T01427), STAT1α 
[T01492], STAT3 [T01493], STAT1β [T01573], STAT4 [T01577], NF-AT2 [T01945], NF-AT4 
[T01946], NF-AT1 [T01948], IRF-3 [T04673], IRF-7A [T04674], STAT5A [T04683], STAT5B 
[T04684], STAT1 [T04759], STAT1:STAT1 [T05692].  
Statistical Analysis 
The correlation between orally shed BKPyV VLs (from TW) and HIV VL, CD4 count 
and age was determined by calculating the correlation coefficient. The correlation between orally 
shed BKPyV VLs (TW) and HAART was determined by Wilcoxon rank sum test. The BKPyV 
VLs in HIVSGD TW, control TW, and urine were compared using the Kruskal-Wallis test with 
pairwise comparisons using Dunn’s multiple comparison test. Samples were grouped by source 
(either HIVSGD TW or urine) and by NCCR architecture (OPQPQQS or any other architecture). 
Differences in viral load between the groups were assessed using two-way ANOVA. Samples 
were also grouped by TFBS and replication efficiency. Low efficiency replicators were defined 
as those with BKPyV VLs < 10
4
 copies/mL, while high efficiency replicators had VL at or above 
this threshold. Differences between these groups were assessed by two-way ANOVA and a 
significant interaction was detected between replication efficiency and TFBS, with certain TFBS 
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being significant in Bonferroni posttests. Multiple BKPyV VLs thresholds were assessed.  The 
choice of thresholds had little effect on the outcome. For example, C/EBPβ was significant at all 
thresholds tested: 10
2
, 10
3
, 10
4
, 10
5
, and 10
6. C/EBPα was also significant at the 104 and 105 
thresholds and p300 at 10
5
. 
The NCCRs with 10 predicted TFBS all had the same combination of TFBS: the 
consensus sites three C/EBPβ sites and one p300 site (CC3C). The viral loads of samples with 10 
TFBS predicted in the NCCR were compared to viral loads of samples with any other 
combination of predicted TFBS using the two-tailed Mann-Whitney U test. The significance 
level for all analyses was set at p=0.05. All significance tests were performed in GraphPad Prism 
5.01. Hierarchical clustering was performed on the number of each TFBS predicted in the full-
length HIVSGD TW NCCRs in R, using the hclust function with heatmap.2 in the gplots 
package. The distance metric used was Euclidean distance. 
 
Results 
BKPyV VLs among patient-derived samples  
HIV + patients were part of a yearlong longitudinal study, where participants were 
screened for HIVSGD-defining lesions and symptoms at baseline, at 6 months and at 12 months. 
Throatwash (TW) samples from 28 HIV + individuals were collected at baseline, BKPyV viral 
loads (VLs) and NCCR architecture was determined and clinical information was collected. 
Nineteen of the HIV + individuals had clinically diagnosed HIV-associated Salivary Gland 
Disease (HIVSGD; Table 2.1.) and 9 were HIVSGD negative (Table 2.2.).  
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Table 2.1. HIVSGD patient-derived BKPyV NCCR block arrangement and viral load 
variation, demographics and HIV-specific clinical information at baseline. This table 
summarizes clinical and BKPyV-specific information collected from 19 patients diagnosed with 
HIVSGD at baseline (study entry). DNA from all throatwash (TW) samples was isolated, 
BKPyV viral loads (VLs) determined and the BKPyV NCCR sequenced and analyzed as 
described in materials and methods. 
a
Throatwash. 
b
Patient age at time point of sample collection 
(yrs). 
c
Male/Female. 
d
Non-coding control region. 
e
Viral load (copies/ml). 
f
Highly Active 
Antiretroviral Therapy, yes/no. 
g
CD4 T cell counts (cells/mm
3
). U; undetectable. DA; data not 
available.  
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Table 2.2. Non-HIVSGD patient-derived BKPyV NCCR block arrangement and viral load 
variation, demographics and clinical information at baseline. This table summarizes clinical 
and BKPyV-specific information collected from 2 HIV + patients without HIVSGD (C) at 
baseline (study entry) and 7 HIV negative renal transplant patients (T). Samples from HIV + 
patients without HIVSGD that did not yield BKPyV were not listed in this table. DNA from all 
clinical samples was isolated, BKPyV viral loads (VLs) determined and the BKPyV NCCR 
sequenced and analyzed as described in materials and methods. 
a
Patient age at time point of 
sample collection (yrs). 
b
Male/Female. 
c
Non-coding control region. 
d
Viral load (copies/ml). 
e
Highly Active Antiretroviral Therapy, yes/no. 
f
CD4 counts (cells/mm
3
). 
g
Throatwash. U; 
undetectable.  
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Demographic information and data pertaining to the HIV status of the patient were 
collected from the HIVSGD patient cohort at study entry. The average HIV VLs and CD4 counts 
were 9x10
3
 copies/ml (range: undetectable – 6x104 copies/ml) and 4x102 cells/mm3 (range: 18-
1x10
3
) respectively. At study entry (baseline) the HIVSGD patients were mostly male (16 males, 
2 females, 1 undetermined), were on average 45 years old (range: 29-60 years) and the majority 
were on HAART (17 on HAART, 2 not on HAART).  
BKPyV VLs in TW samples from HIV + patients without HIVSGD (negative controls) 
and urine samples from HIV naive transplant patients (positive controls) were assessed (Table 
2.2.). Based on previous findings, HIV + patients without HIVSGD were expected to shed little 
or no BKPyV via TW (7, 8). Transplant patients, diagnosed with BKPyV-associated 
nephropathy (BKVN), are known to shed high BKPyV VLs in the urine, ranging from 10
4 
to 10
10 
BKPyV copies/ml (28, 48, 49). Baseline HIVSGD TW BKPyV VLs ranged from 2.9 to 2.4x10
8
 
copies/ml, with a mean of 2x10
7
 copies/ml. This analysis excluded samples HIVSGD14, 
HIVSGD16 and HIVSGD17 from which the available DNA volume was limited and BKPyV VL 
determination was not possible (DA, Table 2.1.). The BKPyV VLs in HIVSGD negative TW 
samples (n=9) were consistently below the linear range of qPCR detection. BKPyV VLs among 
transplant patient urine samples ranged from 1x10
7
 to 3x10
9
 copies/ml (Fig. 2.1.). There was a 
significant difference between BKPyV VLs of transplant patient urine samples (n=8) compared 
to HIVSGD negative TW samples (n=9) (p<0.001). More importantly, HIVSGD TW VL (n=16) 
and HIVSGD negative TW VL (n=9) were significantly different at baseline (p<0.01), 
highlighting the striking differences in oral BKPyV VLs detected among HIV + patients with 
and without HIVSGD. A potential association between orally shed BKPyV levels and factors 
reflecting the patients HIV status were assessed, including HIV VLs, CD4 counts and HAART 
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treatment. None of these factors had a statistically significant correlation with oral BKPyV VLs 
(correlation value ≥ 0.2). Furthermore, no correlation between orally shed BKPyV levels and 
geographical residential location (by counties) was found. The HIV patient cohort resides in 
North Carolina (NC) counties spanning a 300 mile radius. Since the majority of patients were 
male (26/28), the association between orally shed BKPyV VLs and gender was not tested. 
Fig. 2.1. BKPyV VL comparison between patient cohorts. This graph visualizes HIVSGD 
TW, control TW and transplant urine sample BKPyV VLs measured via qPCR at baseline. The 
“Control TW” cohort represents the negative control and is formed by HIV + patients without 
HIVGSD. HIVSGD TW VLs were significantly higher than control TW VLs. Transplant urine 
VLs were significantly higher than HIVSGD and control TW VLs. P values were assessed via 
non-parametric one way ANOVA (Kruskal Wallis) test. Depicted are each data point with the 
mean and the standard errors of the mean (SEM). 
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In order to monitor BKPyV longitudinally, DNA was isolated from 5 HIVSGD patient-
derived TW samples at a second time point (1 year). Despite the relatively high BKPyV VLs 
among HIVSGD TW samples at baseline, none of the TW samples collected past baseline had 
BKPyV VLs above the detection level (not shown). Further, no BKPyV NCCR sequences could 
be PCR amplified from the samples past baseline. Hence, they were considered BKPyV 
negative. 
BKPyV detection and NCCR block alignment analysis of patient-derived samples 
All DNA samples were subject to BKPyV NCCR amplification. Samples yielding 
consistent NCCR products via PCR, were subsequently sequenced off-site and were considered 
BKPyV positive. PCR amplification likely detects the most prevalent NCCR species. Hence, 
there may be additional BKPyV subspecies undetected by PCR that may be identified by 
cloning. All 19 HIVSGD samples (100%), all 8 transplant urine samples (100%) and 2 HIV 
positive HIVSGD negative control samples (22%) were BKPyV NCCR positive (Table 2.3.). 
Resulting NCCR sequences were analyzed for block architecture using Vector NTI. The BKPyV 
NCCR architecture is traditionally based on the following system: 
TTTGCAAAAATTGCAAAAGAATAGGGATTTCCCCAAATAGTTTTGCTAGGCC 
TCAGAAAAAGCCTCCACACCCTTACTACTTGAGAGAAAGGGTGGAGGCAGAGGCGG
CCTCGGCCTCTTATATATTATAAAAAAAAAGGC - O block sequence, 
CACAGGGAGGAGCTGCTTACCCATGGAATGCAGCCAAACCATGACCTCAGGAAGGA
AAGTGCATGACTG – P block sequence, 
GGCAGCCAGCCAGTGGCAGTTAATAGTGAAACCCCGCC – Q block sequence, 
GGCAGCCAGCCAGTGGCAGTTAATAGTGAAACCCCGCCA – R block sequence and 
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GACAGACATGTTTTGCGAGCCTAGGAATCTTGGCCTTGTCCCCAGTTAAACTGGACA
AAGGCC – S block sequence (20, 21). Greater than or equal to 70% sequence similarity to these 
block sequences was required for NCCR block identification using Vector NTI. The NCCR 
architecture of three previously described BKPyV laboratory strain sequences (MM, Dunlop and 
VR837) was confirmed as a control measure (9). Archetypic OPQRS NCCRs were detected in 4 
out of 8 transplant urine-derived samples. Rearranged NCCR block sequences, that differed from 
the archetypic NCCR architecture, were detected in 25/29 (86%) of the clinical samples. A 
common rr NCCR OPQPQQS alignment was recovered from 18/19 HIVSGD TW samples 
(94.7%, Table 2.1.). The only HIVSGD sample (HIVSGD4) that did not carry this common 
alignment had an OPQPQQ NCCR alignment, which differed from the signature alignment only 
in that it lacked the final S block. HIVSGD negative oral samples did not carry the signature 
alignment; the block alignment OPPQRS was detected in two HIV + HIVSGD negative-derived 
TW control sequences (C1, C2). Three distinct block alignments were detected in transplant 
urine samples including: OPQRS (T2, T3, T5, T7), OPQPQQS (T4-2, T6), OPQ (T1) and PQRS 
(T4-1) (Table 2.3.). Compared to the transplant urine-derived NCCR architectures, the HIVSGD 
NCCR OPQPQQS architectures were highly homologous (Table 2.2.). This rr NCCR OPQPQQS 
alignment was also detected in 2 transplant urine samples (T4-2 and T6) and 1 laboratory strain 
MM BKPyV. The Fisher's Exact Test was used to determine whether HIVSGD-derived BKPyV 
was more likely to contain the OPQPQQS architecture than HIV + HIVSGD negative-derived or 
transplant patient-derived BKPyV. Indeed, HIVSGD patient-derived substrains were 72 times 
more likely to have the OPQPQQS block arrangement than the other substrains (OR:72, 95% CI: 
5.67-914.3). 
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Table 2.3. NCCR architectures among clinical samples at baseline. This table depicts all 
BKPyV NCCR block architectures found among the analyzed clinical samples. The NCCR of 
94.7% HIVSGD throatwash (TW)-derived BKPyV resulted in a matching NCCR block sequence 
(bold, signature alignment). Patients diagnosed with HIVSGD at any time point over the one 
year study are considered HIVSGD positive. 
a
Archteype BKPyV NCCR. 
b
BKPyV positive 
samples over total number of samples. 
c
Laboratory strain BKPyV. 
 
 
HIVSGD BKPyV NCCR nucleotide polymorphisms 
To further analyze the clinical BKPyV promoters, the degree of divergence among the 
underlying nucleotide NCCR sequences was determined. Distance values (displayed in 
parenthesis) between clinical NCCR nucleotide sequences were calculated using the neighbor 
joining algorithm and visualized by a Guide Tree (Fig. 2.2A). Cluster I contained NCCR 
sequences from HIVSGD negative transplant patient urine (T) and HIV + HIVSGD negative TW 
(C) samples. Cluster II contained NCCR sequences from following HIVSGD patients: 3, 4, 5, 7, 
9, 10, 11, 12 and 13. Cluster III contained a second group of NCCRs from HIVSGD patients: 2, 
6, 14, 15, 16, 17, 18, 19 and 21. The following HIVSGD NCCR sequences within Cluster III 
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were identical: 6, 14, 15, 16, 17 and 18. Interestingly, HIVSGD1 did not aggregate within the 
three clusters. The three clusters visually emphasize the differences between HIVSGD-derived 
NCCR sequences as compared to the control groups. Importantly, the clusters highlight the 
significant sequence similarity detected among HIVSGD-derived NCCR structures as compared 
to the other clinical isolates. Most interestingly, despite the block homology, underlying 
nucleotide polymorphisms were detected among the OPQPQQS HIVSGD NCCRs. NCCR 
nucleotide sequence alignment analysis (including all HIVSGD NCCRs and laboratory BKPyV 
strain MM NCCR) revealed identical P and Q blocks (not shown). Most sequence variation was 
detected within the O block (Fig. 2.2B) and minor polymorphisms were detected in the S block 
(Fig. 2.2C). The first 50 bp of the O block contained the majority of differences with only 4 
conserved regions: O16 (1), O27 (2), O33-34 (3) and O45 (4) (Fig. 2.2B). Only HIVSGD2 and 
HIVSGD4 displayed additional nucleotide differences outside of this 50 bp region; HIVSGD2: 
cytidine insertion (C) at O89 and adenosine (A) insertion at O94 and HIVSGD4: A-guanosine (G) 
transition at O61. Within the NCCR S block, the following polymorphisms were detected: G-A 
transitions at S441 for HIVSGD7 and HIVSGD10 and a thymidine (T)-C mutation at S451 for 
HIVSGD2 (Fig. 2.2C). 
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Fig. 2.2. Nucleotide polymorphism underlying the OPQPQQS NCCR block 
homology. A. This graph depicts the Guide Tree built based on NCCR sequences retrieved from 
clinical samples. NCCR nucleotide sequences were aligned by Vector NTI. Distance values (in 
parenthesis) designated relative degrees of divergence among the sequences. The Guide Tree 
NCCR analysis aggregated clinical BKPyV in 3 clusters (excluding HIVSGD1). Cluster I 
contained the NCCRs of HIVSGD negative urine- and TW-derived BKPyV strains. Clusters II 
and III contained exclusively HIVSGD BKPyV NCCR sequences. B./C. NCCR nucleotide 
sequence alignment of HIVSGD patient-derived BKPyV bearing the OPQPQQS signature 
alignment along with MM exposed underlying nucleotide sequence that were present  despite 
NCCR block homology.  The O (B.) and S block (C.) carried the majority of the sequence 
variety, while the P and Q blocks were sequence identical (not shown).  
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Full-length NCCR TFBS 
To determine whether the detected polymorphisms potentially influenced viral 
transcription, TFBS were predicted for all 19 HIVSGD BKPyV NCCRs, laboratory strains MM, 
Dunlop, VR837 and transplant urine-derived T1. The ALGGEN PROMO prediction analysis 
included two previously characterized NCCRs (HIVSGD19 and HIVGSD21) (9). Table 2.4. 
describes the predicted TFBS types (first column) for each BKPyV NCCR substrain (top row). 
TFBS abbreviations are listed on the legend (Table 2.4., left). To determine whether the presence 
or combination of specific TFBS was correlated with increased in vivo replication efficiency a 
multiple linear regression analysis was performed (not shown). None of the predicted TFBS 
coefficients and (increased or decreased) in vivo BKPyV VL associations were statistically 
significant. Next, in vivo BKPyV VLs and TFBS were grouped via hierarchical clustering to 
determine whether specific TFBS groups may cluster with increased or decreased VLs (not 
shown). The analysis yielded clusters that grouped members of the same signaling pathway but 
did not identify significant associations with increased or decreased VLs despite a detected trend 
between NCCR TFBS CCAAT/enhancer binding factor (C/EBP)β and higher BKPyV 
replication efficiency. Grouped were different members of the C/EBP family, as were different 
members of the NF-AT family and members of the STAT family.  
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Table 2.4. Predicted TFBS for full-length NCCR via ALGGEN PROMO. Visualized are the 
types of predicted TFBS (first column) for each BKPyV NCCR substrain (top row). The top row 
lists the name of analyzed full-length NCCR sequences, which included 19 HIVSGD BKPyV, 3 
laboratory strains and 1 urine-derived strain isolated from a patient diagnosed with BKPyV-
associated nephropathy (BKVN). TFBS included for the PROMO TFBS prediction program are 
listed in the materials and methods section. TFBS abbreviations are listed on the legend (left). 
a
TFBS Abbreviation.  
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To further analyze the potential association between the frequency of certain predicted 
TFBS or TFBS combinations and high or low BKPyV in vivo shedders, HIVSGD TW samples 
were categorized as high or low replicators based on an oral VL threshold of 10
4
 BKPyV 
copies/ml (Fig. 2.3.). TFBS predicted for each full-length HIVSGD BKPyV NCCR within these 
groups were compared by two way ANOVA. C/EBPα and C/EBPβ, were significantly different 
and more abundant within the higher replicators (p<0.05, p<0.001). Interestingly, the threshold 
choice of 10
4
 BKPyV copies/ml had little effect on the outcome, as C/EBPβ was associated with 
significantly higher VLs at all tested thresholds (10
2
, 10
3
, 10
4
, 10
5
, and 10
6 
copies/ml). C/EBPα 
was significant at both the 10
4
 and 10
5
 copies/ml thresholds and p300 at the 10
5 
copies/ml 
threshold (p<0.05). Interestingly, a potential association between NCCR TFBS C/EBPβ and 
higher BKPyV replication efficiency was also observed in the hierarchical clustering analysis of 
TFBS predicted for the full-length BKPyV NCCR despite it not being statistically significant 
(mentioned earlier, not shown). 
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 Fig. 2.3. TFBS divergence based on BKPyV VL threshold. This graph depicts varying 
numbers of TFBS per threshold group. HIVSGD TW samples were grouped according to a 
threshold of 10
4
 BKPyV copies/ml, and respective TFBS predicted for full-length HIVSGD 
BKPyV NCCRs were compared via a two way ANOVA. The analysis allowed determining 
whether the frequency of a certain predicted TFBS may be significantly different among higher 
or lower BKPyV replicators. C/EBPα and C/EBPβ (see *) were significantly different and more 
abundant within the higher replicators. The threshold choice had little effect on the outcome as 
C/EBPβ was significant at all thresholds tested: 102, 103, 104, 105, and 106 copies/ml. C/EBPα 
was significant at the 10
4
 and 10
5
 copies/ml thresholds and p300 at 10
5 
copies/ml.  
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O Block NCCR TFBS 
The NCCR O block is critical to the viral life cycle since contains the start codon for the 
early BKPyV gene expression, a palindrome of two inverted repeat sequences, a 20-bp A/T 
region (45). Given the considerable sequence variation detected within this block (Fig. 2.2B) 
TFBS predicted exclusively for the O block were analyzed. TFBS C/EBPβ (C), Tag (T), p300 
(3) and NF-kB (N) were predicted within the HIVSGD BKPyV NCCRs and were assigned to 
nucleotide stretches (Table 2.5.). Interestingly, all of the included HIVSGD BKPyV NCCR O 
blocks carried six common TFBS; resulting in six consensus binding sites: four Tag and two 
p300 binding sites (not shown). Based on total number of TFBS, five NCCR O block groups 
were formed containing 7, 8, 9, 10 or 11 total TFBS. The group with a total number of 10 TFBS 
carried a TFBS combination of “CC3C” unique to this group and contained the highest number 
of C/EBPβ and p300 TFBS (group 11 was excluded for statistical analysis because it only 
contained a single NCCR).  
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Table 2.5. Predicted TFBS for the NCCR O block. A. TFBS AP-1, CREB, NF-1, C/EBPβ, 
C/EBPδ, NF-kB, NF-kB1, p53, Sp1, Tag and p300 were included for the O block ALGGEN 
PROMO analysis (see materials and methods). TFBS C/EBPβ, Tag, p300 and NF-kB were 
predicted. Each substrain contained two p300 and four Tag predicted TFBS, which were termed 
consensus sites (not shown). Shown are the TFBS predicted in addition to the consensus sites 
and the total number of TFBS for each substrain (last row/grey). Based on total number of TFBS 
5 groups of NCCR O blocks were formed (7, 8, 9, 10 and 11 total TFBS).  
 
 
Comparing in vivo VLs from HIVSGD BKPyV NCCRs carrying highest predicted 
number of C/EBPβ and p300 in the O block (“CC3C” group) to all others (“Other” group) 
yielded a statistically significant difference (p = 0.0414, Fig. 2.4A). TFBS group medians and 
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respective VL plots detected a positive trend. Increased VLs were associated with an increased 
number of predicted C/EBPβ or p300 (Fig. 2.4B). These results suggest that the presence of the 
TFBS combination C/EBP-p300 within the HIVSGD BKPyV NCCR may enhance BKPyV in 
vivo replication efficiencies.  
 
Fig. 2.4. O block TFBS analysis. A. The graph shown compares clinical BKPyV VL (y-axis) 
based on predicted TFBS (x-axis). Two groups were formed. The “CC3C” group included 
clinical BKPyV predicted to have TFBS combination C/EBPβ, C/EBPβ, p300, C/EBPβ within 
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the O block (10 total TFBS). The “Other” group designated BKPyV O blocks differing from that 
TFBS combination. Depicted are the median and the interquartile range of each group. A 
statistically significant difference (p = 0.0414) between VLs from the CC3C (10 TFBS group) 
group and “other” was determined via a Mann-Whitney U test. The “CC3C” group contained 
higher VLs than “others” not containing that specific combination of TFBS, potentially 
suggesting that the presence of this combination or frequency of TFBS may be endowing higher 
in vivo replication efficiencies. B. Since increased total number of TFBS correlated with 
increased C/EBPβ TFBS, NCCR O block groups with equal number of total TFBS were 
correlated to VL (BKPyV copies/ml). Plotting the median of each total TFBS group and 
respective VLs resulted in a positive trend, associating increasing sample VL with increasing 
number of predicted C/EBPβ TFBS (see Table 6 for detailed listing of TFBS). Black squares 
represent single data point, the thick black bars represent the median of measured BKPyV VLs 
and the thin black error bars represent interquartile range.  
NCCR promoter activity and in vitro replication efficiency 
HIVSGD BKPyV NCCR promoter activity and in vitro replication efficiency were 
assessed in human salivary gland cells, mimicking the in vivo oral compartment. The BKPyV 
NCCR promoter of HIVSGD substrains (HIVSGD1, HIVSGD2, HIVSGD3, HIVSGD11), MM 
and Dunlop were cloned into luciferase (luc) reporter constructs, to test promoter induction in 
human salivary gland (HSG) cells. Cloned reporter constructs were transfected and promoter 
activity measured via a luciferase assay 48hrs post-transfection. Relative light unit (RLU) 
measurements, normalized to pBasic, allowed the comparison and ranking of promoter activities. 
Ranked from highest to lowest were HIVSGD11, HIVSGD3, HIVSGD2, HIVSGD19, 
HIVSGD1, MM, HIVSGD21, and Dunlop (Fig. 2.5A). All but one HIVSGD promoter (83%) 
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was more readily induced than laboratory strains, suggesting basal promoter activity of HIVSGD 
NCCR BKPyV was stronger than laboratory strains MM and Dunlop in HSG cells. Higher 
promoter activity may be associated with the signature NCCR block sequence OPQPQQS as the 
lowest activity was recorded by Dunlop which carries an OPPPS NCCR architecture. All the 
cloned NCCRs had the same number of predicted p300 TFBS (18). Hence, we were unable to 
confirm p300 as driver for differences in promoter activity. Increased predicted C/EBP binding 
sites did not correlate with augmented promoter activity in vitro either. HIVSGD21, the least 
active HIVSGD promoter, had the highest number of predicted C/EBPβ sites (6) compared to the 
other HIVSGD clones. HIVSGD11, containing the least C/EBPβ (2) compared to the other 
HIVSGD clones, exhibited the most active promoter (Table 2.5., Fig. 2.5A). However, 
HIVSGD11 BKPyV NCCR had the most AP-1 (A) and the least NF-1 (NF1) TFBS compared to 
predicted sites from clones HIVSGD and laboratory strains MM and Dunlop. Overall, a 
predicted increase in NCCR C/EBP and p300 TFBS among more readily induced BKPyV 
promoters was not confirmed in vitro, but it was determined that all but one HIVSGD promoter 
(83%) was more readily induced than laboratory strains in HSG cells.  
In vitro replication efficiency was assessed by the transfection of HIVSGD BKPyV 
whole genomes. Whole genome BKPyVs were cloned for the following substrains: HIVSGD2, 
HIVSGD15, HIVSGD17, HIVSGD18, MM, VR837, Dunlop and transplant urine-derived T1. 
Cloned genomes were excised from their backbones, religated and transfected into HSG cells. 
Media from these cells was collected daily for 15 days and BKPyV VLs (copies/ml) quantified 
to monitor viral replication efficiency (Fig. 2.5B). All HIVSGD BKPyV substrains replicated 
well within HSG cells, consistently yielding BKPyV VLs above 10
4
 copies/ml and up to 10
8
 
copies/ml. HIVSGD15 and Dunlop BKPyV were the least efficient replicators and yielded VLs 
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ranging from 10
2
 to the 10
5
 copies/ml over the 15-day time span. Based on average VLs over 15 
days the in vitro replication efficiencies ranked from highest to lowest: HIVSGD19, HIVSGD18, 
MM, T1, VR837, HIVSGD17, HIVSGD21, HIVSGD15 and Dunlop (Fig. 2.5B). All but one 
cloned HIVSGD substrain (HIVSGD15) replicated more efficiently than laboratory strain 
Dunlop in HSG cells. Predicted C/EBP and p300 sites within the full-length HIVSGD BKPyV 
NCCR did not correlate with increased in vitro replication efficiency of whole genome HIVSGD 
BKPyV in HSG cells. Dunlop, for example, consistently carried lowest VLs and yet had the 
highest number of predicted C/EBPβ (6) and p300 (20) sites compared to other NCCRs. 
HIVSGD19, containing fewer C/EBPβ (4) and the same number of p300 (18) sites as compared 
to other whole genome HIVSGD BKPyVs clones, yielded the highest VLs (Table 2.5, Fig. 
2.5B). While the relationship between viral replication and the predicted increase in NCCR 
C/EBP and p300 TFBS was not confirmed in vitro, it was determined that all HIVSGD strains 
replicate readily in HSG cells. The HIVSGD NCCR architecture may lend to this replication 
ability. High VLs were recorded for the laboratory strain MM, which like HIVSGD BKPyV 
contains the OPQPQQS architecture. Urine-derived T1 (OPQ) and laboratory strain VR837 
(OPQPQS) however replicated efficiently as well, despite not carrying the HIVSGD architecture 
OPQPQQS. The laboratory strain Dunlop (OPPS), that lacked any Q blocks and did not carry the 
OPQPQQS architecture, was the least efficient in vitro replicator and had the weakest promoter 
(Fig. 2.5).  
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Fig. 2.5. In vitro BKPyV promoter activity and replication efficiency. A. The schematic is a 
representative result of BKPyV promoter activity within human salivary gland (HSG) cells. 
BKPyV promoter activity of 6 HIVSGD-derived and three laboratory strain-derived reporter 
constructs (in the early direction) were recorded via a luciferase (luc) assay 48 hours post-
transfection. All but one HIVSGD strain (HIVSGD21) were more readily induced than 
laboratory strains MM and Dunlop. B. The schematic is a representative result of BKPyV VLs 
quantified over 15 days after transfection of human salivary gland (HSG) cells with cloned 
HIVSGD and laboratory strain BKPyV. All HIVSGD isolates replicated readily in HSG cells 
and all but one (HIVSGD15) replicated more efficiently than laboratory strain Dunlop. In vitro 
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replication efficiencies of HIVSGD BKPyV were determined post-whole genome BKPyV 
transfection and graphed along with in vivo BKPyV VLs.  
 
Discussion  
HIV-associated Salivary Gland Disease (HIVSGD), a commonly diagnosed salivary 
gland-associated complication in HIV + individuals, has been linked to the BK polyomavirus 
(BKPyV) (7, 8). The BKPyV non-coding control region (NCCR) is the main determinant of viral 
replication in vitro (19) and archetypic BKPyV NCCR rearrangements occur readily in vitro and 
in vivo (11, 29, 30, 35-37, 41). The shift from archetype to rr NCCR has been linked to overall 
functional differences in BKPyV viral fitness, including higher replication capacity, higher 
plasma viral loads and increased cell damage (24, 25, 31, 37, 38). Determining whether 
HIVSGD BKPyV promoter rearrangements endow higher replication levels and increased 
virulence may facilitate elucidation of BKPyV pathogenesis and potentially allow for NCCR 
architectures to serve as biomarkers or treatment targets. A previous study detected a conserved 
OPQPQQS NCCR architecture in two HIVSGD-derived BKPyV isolates and showed evidence 
of oral tropism and adept viral replication in human salivary gland (HSG) cells (9). The present 
study screened additional 17 clinical HIVSGD throatwash (TW) samples for BKPyV and 
characterized the NCCR promoter region. Here we described the first comprehensive assessment 
of oral BKPyV NCCR block arrangement and activity, along with underlying sequence 
variations in the context of transcription factor binding sites (TFBS). Finally, we determined in 
vitro NCCR promoter activity and viral replication capacities of the oral clinical isolates in HSG 
cells.  
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The BKPyV NCCR architecture and viral loads (VLs) from a cohort of 36 immuno-
suppressed individuals were assessed including 19 HIVSGD TW samples, 9 HIV + HIVSGD 
negative TW samples and 8 urine samples from HIVSGD negative transplant patients (Table 
2.1.). First, we aimed to confirm previously published data showing that HIVSGD patients shed 
increased BKPyV VLs orally, corroborating a potential link between HIVSGD and BKPyV (7, 
8). The BKPyV VLs in HIVSGD negative TW samples (n=9) were consistently below the qPCR 
detection level and significantly lower than HIVSGD positive TW (n=16) (p<0.01) and 
transplant urine samples (n=8) (p<0.001). Interestingly, the mean BKPyV VL of both HIVSGD 
positive TW samples (2x10
7
 copies/ml) and the urine samples (1x10
9
 copies/ml) were 
comparable and reflected BKPyV VLs previously reported in the urine (mean; 2x10
8
 copies/ml)  
and plasma (mean: 2x10
7
 copies/ml) of patients suffering from BKPyV-associated nephropathy 
(BKVN) (48), implying that the salivary glands may be a potential compartment suitable for 
BKPyV replication, pathogenesis and potential salivary transmission. High levels of orally shed 
virus may potentially incite a pathogenic response by inducing direct cytolytic effects on the 
salivary gland cells or by activating the immune system. Detection of HIVSGD TW VLs up to 
10
8
 copies/ml (Table 2.1.) suggested that HIVSGD BKPyV were efficient in vivo replicators 
under conditions provided at study entry.  
Notably, 94.7% of the HIVSGD TW samples carried a common rearranged (rr) BKPyV 
NCCR block alignment OPQPQQS (Table 2.4.)(9). A single HIVSGD-derived BKPyV did not 
carry the distinct NCCR alignment (HIVSGD4) and revealed an OPQPQQ block combination, 
differing from the signature alignment by the lack of the S block. The OPQPQQS architecture 
was not simply associated with HIV as the two HIV + individuals that did not have HIVSGD had 
a distinct block arrangement.  However, the OPQPQQS NCCR block combination was also 
68 
 
detected in two of the eight urine samples from transplant patients, which corroborated the 
substrain’s potential biological significance. Detection of expected NCCR structures in urine 
samples (archetypic) and laboratory strains (previously published) and overall detection of eight 
distinct NCCR block alignment groups (Table 2.3.) confirmed the validity of our NCCR 
sequence results. Interestingly, HIVSGD NCCR block architectures were more homologous than 
urine-derived BKPyV NCCRs which displayed a range of NCCR arrangements (OPQPQQS, 
OPQRS, OPQ and PQRS; Table 2.3.).  
The phylogenetic analysis emphasized the NCCR architecture homology among 
HIVSGD BKPyV but also reflected underlying nucleotide polymorphisms (Fig. 2.2A). These 
results were similar to a study published by Drew et al.,where urine-derived clinical isolates 
were described (50) that carried overall block similarities but differed by single nucleotide 
polymorphisms. The sequence analysis revealed that most polymorphisms were found with the O 
and the S blocks (Fig. 2.2.). Importantly, there was a relationship between the HIVSGD block 
sequence OPQPQQS and enhanced promoter activity and replication potential (Fig. 2.5.). Five 
out of six (83%) of the HIVSGD NCCR promoters were more active than laboratory strain 
promoters in HSG cells (Fig. 2.5A) and all HIVSGD strains replicated readily in salivary gland 
cells in vitro (Fig. 2.5B). Interestingly, all but one HIVSGD substrain replicated more efficiently 
than laboratory strain Dunlop in HSG cells over a 15-day time span (Fig. 2.5B).  
Based on the significance of the BKPyV promoter to the viral life cycle (19) and the link 
between rearranged promoters and higher replication capacities and increased cell damage (24, 
25, 31, 37, 38), it appeared that the HIVSGD OPQPQQS rearrangement may have endowed 
facilitated replication relative to laboratory strains. P block repetitions within the NCCR have 
been shown to result in greater promoter activity (51-53). P and S block preservations and R 
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block deletions seem to be selected for in clinically isolated BKPyV in past publications (38, 41). 
It is likely that P block duplications and R block deletions, as compared to archetype, may 
provide in vitro and in vivo replication advantages. The P and the S block were conserved, the R 
block deleted and additional 2 Q blocks added in HIVSGD NCCR compared to archetype 
BKPyV, which is known to replicate with great difficulty in vitro. Three Q blocks were added 
and 1 P block was removed compared to Dunlop BKPyV, which did not replicate well in 
salivary gland cells. Clearly, future work will have to elucidate the potential driving force of 
each block in the BKPyV NCCR context. JCPyV the closely related polyomavirus member 
mentioned above has been studied in more detail than BKPyV. JCPyV exhibits tropism for 
oligodendrocytes in the brain and is the etiological agent of the neurodegenerative disease 
progressive multifocal leukoencephalopathy (PML) (54). Similar to BKPyV, the JCPyV 
promoter has been found to contain TFBS and rearrange readily in vivo (55-59). It is known that 
JCPyV promoter rearrangements lead to alterations of TFBS which affect the transcriptional 
pattern of the promoter and increase the viral replication capacity in the brain and ultimately the 
viral disease potential (60). TFBS Tst-1, NF-1, Sp1, GBPi, NF-kB, YB-1, Pura, and GF-1 
specifically determine the tropism of JCPyV to glial cells in the brain (61-68). While host factors 
contribute to the viral pathogenic capacity and likely fluctuate between individuals and over time 
(61) both JCPyV and BKPyV promoter rearrangements may drive viral replication and therefore 
pathogenicity in vivo.   
While BKPyV NCCR TFBS in clinical samples (21, 29, 38, 69-71) and the relationship 
between TFBS and promoter activity or in vitro replication have been studied (22, 25, 30, 72) 
little published work assesses the correlation of NCCR TFBS and clinical VLs. Priftakis et al. 
attempted to correlate a C/G mutation in the NCCR Sp1 site with increased BKPyV VLs  in 
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patients with hemorrhagic cystitis (HC) but could not confirm it (73, 74). We predicted TFBS for 
the clinical and laboratory strain full-length (Table 2.4.) and O block (Table 2.5.) BKPyV 
promoters and analyzed a potential correlation between in vivo VLs and sets of TFBS. A 
potential association between NCCR TFBS C/EBPβ and p300 and higher in vivo BKPyV 
replication efficiency was detected by in silico analysis (Fig. 2.3. and Fig. 2.4.). Previous studies 
predicted C/EBPβ binding within the BKPyV NCCR and determined that C/EBPβ and p65 
(subunit of NF-kB) stimulated NCCR transcription in the early direction in transfection 
experiments, in CV-1 monkey kidney cells), suggesting C/EBPβ was important for early 
promoter induction (23, 75). However, despite the long-held hypothesis that there is a link 
between NCCR TFBSs and BKPyV replication efficiency (16, 21, 53), subsequent in vitro 
experiments performed in this study did not confirm a correlation between TFBS C/EBPβ and 
p300 and promoter activity (Fig. 2.5A) or viral replication levels (Fig. 2.5B). Factors other than 
C/EBP and p300, such as AP-1, are thought to increase archetypic BKPyV promoter 
transcriptional activity (76), and NF-1, is thought to be a repressor of the BKPyV promoter (77).  
These factors may override the potential C/EBP and p300 effect in vitro. Alternatively, basal 
levels of C/EBP in salivary gland cells may be different in vitro than in vivo. Similar to the 
clinical BKPyV study performed by Gosert et al. (37), early clinical rr BKPyV NCCR promoters 
displayed strong gene expression but no conclusive TFBS alterations could be identified as 
directing promoter activity and replication efficiency. Furthermore, overall NCCR promoter 
activity, in vivo and in vitro BKPyV VLs did not consistently reflect each other. The in vivo and 
in vitro differences may have been associated with endogenous factors present in in vivo that 
were not present in vitro. Promoter activity and in vivo or in vitro replication levels may also be 
associated with  BKPyV genome aberrations outside of the NCCR that could dramatically affect 
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the viral life cycle (9). Clearly, further work is required to determine the importance of TFBS in 
the multifaceted organization of BKPyV NCCR-mediated gene expression.  
In summary, HIVSGD patients shed relatively high BKPyV VLs via the oral cavity and a 
highly homologous OPQPQQS NCCR block architecture sequence was detected among 19 
HIVSGD BKPyV NCCR oral isolates (Table 2.3.). While it is unclear whether the OPQPQQS 
NCCR signature may be an adaptive response or may promote salivary gland cell tropism, this 
study determined that cloned HIVSGD BKPyV isolates displayed active promoter activity and 
efficient replication capability in human salivary gland cells in vitro. Overall, the high frequency 
of a viable OPQPQQS BKPyV substrain among HIVSGD TW samples corroborated the 
presence of a stable, biologically significant and potentially pathogenic substrain that may be 
linked to HIVSGD pathogenesis. 
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CHAPTER 3: 
REPLICATION OF ORAL BK VIRUS IN HUMAN SALIVARY GLAND CELLS
1
 
Overview 
BK polyomavirus (BKPyV) is the most common viral pathogen among allograft patients. 
Increasing evidence links BKPyV to the human oral compartment and to HIV-associated salivary 
gland disease (HIVSGD). To date, few studies have analyzed oral-derived BKPyV. This study 
aimed to characterize BKPyV isolated from throatwash (TW) samples of HIVSGD patients. The 
replication potential of HIVSGD-derived clinical isolates HIVSGD-1 and HIVSGD-2, both 
containing the non-coding control region (NCCR) architecture OPQPQQS, were assessed and 
compared to urine-derived virus. The BKPyV isolates displayed significant variation in 
replication potential. Whole genome alignment of the two isolates revealed three nucleotide 
differences that were analyzed for a potential effect on the viral life cycle. Analysis revealed a 
negligible difference in NCCR promoter activity despite sequence variation and emphasized the 
importance of functional Tag for efficient replication. HIVSGD-1 encoded for full-length Tag, 
underwent productive infection in both human salivary gland cells and kidney cells and 
expressed viral DNA and Tag protein. Additionally, HIVSGD-1 generated DNAse resistant 
particles and by far surpassed the replication potential of the kidney-derived isolate in HSG cells. 
HIVSGD-2 encoded a truncated form of Tag and replicated much less efficiently. Quantitation of 
infectious virus, via the fluorescent forming unit assay, suggested that HIVSGD BKPyV had 
                                                          
1
 This chapter previously appeared as an article in the Journal of Virology. The original citation is as follows: 
Burger-Calderon, R. et al. “Replication of Oral BK Virus in Human Salivary Gland Cells”, J. Virol. 2014, 88(1): 
559. 
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preferential tropism for salivary gland cells over kidney cells. Similarly, results suggested that 
kidney-derived virus had preferential tropism for kidney cells over salivary gland cells. Evidence 
of HIVSGD-derived BKPyV oral tropism and adept viral replication in human salivary gland 
cells corroborated the potential link between HIVSGD pathogenesis and BKPyV. 
 
Introduction 
BK polyomavirus (BKPyV) was first isolated from the urine of a renal allograft recipient 
in 1971 and was subsequently identified as a member of the small DNA tumorvirus family (1). 
BKPyV infection is ubiquitous and seroconversion of up to 90% of the world’s population by the 
age of 10 suggests that BKPyV transmission takes place during early childhood (2, 3). BKPyV 
primary infection is asymptomatic and persists latently in the kidney of immunocompetent 
individuals (4). Reactivation occurs under immune-suppressed conditions, such as those 
experienced by patients receiving organ transplants and patients infected with HIV (5). BKPyV 
reactivation among kidney transplant patients has been associated with BKPyV nephropathy 
(BKN), which is by far the most significant complication among renal transplant patients (6-8).  
The BKPyV genome (5 kb) is divided into three major components: the early region, the 
late region and the bidirectional viral promoter, also known as non-coding control region 
(NCCR). The NCCR is the major determinant of in vitro replication (9) and is arbitrarily divided 
into five block sequences: O (142 bp), P (68 bp), Q (39 bp), R (63 bp) and S (63 bp). The blocks 
contain the origin of DNA replication and an array of transcription factor binding sites (TFBS) 
(10-13). The late region encodes the agnoprotein and the structural proteins VP1, VP2 and VP3 
(4, 14). The early BKPyV genome region encodes the non-structural viral proteins: large, small 
and mini T antigen (Tag). Large Tag is critical for the viral lifecycle and drives the host cell into 
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the S phase (4, 15-17). Viral DNA synthesis is initiated by Tag’s helicase activity, which 
unwinds the origin of replication within the viral NCCR promoter (4) and subsequently recruits 
DNA synthetic machinery (5). As the major BKPyV transforming viral oncoprotein, Tag 
interacts with both pRb and p53, instigating deregulated cell growth. The Tag transformation 
potential is linked to the p53-binding domain located near the carboxy- terminus of the protein 
(18). Upon initiation of DNA replication, Tag induces late viral gene expression, and represses 
early gene expression (19).  
Given its historic link to renal pathogenesis, BKPyV has been considered a kidney-tropic 
virus. Data however suggest a connection between BKPyV and the oral compartment. Both 
respiratory (5) and fecal-oral (20) routes have been suggested as likely transmission pathways. 
BKPyV DNA has been detected in tonsillar biopsies from immunocompetent children (21-23) 
and nasopharyngeal aspirates of immunocompromised and immunocompetent individuals 
(children and adults) (24). Finally, our group has suggested a potential link between BKPyV and 
the oral malady HIV-associated Salivary Gland Disease (HIVSGD) (25, 26).  
HIVSGD is among the most important HIV/AIDS-associated lesions (27). HIVSGD 
pathogenesis is not well understood and present treatment strategies focus solely on symptom 
alleviation (25). HIVSGD is characterized by salivary gland enlargement and damage that incites 
xerostomia (28-31). HIVSGD diagnosis has been tied to an increased risk of lymphoma 
development in HIV-infected individuals (32). Finally, affected patients may suffer stigma as 
HIVSGD’s outward appearance suggests HIV infection. As for HIVSGD etiology, molecular 
evidence has previously established an association between polyomaviruses (PyV) and salivary 
gland pathology. Rodent models demonstrated that PyV injection resulted in salivary gland 
tumors in mice (33). In vivo, HIVSGD patients shed twenty-fold higher levels of BKPyV in 
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throatwash (TW) and plasma (viremia) compared to HIV positive patients without HIVSGD and 
compared to HIV negative individuals (25). Moreover, our group has demonstrated successful 
replication of a BKPyV laboratory strain in human salivary gland cell lines (HSG and HSY) in 
vitro (26). While contemporary advances have allowed efficient in vitro cultivation of archetype 
BKPyV in kidney cells (providing Tag in trans (34)), studies analyzing clinical BKPyV isolates 
have been limited, kidney-focused and have not assessed salivary gland infection (9, 35-38). 
Molecular evidence demonstrates that the in vivo replication compartments of urine and plasma-
derived BKPyV are distinct (39, 40). Similarly, the salivary gland may provide an additional 
BKPyV replication compartment in HIVSGD (41).  
In the current study HIVSGD-derived BKPyV underwent successful replication in human 
salivary gland (HSG) cells, providing proof of concept that salivary glands of HIVSGD patients 
may be replication competent. We further compared the replication potential of TW-derived 
BKPyV clinical isolates to urine- and laboratory-derived BKPyV in human salivary gland (HSG) 
cells and in kidney cells (Vero). The replication potential of the clinical isolates HIVSGD-1 and 
HIVSGD-2 differed greatly despite the two isolates bearing the same NCCR architecture 
(OPQPQQS) and their genomes differing by only three nucleotides. The replication inefficiency 
of HIVSGD-2 was likely caused by the introduction of a stop codon that produced a truncated 
Tag mutant. Interestingly, HIVSGD-1 BKPyV encoded full-length Tag, replicated efficiently, 
and displayed preferential tropism for salivary gland cells over kidney cells, as suggested by 
quantitation of infectious virus.   
 
 
 
  
 
84 
Materials and Methods 
Patient Information and Sample Collection 
HIVSGD positive individuals from the UNC hospital dental clinic were selected for 
throatwash (TW) collection under IRB approved studies. Urine samples from HIV negative 
patients were kindly donated and collected under the supervision of Dr. Nickeleit at UNC 
hospitals. Patient samples were centrifuged, DNAse treated and DNA isolated via Qiagen 
DNeasy kit as described by the manufacturer. 
BKPyV NCCR Sequencing  
The BKPyV NCCR was PCR amplified (Vent polymerase, New England BioLabs Inc.) 
with primers BKPyVTU1F and BKPyVTU1R (37) from patient sample DNA and products 
subsequently sequenced by Genewiz (www.genewiz.com). NCCR amplification and sequencing 
was repeated a minimum of three times per patient sample. Resulting NCCR nucleotide sequence 
was analyzed and aligned by the Vector NTI program. Vector NTI identified the block motifs 
with minimum similarity of 70% to original block sequences (10). 
Whole Genome BKPyV Cloning  
Whole genome (wg) BKPyVs, including the naturally occurring BamH1 restriction 
fragment recognition sites, were PCR amplified from clinical samples with primers BKPyVWGF 
(VP1 Forward: 5’-GCGGGATCCAGATGAAAACCTTAGG-3’) and BKPyVWGR (Reverse: 
5’- GCGGGATCCCCCATTTCTGG-3’), using the Expand Long Range dNTPack (Roche) as 
described by manufacturer. Amplified wg BKPyV products were purified by QIAquick PCR 
Purification Kit (QIAGEN) as described by manufacturer. Purified HIVSGD-2 and U1 wg 
BKPyV DNA was cloned via the TOPO TA Cloning Kit (Invitrogen) as described by 
manufacturer. Purified HIVSGD-1 DNA and pUC18 vector (2.6 kb) from Stratagene were 
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digested separately with restriction endonuclease BamH1, isolated, ligated via T4 DNA Ligase 
(BioLabs). DH5 alpha bacterial cells (Invitrogen) were transformed with the HIVSGD-1, 
HIVSGD-2 and MM ligation products. All bacterial-derived constructs were isolated via 
QIAfilter Plasmid Midi Kit (QIAGEN) post-24hrs incubation at 37 °C.     
Virus, Transfection and Infection Conditions 
Clinical BKPyV cloned by us: HIVSGD-1, HIVSGD-2 and U1. 
Commercially available infectious BKPyV: VR837 (ATCC) 
Laboratory-derived Dunlop BKPyV clone, kindly donated by Dr. Michael J. Imperiale  
Laboratory-derived MM (ATCC 45026) BKPyV clone (42) is commercially available. 
Interestingly, MM BKPyV NCCR and Tag sequencing results obtained in this study 
(BankIt1648707 KF445133 and BankIt1648650 and KF445132 respectively) were not 
homologous with previously published sequence (GenBank V01109).   
BKPyV Transfection: Cloned BKPyV was cut out of its respective backbones by over 
night (37°C) BamH1 endonuclease digestion; HIVSGD-1 (pUC18), HIVGD-2 (pCR2.1), U1 
(pCR2.1) and MM (ATCC 45026, pBR322). Wg BKPyV cloned into pCR2.1 were digested with 
endonuclease Taq1a for an additional 3hrs at 65°C. Wg BKPyV cloned into pBR322 was 
digested with endonuclease BsAa1 for an additional 3 hrs at 37°C. All digested samples were run 
on a 2% EtBr agarose gel and 5kb bands isolated in order to obtain wg BKPyV. Wg BKPyV 
DNA was purified via QIAquick Gel Extraction Kit (Qiagen) as instructed by manufacturer and 
re-ligated via T4 DNA Ligase (BioLabs), over night at 16°C. Episomal viral DNA was 
subsequently purified via phenol-chloroform. Single layers of HSG and Vero cells were 
passaged by trypsinizing (~15 mins) and resuspended in 2% FBS and 1% penicillin–
streptomycin culture medium and subsequently seeded at ~30% confluency. Episomal BKPyV 
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was introduced into the cells via lipid-mediated gene delivery, using TransIT®-LU1 (Mirus) 
according to the manufacturer’s protocol. Media was changed 48 hrs pt. Media and cells were 
collected at different time points for further analysis. 
Infection: Equal amounts of infectious clinical and laboratory strain BKPyV (determined 
via FFA) were used for infection of HSG and Vero cells: Part 2 of the in vitro model (Fig. 4). 
Supernatant of transfected HSG cells carrying infectious BKPyV were passed through 0.45μm 
filters and added to fresh HSG and Vero cells. 
Cell Culture  
Human submandibular salivary gland epithelial cells, a.k.a. HSG cells, from 
adenocarcinoma. (43) were obtained from Dr. B. Baum (NIH) and maintained in McCoy’s 5A 
medium (Sigma), supplemented with 10% fetal bovine serum (FBS; Sigma), and 1% penicillin–
streptomycin (P/S; Gibco). African green monkey kidney epithelial cells, a.k.a. Vero cells, were 
obtained from the American Type Culture Collection (ATCC), maintained in Dulbecco's 
minimal essential medium (DMEM; Sigma), supplemented with 10% FBS and 1% P/S. Both cell 
lines were incubated in humidified atmosphere at 37°C and 5% CO2. 
Reporter Construct Formation 
Primers BKPyVTU1F and BKPyVTU1R (37) were used to amplify the BKPyV NCCR 
with flanking Sac1 restriction fragment recognition sites via PCR (Vent polymerase, New 
England BioLabs Inc.). Amplified DNA products were purified by QIAquick PCR Purification 
Kit (QIAGEN) as described by manufacturer. Purified DNA and pGL3-Basic vector (5 kb) from 
Promega were digested separately with restriction endonuclease Sac1, isolated and ligated via T4 
DNA Ligase (BioLabs). DH5 alpha bacterial cells (Invitrogen) were transformed with products 
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and constructs were isolated via QIAfilter Plasmid Midi Kit (QIAGEN) after 24hrs incubation at 
37°C.    
BKPyV NCCR Promoter Activity 
HIVSGD-1 and HIVSGD-2 BKPyV NCCR promoter activity was measured with and 
without the presence of wild-type large Tag in HSG cells via the luciferase (luc) reporter assay 
(pGL3 vectors, Promega). Cloned reporter constructs (1 μg) were transfected into HSG cells via 
lipid-mediated gene delivery, using TransIT®-LU1 (Mirus) according to manufacturer’s 
protocol.  pCDNA RFP was co-transfected along with and without Tag (0.5  g) expression 
plasmid (in pCMV myc; kindly provided by Dr. L. Jeffers). The Tag expression plasmid encoded 
for VR837 BKPyV-derived full-length wild-type large Tag. Cells were collected from each 
treatment according to the Luciferase Assay protocol (Promega) at 48 hrs. Luc activity of 
HIVSGD clones, pGL3 control vector (positive control, not shown) and pGL3 basic vector 
(negative control) were measured in a microplate format by the LMAX luminometer (Molecular 
Devices). HIVSGD luc activity was normalized to pGL3 basic. 
Fluorescent Focus Assay (FFA) 
Vero cells (50% confluency) were infected with varying volumes of filtered (0.45µm) 
supernatant from transfected HSG cells and incubated over four days. Where low levels of virus 
were present, higher volumes were utilized in order to attain infection. These differences in 
volumes used for Vero cell infection are accounted for in fluorescent forming units (FFU)/µl 
calculations (44). Vero cells were fixed in 50:50 Methanol/Acetone, air-dried and stored at -80 
°C over night 4dpi. Cells were rehydrated with phosphate buffered saline (PBS) the next day and 
incubated with anti-JC/BK polyomavirus primary antibody NCL JCBK (Novocastra, Leica; 1:10 
dilution in PBS for 30 mins at 37 °C and 30 mins at room temperature (RT). The secondary 
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antibody goat anti-mouse Alexa Flour 488 (Life Technologies; 1:100 dilution in PBS) was added 
for 1hr at RT after washing the cells with PBS twice. Cells were washed with PBS prior to 
DAPI/DNA stain addition (1:10,000) and fluorescent microscopy analysis (Olympus IX81). 
BKPyV infected cells were counted at 20X magnification for a minimum of 10 fields per dish 
and FFUs were calculated as described in (44). FFU values were graphed for each treatment and 
depicted as FFU/μl or FFU/ μl +1 in order to transform the zero values for the log10-based y-
axis. 
BKPyV DNA detection via Southern Blot hybridization 
BKPyV episomes were transfected (see above for BKPyV DNA and transfection details) 
into HSG cells at the following concentrations 0.39 μg Dunlop, 0.45 μg U1, 0.72 μg HIVSGD-1, 
0.9 μg MM and 0.9 μg pcDNA3 DNA. Differential amounts of DNA were transfected for the 
Dpn1 resistance assay. Hence, this assay was not intended to compare BKPyV replication levels. 
All succeeding experiments were intended to evaluate relative viral replication levels and 
transfections were done with equal amounts of BKPyV DNA. Low molecular weight DNA was 
isolated from HSG cells 6dpt by a previously described (45) modified Hirt Method, digested by 
endonucleases Sau3a and Dpn1, electrophoresed on a 7% agarose gel and transferred onto a SPC 
membrane by the Whatman Nytran SPC Turbo Blotter (General Electric), as described by the 
manufacturer. Membrane-associated BKPyV DNA was detected by hybridization to randomly 
primed wg MM BKPyV (ATCC 45026) 
32
P-labeled DNA probe and exposed to film (Kodak). 
Expected MM BKPyV DNA band sizes according to mapped Dpn1/Sau3a cut sites: 1522, 681, 
529, 451, 432, 346, 294, 230, 216, 129, and 116 bp. 
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Encapsidated viral DNA isolation and qPCR amplification 
Transfected and infected HSG and Vero cell supernatant was passed through 0.45μm 
filters and DNAse treated (Promega), removing debris/cells and non-encapsulated viral DNA 
respectively. DNA was isolated using QIAamp DNA Blood Mini Kit (QIAGEN) as instructed by 
the manufacturer. Viral load (VL) was quantified via quantitative real-time PCR (qPCR) analysis 
using Roche LightCycler 480 Syber Green I Master Mix as a detector in the Roche Light Cycler 
480 by using previously published primers for VP1 (46). BKPyV plasmid, kindly donated by Dr. 
Nickeleit, was used to establish a standard curve and for subsequent quantification of 
encapsidated viral genomes present in the cellular supernatant.  
Transmission Electron Microscopy (TEM) 
Three-milliliters of transfected, infected or control HSG and Vero cell supernatant was 
spun at 13,000 rpm for 30 mins at 4°C in order to remove cellular debris and then at 290,000 rpm 
for 1hr at 4°C by ultracentrifugation in order to concentrate BKPyV and decrease the suspension 
volume. Metal grids were subjected to purified supernatant and treated with 2% uralic acetate for 
negative staining. Virus was subsequently visualized via EM910 transmission electron 
microscopy (Zeiss) utilizing a Gatan SC1000 camera.  
Immunoblotting 
Episomal BKPyV DNA (0.3 μg) was transfected into HSG cells and whole cell lysates 
harvested with 1% SDS lysis buffer 4 days post-transfection. Protein was quantified using the 
BioRad protein assay, and equal amounts electrophoresed on a 10% Bis–Tris polyacrylamide 
minigel (Invitrogen). Tag antibody PAb416 (Genetex; 1:200) in 5% non-fat dry milk in 0.1% 
Tween-20 PBS (PBS-T) was used to detect Tag expression post wg BKPyV transfection of HSG 
cells. cMyc-tagged Tag expression was detected via anti c-Myc antibody (Santa Cruz; 1:1000) 
  
 
90 
post-reporter construct transfection of HSG cells. Actin expression was detected via the (C-11)-R 
sc-1615-R antibody (Santa Cruz Biotechnology; 1:1000) in 5% non-fat dry milk (as above). 
Blots were washed in PBS-T three times for 10 mins at RT and probed with a horseradish 
peroxidase-conjugated secondary antibody (Promega 1:10,000), exposed to SuperSignal West 
Pico Chemiluminescent substrate (Thermo scientific) and exposed to film (Kodak). Band 
intensity was measured via densitometry. Relative band density was determined by normalizing 
Tag to actin expression via Gene Tools from Syngene. 
 
Results 
HIVSGD-1 and HIVSGD-2 BKPyV isolation and sequence analysis  
Throatwash (TW) samples were collected from two HIV positive subjects with diagnosed 
HIVSGD. To obtain kidney-derived BKPyV, urine was collected from an HIV negative lung 
transplant patient with diagnosed BKPyV nephropathy (BKN). Patient demographic data (HIV 
status, other clinical status, age and sex) was collected and BKPyV viral load (VL) was 
determined. Whole genome BKPyVs were cloned from each sample and the viral NCCR 
promoters were sequenced (Table 1). All three clinical samples had high VLs ranging from 
1.7x10
5
 to 1.7x10
9 
copies/ml. Similar to the laboratory strain MM, both of the HIVSGD-derived 
BKPyV isolates had OPQPQQS NCCR block alignments. The transplant urine sample carried 
BKPyV with a OPQ NCCR block alignment. The NCCR architecture of previously studied 
laboratory strains MM, Dunlop and VR837 BKPyV were sequenced as a control measure and 
recovered correctly (Table 3.1). Alignment of the whole genome nucleotide sequences of 
HIVSGD-1 and HIVSGD-2 BKPyV detected 99.9% whole genome similarity. The three single 
nucleotide differences were: (1) a single bp thymidine (T) deletion between sequences that 
  
 
91 
encoded agnoprotein and VP2, (2) a thymidine/cytidine transition (T/C) within the NCCR and 
(3) a single bp adenosine (A) deletion within the Tag coding sequence (Fig. 3.1A). All three 
mutations were analyzed for potential biological significance. The T deletion located between 
the genes encoding for agnoprotein and VP2 was assumed to be least important since this 
mutation did not affect either of the adjacent open reading frames, VP2 and agnoprotein (Fig. 
3.1B).  
 
 
 
Table 3.1. Demographics and viral characterization of clinical BKPyV isolates. Clinical 
whole genome BKPyV was cloned from two HIVSGD TW samples (HIVSGD-1 and HIVSGD-
2) and one transplant patient urine sample (U1) for in vitro analysis. Laboratory strains Dunlop, 
VR837 and MM served as laboratory control strains. 
a
Patient age at time point of sample 
collection (yrs). 
b
BKPyV viral load (copies/ml). 
c
Non-coding control region. 
d
HIV-associated 
Salivary Gland Disease. 
e
Throatwash. 
f
Male. 
g
BKPyV nephropathy. 
 
 
Patient-derived  HIV Status  Clinical Status Source Agea    Gender  VLb NCCRc  
HIVSGD-1 HIV +  HIVSGDd TWe 47 Mf 1.76x105 OPQPQQS 
HIVSGD-2  HIV +  HIVSGDd TWe 60 Mf 2.57x105   OPQPQQS 
U1 HIV -  BKNg, lung transplant urine  31 Mf 1.79x109        OPQ 
Laboratory-derived Origin   NCCR 
   Dunlop      laboratory-derived clone     OPPPS 
   VR837       ATCC, infectious virus     OPQPQS 
   MM             ATCC, clone   OPQPQQS 
Table 1
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VP2 protein  AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA    MAAGAAAAAAAAL AAAAL  
HIVSGD-1  GACTCTGTAAAAGACTCCTAGGTAAGTAATCCCTTTTTTTTTGTATTTCCAGGTTCATGGGTGCTGCTCTAGCACTT  
HIVSGD-2  GACTCTGTAAAAGACTCCTAGGTAAGTAATCCCTTTTTTTT-GTATTTCCAGGTTCATGGGTGCTGCTCTAGCACTT  
Agnoprotein  DAASAAVAAKAADAASAA.   
5’ 
 
 3’ 
 
  NCCR 
Agno 
VP3 
VP1 VP2 
Tag 
tag 
Intron 
B
a
m
H
1
 
1 2 3 
Figure 1A
Figure 1B
A 
 
 
 
B 
 
Figure. 3.1. Whole genome sequence comparison between HIVSGD BKPyV isolates 
revealed three polymorphisms. A. Schematic shows linearized BKPyV genome and encoded 
viral proteins. Black bars and numbers denote the three single base pair polymorphisms (1-3) 
differentiating whole genomes HIVSGD-1 and HIVSGD-2: 1. Thymidine deletion between the 
open reading frames (ORFs) encoding for agnoprotein and VP2. 2. Thymidine to cytidine 
transition within the non-coding control region (NCCR). 3. Adenosine deletion within the ORF 
encoding for Tag. B. The depicted DNA stretches show the thymidine deletion between the 
ORFs encoding for agnoprotein and VP2 found within HIVSGD-2 but not HIVSGD-1.  
 
 
The HIVSGD-1 and HIVSGD-2 NCCRs differed by a T/C transition located within the S 
block of the viral promoter. To assess the potential biological significance of this nucleotide 
transition, putative human transcription factor binding sites (TFBS) were predicted within this 
region of the NCCR. Identical TFBS (Smad3, Smad4, C/EBPα, AP-2αA and E47) were 
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HIVSGD-2  GACTCTGTAAAAGACTCCTAGGTAAGTAATCCCTTTTTTTT-GTATTTCCAGGTTCATGGGTGCTGCTCTAGCACTT  
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predicted for both HIVSGD-1 and HIVSGD-2 (Fig. 3.2A). Next, in vitro promoter activity was 
assessed to determine whether the transition led to differential promoter activity despite 
homologous TFBS. HIVSGD-1 and HIVSGD-2 NCCR-pGL3 reporter constructs were generated 
in the early and in the late directions. NCCR reporter and pGL3 basic control constructs were co-
transfected with (black bar) and without (white bar) full-length VR837-derived Tag in HSG cells 
(Fig. 3.2B and 3.2C). Promoter activity was determined as fold luciferase (luc) induction over 
pGL3 basic. Tag protein expression was confirmed by immunoblot analysis. Similar promoter 
activity levels were achieved for both HIVSGD-1 and HIVSGD-2 in the early direction, 
independent of Tag presence or absence: 2.7 vs. 2.4 fold and 12 vs.11.4 fold induction 
respectively (Fig. 3.2B). HIVSGD-2 promoter activity was higher than HIVSGD-1in the late 
direction independent of Tag presence or absence: 54 vs. 31 fold and 7 vs. 2 fold induction 
respectively (Fig. 3.2C). Overall, NCCR activity differences between HIVSGD -1 and HIVSGD-
2 were nominal. Functional Tag is known to suppress the BKPyV NCCR in the early and induce 
in the late direction (4). Hence, the observations made here suggested that the cloned HIVSGD 
NCCRs were functional within the reporter constructs.  
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A 
B C
 
 
Figure. 3.2. Similar trends in promoter activity were detected for HIVSGD-1 and 
HIVSGD-2 BKPyV. A. Schematic represents HIVSGD BKPyV NCCR block architecture and 
thymidine/cytidine transition within the S block. Identical human putative transcription factor 
binding sites (TFBS) were predicted for HIVSGD-1 and HIVSGD-2 despite the transition: E47, 
Smad3, Smad4, C/EBPα (C/EBP) and AP-2αA (AP). B./C. Graphs show NCCR luciferase (luc) 
activity in the presence and absence of wild-type Tag for the early (B.) and the late (C.) promoter 
direction. Luc activity was depicted as fold induction relative to pGL3 basic (pGL3 B) and error 
bars represent standard deviations. Tag (Myc-tagged Tag ~82kDa) and actin (~45kDa) protein 
expression were visualized by immunoblotting.  
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The adenosine (A) deletion detected within the Tag nucleotide sequence of HIVSGD-2 
but not within HIVSGD-1 was analyzed for potential biological significance (Fig. 3.3A). 
ClustalW (47) based Tag amino acid sequence alignment of HIVSGD-1, HIVSGD-2 and the 
SV40 pRb binding domain (1GH6:ChainA) located the deletion distal to the pRb binding site of 
the Tag viral protein and detected 82.5% sequence identity between SV40 and HIVSGD-1 full-
length Tag. The deletion was predicted to introduce an early stop codon that truncated the 
original Tag nuclear translocation signal from PKKKRKV to PKKKER (Fig. 3.3B). HIVSGD-2 
Tag, that carried the early stop codon, was calculated to express a Tag mutant of 15.6 kDa 
instead of the 80.5 kDa full length Tag expressed by BKPyV HIVSGD-1 (Fig. 3.3C). A 
schematic model of full-length HIVSGD-1 and truncated HIVSGD-2 Tag was created using the 
HHPred and MODELLER structural prediction tools (48). This truncating deletion was likely the 
most significant of the three nucleotide mutations due to the importance of Tag for the viral life 
cycle. 
Assessment of HIVSGD BKPyV replication in vitro: post-transfection 
The post-transfection replication potential of HIVSGD-1 and HIVSGD-2 BKPyV was 
assessed within human salivary gland and kidney cells (Fig. 3.4). BKPyV clones of throatwash-
derived HIVSGD-1 and HIVSGD-2, kidney-derived U1 and laboratory strains MM and Dunlop 
were used for in vitro analysis (Table 3.1).  Laboratory strain VR837 was used as infectious 
BKPyV positive control. 
The capacity for de novo BKPyV DNA synthesis post-salivary gland cell (HSG)-
transfection was determined. HSG cells were transfected with HIVSGD-1 (encoding full-length 
Tag), U1, MM and Dunlop BKPyV episomes and evaluated using a restriction enzyme resistance 
assay. The Dpn1/Sau3a enzyme resistance assay allowed discernment between transfected 
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BKPyV genomes (methylated bacterial plasmid DNA) and BKPyV genomes made de novo (non-
methylated eukaryotic DNA). DNA was isolated six days post-transfection (dpt), digested with 
Dpn1 and Sau3a and visualized by Southern blot (Fig. 3.5). Dpn1 and Sau3a cleaved the same 
restriction sites, but Dpn1 digested exclusively bacterial and not eukaryotic methylation patterns, 
while Sau3a digestion was methylation pattern-independent (9, 49). While multiple bands were 
detected post Sau3a digestion, clear differences in the banding pattern are detected upon 
comparison to Dpn1 digestion for both HIVSGD-1 and of MM BKPyV DNA. The detection of 
HIVSGD-1 (Fig. 3.5B; lane 5 vs. lane 6) and MM (Fig. 3.5A; lane 7 vs. lane 8) DNA bands post-
Sau3a, but not post-Dpn1 digestion, in the range of 100bp to 1600bp, suggested that the detected 
BKPyV DNA was of eukaryotic origin and therefore HIVSGD-1 and MM BKPyV underwent 
whole genome replication in HSG cells. While not all bands are distinct, they corresponded to 
mapped MM BKPyV (GenBank V01109.1) Dpn1/Sau3a cut sites resulting in fragments ranging 
from 1kb to 1.6kp. BKPyV DNA bands between 1.6kb and 5kb and are likely due incomplete 
digestion and prominent bands at ~5kb (Fig. 3.5A, lane 7) correspond to whole genome BKPyV 
as previously reported (9). In summary, the enzyme resistance assay suggested that both 
HIVSGD-1 and MM BKPyV DNA were made de novo in transfected HSG cells. The intention 
of this assay was not to compare BKPyV replication levels, but to firmly establish that HIVSGD-
1 BKPyV could replicate its DNA in human salivary gland cells. Faint kidney-derived U1 
BKPyV DNA bands were visualized upon long exposure, suggesting potential replication (Fig. 
3.5A, lane 3 and lane 4).  
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Figure. 3.3. HIVSGD BKPyV Tag sequence analysis revealed a premature stop codon in 
HIVSGD-2. A. The depicted BKPyV DNA sequences show the Tag adenosine (A) deletion 
found within HIVSGD-2 but not HIVSGD-1. B. Alignment of the Tag amino acid sequences of 
HIVSGD-1, HIVSGD-2 and the SV40 pRb binding domain (1GH6:chainA) via ClustalW 
localized the deletion distal to the pRb binding domain. The deletion was predicted to alter the 
original PKKKRKV nuclear translocation signal found within HIVSGD-1 into PKKKER (see 
square) in HIVSGD-2. C. The deletion was further predicted to introduce an early stop codon 
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(see square) and subsequently truncate HIVSGD-2 Tag. Schematic models of full-length 
HIVSGD-1 Tag (wildtype, 80.5 kDa protein) and truncated HIVSGD-2 Tag (15.6 kDa protein) 
were created using the HHPred and MODELLER structural prediction servers (sequence and 
model coloring coincide). Left depicting full-length and right truncated sequence and schematic 
models respectively.  
 
 
Figure. 3.4. Multi-step salivary gland cell in vitro system for viral fitness assessment. The 
diagram shows the two parts of the in vitro model: Part 1: human salivary gland cell (HSG) 
transfection with episomal BKPyV. Part 2: HSG and Vero cell infection with transfection-
derived BKPyV.  
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Figure. 3.5. HIVSGD-1 and MM BKPyV DNA were made de novo in human salivary gland 
cells. Panel A and panel B show the same blot at different exposures (A. 15 min and B. 1 min 
exposure). Low molecular weight DNA was isolated 6 days post-HSG cell transfection with 
Dunlop, MM, U1 and HIVSGD-1 BKPyV DNA. pcDNA3 DNA transfection served as negative 
control. Isolated DNA was digested with endonucleases Dpn1 (D1) and Sau3a (S3) and 
visualized via Southern blot. Dpn1 and Sau3a cut the same sites, but Dpn1 recognizes 
exclusively bacterial and not eukaryotic methylation patterns. DpnI resistance assay allows 
differentiation of BKPyV DNA that was transfected (of bacterial origin) and BKPyV DNA that 
was made de novo by HSG cells (of eukaryotic origin). Detection of stronger DNA bands (at 
expected size) post-Sau3a digestion vs. post-Dpn1 digestion as seen for BKPyV HIVSGD-1 and 
MM DNA (lane 5 vs. lane 6 and lane 7 vs. lane 8) suggested that BKPyV DNA was made de 
novo by transfected HSG cells. No Dunlop BKPyV DNA (lanes 1 and 2) and faint U1 (lanes 3 
and 4) bands were found.  
Tag protein expression reflects successful transition through the early BKPyV life cycle. 
The consequence of the HIVSGD-2 Tag mutation on its protein expression was assessed. Levels 
of Tag protein expression were determined five days post-HSG transfection and compared 
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among clinical isolates HIVSGD-1, HIVSGD-2, U1 and laboratory strain MM BKPyV by 
Western Blot (Fig. 3.6A). The laboratory strain Dunlop BKPyV was not further assessed as HSG 
cells were unable to support DNA replication (Fig. 3.5). The harvest time point was selected 
based on previous studies that detected Tag protein expression 4 dpt (26, 34). Tag was 
normalized to beta-actin expression, a loading control (Fig. 3.6B). Highest Tag expression was 
detected for HIVSGD-1 (full-length, ~80kDa), followed by MM and U1 BKPyV (Fig. 6B). Both 
full-length and truncated (~15 kDa, not shown) forms of Tag protein were below the level of 
immunoblot detection for HIVSGD-2. No Tag protein was detected in mock infected negative 
controls. 
To further evaluate the replication potential of each isolate, encapsulated BKPyV virions, 
released from transfected HSG cells were quantified. At 6 dpt, BKPyV viral loads (VLs) of 
filtered and DNAse treated media from transfected HSG cells were determined by quantitative 
real time PCR (qPCR). The supernatant of all BKPyV transfected HSG cells carried 
encapsulated BKPyV DNA. MM and HIVSGD-1 transfected HSG cells supported similarly high 
VLs, with 3.5x10
7 
and 2.4x10
7
 copies/μl respectively. U1 and HIVSGD-2 VLs were significantly 
lower than HIVSGD-1, with VLs of 1.4x10
3
 and 2.6x10
2
 copies/μl respectively (Fig. 3.7A). 
Differences between HIVSGD-2 and U1 VLs each compared to HIVSGD-1 were highly 
statistically significant (p=0.0001). HIVSGD-1 was the most efficient replicator, followed by 
MM, U1 and HIVSGD-2. Interestingly, low levels of HIVSGD-2 virions were detected, despite 
the Tag mutation and lack of Tag expression, described above. To confirm the presence of 
BKPyV virions, HSG supernatant (6 dpt) was analyzed by transmission electron microscopy 
(TEM). BKPyV particles were detected by TEM for HIVSGD-1 and MM but were not detected 
for lower replicators U1 or HIVSGD-2 BKPyV (Fig. 3.7B). Morphological features of HIVSGD-
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1 and MM BKPyV were reminiscent of icosahedral (T=7) symmetrical BKPyV particles with a 
diameter of 45nm (4) that have been visualized in in vitro-derived supernatants (34) and patient-
derived fluids (50).  
The titer of infectious HSG transfection-derived BKPyV virions was determined via the 
fluorescent focus assay (FFA). FFA provided antibody based detection of intracellular PyV 
proteins post-infection (44). Vero cells were exposed to HSG cell supernatant containing 
BKPyV, incubated for 4 days and infected cells were quantified. Intracellular PyV structural 
proteins (VP1, VP2, VP3; green) were detected for HIVSGD-1, HIVSGD-2 and laboratory strain 
MM, but not for U1 BKPyV or mock infection (Fig. 3.8). As in previous studies (44), PyV 
proteins were detected exclusively in the nucleus (DAPI/blue) of infected Vero cells (Fig. 3.8C). 
Infectious BKPyV VR837, which has been shown to replicate permissively in HSG and Vero 
cells (26) served as positive control.  HIVSGD-1, MM and HIVSGD-2 scored 80, 50 and 1 
FFU/μl respectively. HIVSGD-1 infected significantly more cells than laboratory strain MM 
(p=0.01) and HIVSGD-2 (p=0.0001, Fig. 3.8B). Despite detectable U1 VLs by qPCR , U1 
BKPyV intracellular proteins were not detected by FFA.  
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A 
 
 
 
 
 
 
          B 
 
 
 
 
 
 
 
 
Figure 3.6. HIVSGD-1 but not HIVSGD-2 expressed BKPyV Tag protein post-HSG cell 
transfection. A. Panel shows protein bands visualized via Western Blotting (WB). Total cell 
lysates were harvested 5 dpt and proteins analyzed by WB, probing for viral Tag (~82kDa) and 
cellular β–actin (~45kDa, loading control). Tag expression levels ranked (high to low): 
HIVSGD-1, MM and U1 BKPyV. No HIVSGD-2 Tag protein was detected. B. The chart shows 
relative protein band density, measured by densitometry and normalized to actin. 
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Figure 3.7. Significantly higher viral loads were detected for HIVSGD-1 than for HIVSGD-
2 BKPyV post-HSG cell transfection. A. The chart shows viral loads (VL) measured from the 
supernatant of HSG cells transfected with BKPyV genomes. HSG cell supernatant was harvested 
6 dpt, filtered, DNAse treated, BKPyV quantified via qPCR and depicted as BKPyV copy/μl. VL 
levels ranked (high to low): MM, HIVSGD-1, U1 and HIVSGD-2 BKPyV. The p values were 
determined via One-way ANOVA and error bars represent standard deviations. B. 
Representative images visualizing HIVSGD-1 and MM BKPyV virions from HSG cell 
supernatant via transmission electron microscopy (TEM) 6 dpt (see black arrows).  
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Figure 3.8. Infectious HIVSGD-1, HIVSGD-2 
and MM BKPyV progeny were detected post-
HSG cell transfection. A. Representative images 
showing HIVSGD-1, HIVSGD-2, MM and VR837 
BKPyV infected Vero cells. Transfected HSG cell 
supernatant was transferred onto Vero cells and 
BKPyV infected cells visualized via FFA. BKPyV 
protein (green) was detected in the nucleus 
(DAPI/blue). VR837 infection served as positive control. The number of infected cells was 
counted for each treatment in a minimum of 10 fields at 20X magnification and FFU/µl values 
were calculated. B. FFU values were graphed for each treatment and depicted as FFU/µl+1. The 
error bars represent the standard deviation and the p values were assessed via One-way ANOVA. 
C. Representative images at higher magnification: IFA, 60X, oil immersion. 
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Clinical and laboratory strain BKPyV: post-infection  
Infections were performed to assess cell-type dependent reproduction of HSG-derived 
BKPyV (Part 2, Fig. 3.4). HSG and Vero cells were simultaneously infected with equal amounts 
of BKPyV that originated from HSG cell transfections; an equivalent of 200 FFU for each viral 
substrain (Part 1, Fig. 3.4). Encapsulated BKPyV virions released from infected HSG and Vero 
cells were quantified by qPCR at 2, 4, 6 and 8 days post-infection (dpi). HIVSGD-1 and MM 
BKPyV VLs increased by 4 and 3 orders of magnitude, respectively, in HSG cells over 8 dpi. In 
Vero cells, HIVSGD-1 and MM BKPyV VLs increased by 5 and 4 orders of magnitude 
respectively over 8 dpi (Fig 3.9A). These results indicated that HSG cell transfection-derived 
HIVSGD-1 and MM BKPyV were infectious and underwent replication in both HSG and Vero 
cells. Encapsulated HIVSGD-2 and U1 BKPyV DNA were not detected from either cell type. 
Interestingly, VL kinetics of BKPyV in Vero and HSG cells were similar upon infection, 
suggesting that virion production was equally efficient in both HSG and Vero cells post-
infection. TEM confirmed BKPyV virion presence and morphology via (8 dpi). Visualized 
particles were classified as BKPyV based on capsid morphology and diameter. BKPyV particles 
were detected in the media of HSG cells infected with HIVSGD-1 and in Vero cells infected 
with HIVSGD-1 and MM BKPyV (Fig. 3.9B). U1 and HIVSGD-2 virions were not identified 
upon inspection. MM BKPyV infected HSG cell media was not analyzed by TEM.  
The infectivity of HSG and Vero derived BKPyV progeny was assessed by FFA (Fig. 
3.10). Vero cells were infected with HSG and Vero cell media 8 dpi and incubated over 4 days. 
PyV structural proteins (VP1, VP2, VP3; green) were detected at 289 FFU/μl for VR837 
(positive control) and no viral proteins were detected in mock infections (Fig. 3.10A). HSG cell 
infection-derived MM and HIVSGD-1 BKPyV both scored 48 FFU/μl whereas U1 scored 5 
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FFU/μl (9.6 fold less). No infectious HIVSGD-2 BKPyV was detected (Fig. 3.10B). 
Interestingly, much lower FFUs were detected in Vero cell infection-derived MM and HIVSGD-
1 BKPyV (10 FFU/μl and 19 FFU/μl respectively) as compared to these viruses of HSG-cell 
origin (48 FFU/μl). These results indicated that HIVSGD-1 and MM BKPyV were more 
infectious originating from HSG (salivary gland) cells than Vero (kidney) cells (Fig. 3.10C and 
3.10D) despite the detection of similar VLs in both cell types (Fig. 3.9). Most strikingly, among 
Vero cell-derived BKPyV, the kidney-derived virus U1 (58 FFU/μl), was most infectious and 
displayed 5.8 fold higher FFU/μl than MM and 3 fold higher FFU/μl than HIVSGD-1 BKPyV. 
Despite the lack of detectable VLs (Fig. 3.9) U1 (kidney-derived) BKPyV scored higher FFUs 
originating from kidney (Vero) cells than salivary gland (HSG) cells (Fig. 3.10C and 3.10D). As 
expected, the lack of measurable HIVSGD-2 BKPyV VL was associated with an inability to 
detect infected cells, whether Vero or HSG cell-derived.  
 
Discussion 
HIV-associated salivary gland disease (HIVSGD) is among the most significant 
HIV/AIDS-associated oral lesions (25). Previously published data by our group suggested a 
correlation between HIVSGD and BKPyV (25, 26). To our knowledge, we are the first to 
analyze HIVSGD BKPyV and to establish a fully permissive salivary gland cell culture model 
supporting productive replication of clinical BKPyV isolates. The present study assessed 
replication differences in genomically similar HIVSGD isolates and compared a kidney-derived 
clinical isolate to HIVSGD clinical isolates. We assessed the non-coding control region (NCCR) 
of these isolates and determined in vitro replication capabilities in both salivary gland and kidney 
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cells. Importantly, this study provides evidence for differences in cell tropism based on the cell 
origin of BKPyV.  
Three clinical BKPyV isolates were characterized and compared: HIVSGD-1 and 
HIVSGD-2 were isolated from the throatwash (TW) samples of HIVSGD positive patients and 
U1 was isolated from the urine sample of a HIVSGD negative transplant patient (kidney-
associated isolate). BKPyV viral loads (VLs) from all three clinical samples were high and 
ranged from 1.7x10
5
 to 1.7x10
9 
copies/ml, likely reflecting immunosuppression in each instance. 
We previously established that VLs in healthy individuals and in HIV positive patients without 
HIVSGD were 3 to 4 logs lower than the VLs detected in HIVSGD positive individuals (25). 
Comparable VLs in the HIVSGD-associated oral fluid samples and in the urine sample of a 
transplant patient diagnosed with BKN suggested a significant increase in shed virus, perhaps at 
pathogenic levels.  
Whole genome sequence alignment of the two HIVSGD clones (HIVSGD-1 and 
HIVSGD-2) determined 99.9% similarity, despite three point mutations (Fig. 3.1A). A thymidine 
deletion was detected between the open reading frames (ORFs) that encoded agnoprotein and 
VP2 (Fig. 3.1A, 1). The deletion was outside of the respective ORFs and was therefore unlikely 
to affect replication. Nevertheless, it was possible that the mutation could have interfered with 
VP2 gene expression via disruption of a potential internal ribosome entry site (IRES) that was 
present in this region of the BKV genome. However, the affected nucleotide stretch did not 
contain a known IRES (Fig. 3.1B).  
The BKPyV NCCR is the main determinant of in vitro replication (9) and rearrangements 
confer significant differences in replication capacity, transforming potential, host cell 
permissivity and tropism (12, 37, 39, 40, 51-53). NCCR rearrangements are defined as changes 
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in the NCCR block sequences as compared to the archetype. The archetypic BKPyV substrain, 
defined by carrying the OPQRS NCCR architecture, is commonly shed in urine (5). We 
sequenced the BKPyV NCCR of the three clinical isolates and detected a common signature 
OPQPQQS block alignment among the HIVSGD TW samples. NCCR block divergence from 
archetype into rearranged (rr) variants, as detected in this study, have been previously recorded 
both in vivo (16, 51, 54, 55) and in vitro (16, 35, 37, 38, 56). Prior studies among transplant 
recipients with prolonged viremia illustrated, that rearranged architectures eventually became 
dominant over the archetype (39). The rr NCCR OPQPQQS may reflect the dominant 
architecture within these HIVSGD patients and may represent a stable and biologically 
significant variant. Despite VP1-based classification of BKPyV genotypes (57), BKPyV variants 
are categorized by NCCR block sequence (58). The OPQPQQS NCCR block alignment was 
previously described in laboratory strain MM, however, to our knowledge, other clinical isolates 
carrying this architecture have not been reported. Importantly, underlying nucleotide differences 
distinguished the HIVSGD clinical isolates from MM. Inclusion of well-described BKPyV 
laboratory strains during NCCR genotyping corroborated the authenticity of our results.  
HIVSGD-1 and MM BKPyV shared NCCR OPQPQQS block architecture, and exhibited 
similar levels of Tag expression, virion production and infectivity. Similar replication efficiency 
between HIVSGD-1 and MM may be explained by the analogous NCCR architecture. HIVSGD-
2, however, consistently lacked signs of efficient in vitro replication. While HIVSGD-2 shared 
the overall NCCR architecture with HIVSGD-1 and MM, the HIVSGD-2 NCCR S block 
contained a thymidine (T)/cytidine (C) transition (Fig. 3.1A, 2). This NCCR transition did not 
lead to differential prediction of putative human TFBS (Fig. 3.2A) or to differences in the early 
promoter activity in the presence or absence of full-length Tag (Fig. 3.2B), thus was an unlikely 
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contributor to differences in replication efficiency. Interestingly, the HIVSGD-2 promoter in the 
late direction was induced more readily, in the presence or absence of full-length Tag, than the 
high replicator HIVSGD-1 (Fig. 3.2C). Based on in vitro results that characterized HIVSGD-2 as 
an inefficient replicator, higher HIVSGD-2 promoter activity in the late direction was unlikely to 
affect its viral fitness. Despite the well-documented importance of the NCCR for BKPyV 
replication, the S block point mutation appeared unlikely to affect viral fitness.  
Inefficient HIVSGD-2 replication was likely associated with the adenosine deletion distal 
to the Tag pRb binding domain. This point mutation was predicted to introduce an early stop 
codon and modify the nuclear translocation signal (Fig. 3.3A and 3.3B). This resulted in the 
expression of a truncated form of Tag that decreased the predicted Tag protein size from 80.5 
kDa to 15.6 kDa. The mutant form of Tag lost the origin-binding domain (OBD), p53 site and 
ATP/helicase domain (Fig. 3.3C) and carried a modified version of the nuclear translocation 
signal (Fig. 3.3A and 3.3B). Tag is central to genome replication and PyV life cycle completion 
(59-61). Insufficient Tag expression has been shown to impede archetypic BKPyV replication in 
vitro (34). It is therefore likely that insufficient Tag expression dramatically inhibited HIVSGD-
2 replication. Remarkably, the isolation of HIVSGD-2 BKPyV from the TW sample and 
generation of progeny virus served as evidence of minimal HIVSGD-2 replication both in vivo 
and in vitro. HIVSGD-2 virus was detected at low levels post-transfection as determined by 
qPCR (VL measurement, Fig. 7) and was infectious as measured by FFA (Fig. 3.8). Two 
potential mechanisms that may have allowed for low levels of HIVSGD-2 replication: 1) in vivo 
- Provision of Tag in trans by other BKPyV substrains. Broekema et al. demonstrated that 
provision of overexpressed Tag allowed the cultivation of archetype BKPyV, a typically low in 
vitro replicator (34). 2) in vitro and in vivo - Low levels of full-length Tag could be produced by 
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ribosomal frame shifting. Ribosomal frame shifting commonly takes place in retroviruses 
facilitated by a slippery A/T-rich heptanucleotide sequence that allows for low protein 
expression despite the presence of a stop codon (62). The A/T rich stretch within HIVSGD-2 
BKPyV Tag located 5’ to the stop codon may allow for frame shifting in the context of BKPyV. 
Moreover, premature truncations of Tag have been detected in other PyVs. Merkel Cell 
polyomavirus (MCV) mutations that prematurely truncated Tag, were found in human tumor-
derived but not in benign sources, and have been postulated to render MCV more malignant (60). 
Likewise, there is the potential that truncation of HIVSGD BKPyV Tag may not only decrease 
replication efficiency but may also be associated with increased in vivo transformation potential.   
HIVSGD BKPyV in vitro viability was assessed by transfection (Part 1, Fig. 3.4) and 
infection (Part 2, Fig. 3.4) of salivary gland cells and kidney cells. Kidney cells represented the 
historically described replication niche. HIVSGD BKPyV fitness was compared to both kidney-
derived substrain U1 and laboratory strain MM (Table 3.1). We hypothesized that shed HIVSGD 
isolates were likely to replicate in salivary gland cells in vivo and by extension these isolates 
would replicate efficiently within HSG cells in vitro. Indeed, HIVSGD-1 consistently exhibited 
high replication competence in salivary gland cells. HIVSGD-1 and MM demonstrated highest 
post-transfection replication efficiency compared to HIVSGD-2 and kidney-derived U1, as 
determined by viral protein concentrations (Fig. 3.6), VLs (Fig. 3.7) and significant levels 
infectious BKPyV progeny (Fig. 3.8). Furthermore, the high replication capability of HIVSGD-1 
was consistent during infection of HSG and Vero cells (Fig. 3.4, Part 2) with high levels of HSG 
cell-released progeny virus (Fig. 3.9). HIVSGD-1, MM and U1 but not HIVSGD-2 completed a 
full life cycle upon secondary viral passage.  
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HIVSGD-1 and MM VL measurements suggested equally efficient virion production 
upon infection of HSG and Vero cells, as replication kinetics were very similar (Fig. 3.9). 
Differences in scored infectious units however, suggested that while replication kinetics and 
progeny output were consistent for HIVSGD-1 and MM, subsequent infectivity was distinct 
depending on cell type and virus origin comparing HIVSGD-1/MM vs. kidney-derived U1 (Fig. 
3.10D). When HIVSGD-1 and MM BKPyV originated from HSG cells rather than Vero cells 
higher FFUs were scored. Likewise, when kidney-derived U1 BKPyV originated from Vero cells 
rather than HSG cells higher FFUs were scored. Differential infectivity suggested HIVSGD 
BKPyV displayed preferential tropism for salivary gland cells over kidney cells. Similarly, U1 
displayed preferential tropism for kidney cells over salivary gland cells. Additionally, we 
recorded a dramatic increase in viral progeny production for Vero cell-derived U1 during the 4 
day Vero cell incubation for the FFA (Fig. 3.10).  This was interesting since U1 VLs were below 
the level of detection for qPCR quantification at 8 dpi (Fig. 3.9), and suggested that kidney-
derived U1 BKPyV was able to produce infectious progeny more efficiently in kidney cells (58 
FFU/μl) than HSG cells (5 FFU/μl, Fig. 3.10). Overall, differential infectivity depending on cell 
origin suggested that U1 displayed kidney tropism and HIVSGD BKPyV displayed salivary 
gland tropism, consistent with their respective in vivo kidney and salivary gland origins. 
Interestingly, previous studies comparing laboratory strain BKPyV replication among a wide 
range of different cell lines detected few differences in replication potential and did not indicate 
specific cellular tropisms (63, 64). These studies assessed over 60 cell types among them were 
lung-, colon-, CNS-, ovary-, renal- and bladder-derived cell lines; salivary gland cells were not 
assessed.   
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BKPyV isolated from the TW of HIVSGD patients is likely relevant to disease in the in 
vivo setting and has now undergone initial in vitro characterization. High BKPyV VLs were 
detected in the oral fluids of two individuals diagnosed with HIVSGD. We identified a common 
NCCR block architecture among HIVSGD-derived BKPyV isolates and successfully cultured 
clinical HIVSGD-derived BKPyV in human salivary gland cells and in kidney cells. Our 
assessment of a high and a low replicating clinical isolate suggested that a single point mutation 
in Tag brought about the stark differences in the in vitro replication potential. The high replicator 
(HIVSGD-1) surpassed the replication potential of the kidney-derived isolate (U1) in human 
salivary gland cells, replicated efficiently in human salivary gland and kidney cells and displayed 
signs of salivary gland tropism.  
Our results are significant, as they corroborate a potential connection between BKPyV 
and HIVSGD and provide an important initial understanding of BKV replication in the oral 
compartment. Our data suggest that HIVSGD TW-derived BKPyV displays preferential tropism 
for salivary gland cells and we have now proven that wild type oral-clinical BKV isolates 
undergo permissive replication in salivary gland cells in vitro. Permissive replication of wild 
type clinical BKV isolates previously thought to occur predominately in renal- and uro-
epithelium may be ongoing at other sites as well. Saliva serves as a transmission vehicle for 
many microorganisms and our data corroborate previous data showing that the oral compartment 
and saliva may function as a transmission vehicle for BKPyV in vivo as well. The small number 
of characterized HIVSGD isolates is a clear limitation of this current study and thus may not be 
representative of all HIVSGD variants. A study encompassing a larger number of isolates, would 
be more representative and needs to be performed. Importantly, this study provides a system for 
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the study of clinical oral BKPyV infection and these observations provide insights to future 
BKPyV pathogenesis, transmission and disease-association studies.  
A 
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Figure 3.9. HIVSGD-1 and MM BKPyV exhibited similar replication kinetics in HSG and 
Vero cells with increasing viral loads post-infection. A. The chart shows viral loads (VLs) in 
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BKPyV copy/μl, measured from the supernatant of infected HSG and Vero cells, 2, 4, 6 and 8 
dpi. Filtered supernatant from transfected HSG cells was used to infect HSG (black) and Vero 
(white) cells at equal viral loads. Supernatant from infected cells was harvested, filtered, DNAse 
treated and BKPyV VL quantified via qPCR. BKPyV HIVSGD-1 VLs increased over 6 orders of 
magnitude and MM over 5 orders of magnitude during the 8 dpi. Encapsulated HIVSGD-2 and 
U1 BKPyV DNA were not detected. Error bars represent standard deviations. Graphed VLs from 
infected HSG cells and Vero cells show similar growth kinetics for BKPyV HIVSGD-1 and 
MM. B. HIVSGD-1 (Vero- and HSG cell-derived) and MM (Vero cell-derived) BK virions were 
detected under TEM 8 dpi. MM BKPyV infected HSG supernatant was not analyzed. No virions 
were detected for HIVSGD-2, U1 and mock infection in HSG or Vero cells (data not shown). 
Mock infections were accomplished by using supernatant from mock transfected cells.  
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Figure 3.10. Cell type-dependent differential infection was detected based on viral origin. 
A. Representative images of FFA controls: positive (VR837 BKPyV infection; 289 FFU/µl) and 
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negative (Mock infection; no virus detected). Infected cells (green) and nuclei (blue) were 
quantified and FFU/µl values calculated. B. Representative images of HIVSGD-1, U1 and MM 
BKPyV infected cells are shown. Supernatant of infected HSG cells (8dpi) was filtered and 
transferred onto Vero cells. HIVSGD-1 and MM and yielded 48 FFU/µl. U1 yielded 5 FFU/µl. 
No infected cells were detected for the HIVSGD-2 treatment. C. Representative images of 
HIVSGD-1, U1 and MM BKPyV infected cells are shown. Supernatant of infected Vero cells (8 
dpi) was filtered and transferred onto Vero cells. Infected cells were visualized via FFA (green), 
quantified and FFU values calculated. HIVSGD-1 yielded 19 FFU/µl, MM yielded 10 FFU/µl 
and U1 yielded 58 FFU/µl. No infected cells were detected for the HIVSGD-2 treatment. D. The 
chart shows FFU values for each treatment, depicted as FFU/µl: HSG cell infection-derived 
BKPyV, (black bar), Vero cell infection-derived BKPyV (white bar). Error bars represent 
standard deviations 
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CHAPTER 4: GENERAL CONCLUSIONS 
HIV/AIDS has become one of the world’s main public health challenges since its first 
reported case in 1981 (1) and opportunistic infections are among the leading causes of death 
among HIV positive individuals. BK polyomavirus (BKPyV) has been emerging as a new 
opportunistic pathogen within that group, possibly carrying harmful implications (2).  
Our work and studies published by other groups suggest that the opportunistic infectious 
agent BKPyV may be the etiological agent of HIV-associated Salivary Gland Disease 
(HIVSGD), an HIV-associated oral malady.  
Today, HIVSGD is among the most common salivary gland presentations among HIV + 
individuals (3) and it is considered a pre-malignant lesion as its diagnosis is associated with 
increased lymphoma incidence (4-7). HIVSGD presents itself as salivary gland enlargement with 
(8) reduced salivary flow rates of the parotid, submandibular, and sublingual glands (3). 
Histologically, the oral disease is characterized by hyperplastic, intraparotid lymph nodes and/ or 
lymphatic CD8 + infiltrates (3). Importantly, common HIVSGD treatment is palliative and there 
are no effective treatment options, mainly due the lack of determined HIVSGD etiology. 
Data suggests that HIVSGD pathogenesis is antigen-driven (9, 10) and members of the 
polyomavirus (PyV) family have been shown to be important etiological agents in 
salivary gland pathology in experimental animal models. Athymic nude rats infected with PyV 
develop a wasting disease that is accompanied by parotid sialoadenitis with intranuclear 
inclusion bodies (11). Another transgenic mouse study shows that mice expressing PyV T 
antigen (Tag) undergo salivary gland tumorigenesis as the animals developed submandibular 
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gland adenocarcinomas (12). Murine and guinea pig animal models reflected HIVSGD on a 
histological level as mouse PyV-induced salivary epitheliomas in neonatal mice were infiltrated 
with T lymphocytes (13). Similar infiltrates were characterized in tumors growing from newborn 
guinea pigs infected with SE polyomavirus that also develop salivary gland enlargements (14). 
The carcinogenic potential of PyV products may explain the risk of increased lymphoma 
formation among HIVSGD patients.  
BKPyV in particular has been shown to display oral tropism in vivo and in vitro. BKPyV 
products has been detected in patient tonsillar tissue (15-17) and Jeffers et al. showed that 
BKPyV is able to infect and reproduce in human salivary gland cells in vitro (18). Based on the 
re-formulated Fredricks and Relman’s postulates (19) our group corroborated that BKPyV 
contributes to HIVSGD, as we detected significantly higher BKPyV viral loads (VLs) in the 
saliva of patients diagnosed with HIVSGD as compared to HIV negative patients (7, 18). 
Furthermore, our group found BKPyV products, but not herpesviral DNA, via PCR and 
immunofluorescence in HIVSGD patient salivary gland biopsies but not in biopsies from patients 
without HIVSGD (20). Hence, there is striking evidence linking HIVSGD to BKPyV.  
BKPyV is known foremost as the etiological agent of BKPyV-associated nephropathy 
(BKVN), which developed into a new epidemic, becoming the most important infectious 
complication affecting kidney transplants. Yet, effective anti-BKPyV treatments are not 
available and BKVN often results in chronic allograft dysfunction and failure (21). Clearly, the 
deleterious implications of BKPyV on public health are significant (22), emphasizing the 
importance of elucidating the pathological process leading to BKPyV-associated disease and 
anti-BKPyV treatments.  
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Clearly there is a lack of HIVSGD treatment options and this gap would be addressed 
once the etiological is determined. We attempted to narrow this gap by further analyzing the 
connection between HIVSGD and BKPyV. Furthermore, the role BKPyV plays during HIVSGD 
pathogenesis needs to be analyzed in order to provide specific treatment targets once BKPyV 
would be unquestionably confirmed as the etiological agent of HIVSGD. We therefore 
characterized HIVSGD-derived BKPyV (Chapter 2), studied BKPyV replication in human 
salivary gland cells (Chapter 3) and analyzed potential mechanisms involved (Appendix 2). 
Finally, general anti-BKPyV drugs need to be explored in tandem in the near future as they are 
not well defined. We therefore tested antiviral drugs in vitro (Appendix 1).  
 
Our work described in CHAPTER 2 (AIM1) was designed to confirm BKPyV as the 
etiological agent of HIVSGD by determining BKPyV viral loads (VLs) in HIVSGD throatwash 
(TW) samples in vivo. We screened TW samples from HIVSGD positive and negative patients 
for BKPyV. Concomitantly, we aimed to characterize HIVSGD-derived BKPyV and determined 
the BKPyV promoter architecture of HIVSGD positive and HIVSGD negative TW-derived 
isolates and transplant patient urine-derived isolates.  
The BKPyV NCCR promoter region was of special interest because it controls viral gene 
transcription and has been found to be the major determinant of in vitro replication (23, 24). The 
NCCR commonly undergoes block deletions and/or duplications and block rearrangements 
bestow remarkable differences in transforming potential and host cell permissivity (24-29). 
Furthermore, rearranged NCCRs have been reported to be more efficient replicators both in vitro 
and in vivo (23, 24, 30-32)  43). We therefore aimed to characterize the NCCR of HIVSGD-
derived BKPyV and order to determine whether there was a prevalent architecture BKPyV that 
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could serve as potential biomarker and to discern whether there was evidence that promoter 
rearrangements endow higher replication levels or tropism. There is evidence that downstream 
events such as transcriptional regulation contributes significantly to viral tropism (24, 33). As 
mentioned earlier, the BKPyV NCCR promoter contains the origin of replication and the 
enhancer/promoter elements of the genome and is the main determinant of BKPyV replication in 
vitro (23). The NCCR is a hypervariable region and comparative studies have suggested that it 
may regulate host cell tropism. These changes have been attributed mainly to the rearrangement, 
duplication or deletion transcription factor binding sites (TFBS) (24, 33-36). It is therefore 
plausible that the interplay of TFBS found within the NCCR sequence of a certain BKPyV 
substrain and transcription factors present within a certain cell type may allow for successful 
completion of a viral life cycle and therefore determine BKPyV tropism. We therefore also 
aimed to predict TFBS present within the BKPyV NCCR architecture of the clinical HIVSGD 
BKPyV isolates.    
Indeed, the study detected a conserved OPQPQQS NCCR architecture among 94.7% 
HIVSGD-derived BKPyV isolates which were confirmed in a study described in chapter 3. The 
BKPyV NCCR architecture and VLs from 36 immuno-suppressed individuals were assessed 
including 19 HIVSGD TW samples, 9 HIV positive/HIVSGD negative TW samples and 8 urine 
samples from HIVSGD negative transplant patients. First, we confirmed previously published 
data showing that HIVSGD patients shed increased BKPyV VLs orally, corroborating a potential 
link between HIVSGD and BKPyV (7, 18) and implying that the salivary glands may be a 
potential compartment suitable for BKPyV replication and pathogenesis. In order to rule out the 
patients HIV status as a co-factor driving BKPyV VLs, the correlation between HIV VLs, CD4 
counts and HAART treatment were tested and were not statistically significant. Furthermore, 
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there was no significant correlation between orally shed BKPyV levels, age, gender and 
geographical residential location. Interestingly, not all patients were BKPyV positive when 
diagnosed with HIVSGD. Patient HIVSGD9, for example, shed BKPyV VLs of 1x10
4 
upon 
entry, despite being HIVSGD negative at that time point. The patient was diagnosed with 
HIVSGD 6 months later however. It is possible that BKPyV reactivates and flares up right 
before the development of HIVSGD symptoms. Additional studies were recently initiated in 
order to further analyze the connection between BKPyV and HIVSGD in the future. A controlled 
longitudinal epidemiologic prospective cohort study was designed to further dissect whether 
BKPyV is the driver rather than a passenger HIVSGD and results will be available before the 
end of the year. The study consists of 3 patient cohorts HIV+ HIVSGD+, HIV+ HIVSGD(-), 
HIV(-) healthy and HIV(-) kidney transplant patients (N=62 >80% power). BKPyV VLs in 
saliva, urine, blood and antibody status will be analyzed and salivary function/protein secretion 
will be correlated with BKPyV titers. 
Given that NCCR changes have been attributed mainly to the rearrangement, duplication 
or deletion of transcription factor binding sites (TFBS), we predicted TFBS among the isolated 
clinical BKPyV promoters. Phylogenetic analysis of the detected BKPyV NCCRs displayed 
nucleotide differences among underlying the block homology. We predicted TFBS for the 
clinical and laboratory strain full-length and O block promoters and analyzed a potential 
correlation between in vivo VLs and sets of TFBS. We found a potential association between 
NCCR TFBS C/EBPβ and p300 with higher in vivo BKPyV replication efficiency by statistical 
analysis. Previous studies predicted C/EBPβ binding within the BKPyV NCCR and showed that 
C/EBPβ and p65 stimulated NCCR transcription in the early direction in transfection 
experiments both suggesting C/EBPβ to be crucial for early promoter induction (37, 38). 
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However, we could not confirm a correlation between TFBS C/EBPβ and p300 and promoter 
activity or in vitro replication levels. Hence, despite the long-held hypothesis that there is a link 
between NCCR TFBSs and BKPyV replication efficiency (36, 39, 40), we could not find 
common TFBS alterations that could be linked to promoter activity.  
Most importantly however, this study classified 19 HIVSGD BKPyV NCCR isolates 
using block sequence, phylogenetic and TFBS analysis, detecting a highly homologous 
OPQPQQS NCCR among HIVSGD TW samples. Hence, our data show that HIVSGD patients 
orally shed considerable BKPyV VLs that carry highly homologous NCCR architectures. Since 
NCCR changes determine host cell tropism (24, 41), this new NCCR architecture may be an 
adaptive response to a switch of host cell type and allow BKPyV replication in the oral cavity. 
This was supported by our data that found all but one HIVSGD promoter (83%) to be more 
readily induced than a laboratory strain in HSG cells, all HIVSGD strains to replicate readily in 
HSG cells and all but one HIVSGD substrain to replicate more efficiently than laboratory strain 
Dunlop in HSG cells over a 15-day time span. Hence, while it is unclear whether this signature 
OPQPQQS NCCR may be an adaptive response to salivary gland cells and/or promote salivary 
gland cell tropism, our study showed that cloned HIVSGD BKPyV isolates displayed active 
promoter activity and efficient replication capabilities in human salivary gland cells in vitro. 
Overall, the high frequency of a viable BKPyV substrain among HIVSGD TW samples suggests 
a stable and potentially pathogenic and biologically significant BKPyV substrain that may be 
linked to HIVSGD pathogenesis. In the future, more comprehensive clinical studies will have to 
be conducted in order to: 1. Confirm BKPyV and the etiological agent of HIVSGD. 2. Confirm 
the characteristic OPQPQQS NCCR architecture among HIVSGD patients and potential 
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biomarker. 3. Define whether BKPyV NCCR rearrangements truly drive increased virulence in 
vivo.  
 
Our work described in CHAPTER 3 (AIM2) was designed to establish an oral cell 
culture system to characterize and compare viral replication levels and tropisms of clinical 
BKPyV isolates in human salivary gland and kidney cells that are likely to have caused HIVSGD 
in vivo.  
In vitro cultivation of biologically relevant BKPyV strains has been inefficient unless Tag 
is provided in trans by over-expression (30) and few studies have successfully cultivated clinical 
BKPyV isolates. The lack of an in vitro system that allows for efficient cultivation of clinical 
BKPyV isolates hinders the complete elucidation of the BKPyV life cycle and pathogenic 
mechanism.  The lack of an established cell culture system that adequately represents the oral in 
vivo compartment and that allows for infection with clinical isolates hinders the systematic 
elucidation of BKPyV pathogenesis in the oral compartment and testing of HIVSGD treatment 
options. Our group therefore established, to our knowledge for the first time, an oral cell culture 
system that allows studying clinical BKPyV isolates, potential pathogenesis and anti-viral 
treatment options. We aimed to corroborate the hypothesis that BKPyV may be the etiological 
agent of HIVSGD by determining whether the clinical isolates replicate within human salivary 
gland cells and whether there is display of oral tropism.  
Three clinical BKPyV isolates were described and compared: HIVSGD-1 and HIVSGD-
2 were isolated from the throatwash (TW) samples of HIVSGD patients and U1 was isolated 
from the urine sample of a HIVSGD negative transplant patient. BKPyV viral loads (VLs) from 
all three clinical samples were high and ranged from 1.7x10
5
 to 1.7x10
9 
copies/ml, likely 
 
 
131 
reflecting the previously established correlation between HIVSGD and BKPyV and BKVN and 
BKPyV. Most interestingly, both HIVSGD-derived BKPyV substrains shared the NCCR 
architecture previously described - OPQPQQS. HIVSGD-1 turned out to be a high in vitro 
replicator in human salivary gland cells as compared to HIVSGD-2 or the urine-derived isolate. 
HIVSGD-2 consistently lacked signs of overall in vitro replication.  
  Whole genome sequence alignment of the two HIVSGD whole genomes determined 
99% similarity, despite three point mutations. 1. A thymidine deletion was detected between the 
open reading frames (ORFs) that encoded agnoprotein and VP2. The deletion was outside of the 
respective ORFs and is therefore unlikely to affect the viral life cycle. 2. A thymidine/cytidine 
transition was detected despite overall NCCR block architecture homology. The transition did 
not lead to differential prediction of putative human TFBS, nor to differences in the early 
promoter activity in the presence or absence of full-length Tag. The transition was thus equally 
unlikely contributor to differences in replication efficiency. 3. An adenosine deletion was 
detected distal to the Tag pRb binding domain and was likely the cause of inefficient HIVSGD-2 
replication due Tag’s central function to genome replication and PyV life cycle completion (42-
44). Furthermore, insufficient Tag expression has been shown to obstruct BKPyV replication in 
vitro (30). The deletion predicted to introduce an early stop codon, modify the nuclear 
translocation signal and result in the expression of a truncated form of Tag. The mutant Tag was 
predicted to lose the origin-binding domain, p53 site and ATP/helicase domain. It is therefore 
likely that insufficient Tag expression dramatically inhibited HIVSGD-2 replication. 
In summary, overall high BKPyV VLs were detected among HIVSGD TW samples, 
corroborating the connection between BKPyV and HIVSGD. A common OPQPQQS NCCR 
block architecture was found among BKPyV isolates from the oral fluids of two individuals 
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diagnosed with HIVSGD. Furthermore, clinical HIVSGD-derived BKPyV was successfully 
cultured in human salivary gland cells and in kidney cells. Our assessments suggested that a 
single point mutation in Tag, causing truncation, lead to a stark difference in the in vitro 
replication potential. Furthermore, the high HIVSGD-derived replicator surpassed the replication 
potential of the kidney-derived isolate in human salivary gland cells and displayed signs of 
salivary gland tropism.  
Permissive replication of wild type clinical BKV isolates is generally thought to happen 
chiefly in renal- and uro-epithelium but the presented data suggested the oral compartment to be 
a likely in vivo replication site as well. The main drawback of the study was the small number of 
characterized HIVSGD isolates and may not be representative of all HIVSGD variants. In the 
future, a study encompassing a larger number of isolates, would be more representative and 
would give a more accurate picture of HIVSGD-derived BKPyV replication kinetics. Still, the 
presented system allows studying clinical oral BKPyV infection and these observations provide 
insights to future BKPyV pathogenesis, transmission and disease-association studies. In the 
future, the oral BKPyV cell culture system may allow determining whether BKPyV infection 
affects cell signaling and homeostasis and may mirror salivary gland dysfunctions in vivo. The 
system may therefore lead to hints towards why HIVSGD patients have reduced saliva 
production and may ultimately contribute to treatment options alleviating HIVSGD patients from 
xerostomia and its deleterious consequences. 
 
Our work described in Appendix 1 describes how the salivary gland cell culture system 
was used to test antiviral treatment options potentially alleviating general BKPyV-associated 
ailments in patients. Antiviral effects of several drugs on clinical BKPyV isolates were 
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characterized in vitro, since there is currently no FDA approved antiviral drug to treat BKPyV 
infection. Previous studies have analyzed the anti-BKPyV effects of following drugs: cidofovir, 
CMX001, leflunomide, ciprofloxacin, and lactoferrin(45-51). However the results were mostly 
ambivalent (48, 49, 52, 53) and all of the listed drugs are likely to have non-specific effects since 
they are approved to treat other DNA virus infections, including hepadnaviruses, herpesviruses, 
adenovirus, papillomavirus, polyoma and poxviruses (54-58). The study presented in appendix 1 
tested three drugs, ciprofloxacin, cidofovir and leflunomide on BKPyV replication in salivary 
gland cells, using the previously described BKV-infected salivary gland in vitro system and 
HIVSGD-derived BKPyV isolates. BKPyV replication was decreased by all three drug types in 
human salivary gland cells, while ciprofloxacin was the most effective. The anti-BKPyV 
mechanisms of each drug are currently unclear and present a future are of interest. It was 
proposed, however that BKPyV inhibition in salivary gland cells may be due to inhibition of a 
host intracellular signaling pathway important for viral replication, such as the Akt or mTOR 
pathway (Jeffers, LK, unpublished). Future clinical studies will have to be done to determine 
which antiviral drug is most effective to treat BKPyV infection in HIVSGD patients, but our 
study suggest ciprofloxacin to be the most efficacious.  
Our work described in Appendix 2 describes a study analyzing the possible connection 
between the metastatis-associated lung adenocarcinoma-associated transcript 1 (MALAT-1) and 
PyV Tag. MALAT-1 was found to be up-regulated in RNA extracted from HIVSGD biopsies 
versus biopsies from patients without HIVSGD and has previously been shown to be up-
regulated in a variety of epithelial carcinomas.  
BKPyV is a small DNA tumorvirus and its tumorigenic capability in experimental 
models is accredited to the presence of the oncoprotein Tag (59). Tag is a nuclear 
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phosphoprotein that wields its transforming abilities by interacting and suppressing cellular 
tumor suppressor proteins p53 and members of the pRb family, which leads to unrestrained host 
cell proliferation (60). Understanding the complete life cycle of the virus and the role Tag plays 
during infection will be critical in the development of possible therapeutic interventions of 
lymphoma formation during HIVSGD pathogenesis. 
We found that Malat-1 regulation was associated with p53 dysfunction and may therefore 
serve as a biomarker for p53-specific transformation. Furthermore, these results suggest Malat-1 
may be a potential biomarker for Tag transformed tissue, such as seen in HIVSGD, since PyV 
Tag suppresses p53 functions.  
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APPENDIX 1:  
EFFECT OF LEFLUNOMIDE, CIDOFOVIR AND CIPROFLOXACIN ON 
REPLICATION OF BK VIRUS IN A SALIVARY GLAND  
IN VITRO CULTURE SYSTEM 
 
Introduction  
BK virus (BKV) belongs to the polyomavirus family and is ubiquitous in the human 
population (1). BKV infection typically occurs during childhood, without specific symptoms, 
followed by a state of non-replicative infection in various tissues, with the urogenital tract as the 
principal site (2). In the setting of relative or absolute cell-mediated immunosuppression, 
dramatic increase in BK viral replication occurs, resulting in the lytic destruction of infected 
uroepithelial cells, which in turn induces the influx of inflammatory immune cells(3). 
Destruction of kidney cells most often occurs in 5-8% of kidney transplants resulting in organ 
loss in half of these cases and is termed BKV-associated nephropathy (BKVN) (4) (5-7). BKV is 
also the cause of BKV-associated hemorrhagic cystitis which occurs in more than 10% of bone 
marrow transplant recipients (8, 9). BKV-associated disease incidence is increasing as a result of 
the growing number of immunocompromised patients, including transplant and HIV, and 
development of better immunosuppressive drugs.  
Currently there is no FDA approved antiviral drug licensed to treat BKV infections 
despite its importance in transplant and immunocompromised patients. Several in vitro and in 
vivo studies however, have been performed to test for their efficacy against BKV including 
cidofovir, CMX001, leflunomide, ciprofloxacin, and lactoferrin(10-16). All of these drugs are 
effective against other DNA viruses including hepadnaviruses, herpesviruses, adenovirus, 
papillomavirus, polyoma and poxviruses (9, 17-20) but have shown mixed results against BKV, 
both in vitro and in vivo in kidney cells (13, 14, 21, 22). Ciprofloxacin (CPRO) is a synthetic 
antibiotic of the fluoroquinolone drug class. Ciprofloxacin’s antibacterial activity functions by 
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inhibiting type II topoisomerases and has been shown to inhibit T antigen helicase activity (20). 
Cidofovir (CDV) is a nucleoside analog that inhibits viral DNA polymerase activity, however 
BKV does not encode for a DNA polymerase. CDV has been shown to inhibit BKV activity in 
vitro in human embryonic lung fibroblast cells (WI-38) (12) and in primary human renal 
proximal tubular epithelial cells (RPTECs)(14). In RPTECs, CDV inhibited BKV replication but 
also decreased host cellular DNA replication and metabolic activity (14). Although CDV has 
shown in vitro activity against BKV, there are conflicting reports of in vivo activity (23, 24). In 
addition, CDV has been shown to be nephrotoxic and must be given intravenously, therefore 
patients need to be hospitalized for drug administration. Most recently, CMX001, a 
hexadecyloxypropyl lipid conjugate of CDV has been shown to inhibit polyomaviruses JCV and 
BKV in human kidney and brain progenitor-derived astrocytes (11, 25). Leflunomide (LEF) is an 
anti-inflammatory drug known to inhibit dihydroorotate dehydrogenase, tyrosine kinase and 
pyrimidine synthesis(12). LEF has been approved to treat rheumatoid arthritis and has shown 
activity against cytomegalovirus and herpesvirus with conflicting reports against BKV(13, 26, 
27).  
We have previously shown that BKV DNA can be detected at high levels in the saliva of 
HIV patients diagnosed with salivary gland disease compared to patients without the disease (28, 
29). HIV-associated salivary gland disease (HIV-SGD) has been universally established as 
among the most important AIDS-associated oral lesions. Oral lesions are important clinical 
indicators of HIV/AIDS by suggesting HIV infection in the undiagnosed individual, indicating 
clinical disease progression and predicting development of AIDS (30). In developing countries 
the incidence of HIV-SGD has been reported to be as high as 48% of HIV-1 infected 
patients(31). Also, HIV-SGD is of particular interest because in 1-2% of patients, malignant 
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lymphomas have been described in association with glandular lesions making this disease a 
premalignant lesion(32, 33). In addition, we have shown that BKV can productively infect 
salivary gland cells in an in vitro model described by Jeffers et al (28).  
All assays to test anti-BKV drugs have been performed in kidney or lung cells (12, 34, 
35). Therefore, an in vitro drug screen against BKV replication in human salivary gland cells 
would be useful to identify new viral targets for drug treatment. The aim of this study was to 
investigate the effect of three drugs, ciprofloxacin, cidofovir and leflunomide on BKV 
replication in salivary gland cells, using the previously described BKV-infected salivary gland in 
vitro culture system, the primary target cells in HIV-associated salivary gland disease. 
 
Materials and Methods 
Subjects, sample collection and cell culture  
HIVSGD patients were recruited from UNC hospitals dental clinic to participate in the 
IRB approved study, where throat wash was collected from patients for viral detection and 
isolation.  Urine from a lung transplant patient was kindly donated by Dr. Volker Nickeleit for 
viral detection and isolation. HSG cells, an epithelial cell line from human submandibular 
salivary gland (36), were obtained as a gift from Dr. B. Baum (NIH) and cultured in McCoy’s 
5A medium (Sigma).  African kidney monkey cells or Vero cells (American Type Culture 
Collection [ATCC]) were also cultured in DMEM (Sigma). All cell types were grown in medium 
supplemented with 10% fetal bovine serum (FBS) (Sigma), unless otherwise stated and 1% 
penicillin-streptomycin (pen/strep) (Gibco) and maintained in a humidified 37
0
C CO2 chamber. 
BKV Gardner strain was obtained from ATCC (VR-837).  
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Whole Genome BKV Cloning 
BKV VP1 gene forward (BKVWGF; 5’-GCGGGATCCAGATGAAAACCTTAGG-3’) 
and reverse primers (BKVWGR; 5’- GCGGGATCCCCCATTTCTGG-3’) including the 
naturally occurring BamH1 restriction fragment recognition sites were used to amplify the whole 
genome (wg) of BKV via PCR from throatwash of HIVSGD patients, and the urine of a lung 
transplant patient using the Expand Long Range dNTPack (Roche) as described by 
manufacturer. Amplified wg BKV products were purified by QIAquick PCR Purification Kit 
(QIAGEN) as described by manufacturer. Purified wg BKV DNA was cloned via the TOPO TA 
Cloning Kit (Invitrogen) as described by manufacturer. Constructs were isolated via QIAfilter 
Plasmid Midi Kit (QIAGEN) post-24hrs incubation of bacterial cells for clone DNA 
amplification at 37 °C.     
Infection and Drug Treatment    
Ciprofloxacin (Sigma), Leflunomide/A771726 (Calbiochem) and Cidofovir (Gilead) 
were dissolved to 150ug/ml, 20ug/ml and 40ug/ml, respectively in McCoy’s 5A medium. HSG 
cells were infected at about 50% confluence with 64 HAUs of BKV as described by Jeffers et al. 
(28). As previously described by Jeffers et al, HSG cells were infected with BK virus for 24h for 
optimal viral entry(28). At 24h post infection virus was removed from the culture medium, 
washed with 1X PBS and replaced with fresh medium with or without drug. At various times 
post infection the cell monolayers or supernatant were further processed for IFA, protein, RNA 
or DNA isolation, as described below.  
Cell viability and cell proliferation assay 
The mitochondrial metabolic activity was monitored by the colorimetric
 
WST-1 assay 
(Roche), measuring the reduction of the tetrazolium
 
salt WST-1 by mitochondrial 
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dehydrogenases. DNA synthesis was
 
quantified by the colorimetric measurement of 
bromodeoxyuridine
 
(BrdU) incorporation into DNA using the cell proliferation enzyme-linked
 
immunosorbent assay (ELISA) BrdU kits (Roche). Both tests were performed in fresh medium 
with or without BKV Gardner in the presence or absence of drug at 3, 4 and 5 dpi. 
RNA isolation and real-time RT-PCR amplification  
Total RNA was extracted using TRizol (Invitrogen) as described by the manufacturer. 
Contaminating DNAs were removed by use of RQ1 DNase kit (Promega) as described by the 
manufacturer. cDNA was generated using 20µg RNA, random primers and the SuperScript
TM
 II 
Reverse Transcriptase (RT) Kit (Invitrogen) as described by the manufacturer. A non-RT 
enzyme reaction was performed for each sample as a negative control for cDNA synthesis. 
cDNA was then subjected to real-time PCR analysis using Roche LightCycler 480 Syber Green I 
Master Mix as a detector in the Roche Light Cycler 480.  Primers for T Ag and VP1 were 
previously described in Dana et al (37) and Ding (38) et al, respectively. Gene expression values 
were normalized to the levels of β-actin transcripts, using the 2– C(T) method, and are 
presented as
 
the changes (n-fold) in T Ag and VP1 transcript levels, with the levels
 
in BKV only 
(no drug) samples arbitrarily set to 1. 
Indirect immunofluorescence (IFA) 
At stated times post-infection, cells were fixed for 10 min with 50% methanol/50% 
acetone, dried at RT then incubated at -20
0
C overnight for antigen retrieval. Fixed cells were 
then thawed at RT, rehydrated with 1XPBS and incubated with PAb416 (Genetex) antibody 
(1:30), specific for SV40 LT-ag and cross reacts with BKV LT-ag for 1 hr at 37
0
C followed by a 
fluorescencein-conjugated anti-mouse (Sigma) antibody (1:20). DAPI (Invitrogen) (1:10,000) 
was used to stain the nucleus. At least ten random fields of positively stained cells were counted 
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to determine percent infection. Nikon FXA with Q camera or Olympus IMT2 fluorescent 
microscopes were used to photograph cells.   
Immunoblotting  
Total cell protein was extracted using RIPA buffer. Protein concentration was determined 
using the BioRad protein assay, and equal amounts of protein were electrophoresed on a 4-12% 
Bis-Tris polyacrylamide minigel (Invitrogen). PAb416 (1:200) (Genetex) in 5% NFDM/PBS-T 
was used to detect T Ag expression and Actin (C-11)-R sc-1615-R (1:1000)(Santa Cruz 
Biotechnology) in 1%BSA/TBS-T for actin expression. After washing in PBS/TBS-T, blots were 
probed with a horseradish peroxidase-conjugated secondary antibody (1:10,000) (Promega). 
Antibody complexes were detected using SuperSignal West Pico Chemiluminescent substrate 
(Thermo scientific) and exposed to film (Kodak). 
Detection of DNase resistant particles 
The detection of infectious virus being released from HSG cells were performed by 
collecting HSG cell supernatant at stated times post infection. To degrade free DNA not 
encapsidated within virions, supernatant was treated with 250U DNase (Promega) or PBS for 15 
min at 56
0
C, followed by enzyme inactivation at 65
0
C for 10 min. To release
 
viral DNA (vDNA) 
from capsids, proteinase K was used as described
 
in the blood and body fluid spin protocol of the 
QIAamp DNA
 
blood minikit (QIAGEN). DNA was eluted in 200 µl of sterile
 
water. Levels of 
viral DNA was determined using primers for T Ag and/or VP1 in quantitative real time PCR as 
described above. A plasmid, pBKV containing the entire genome of BKV, a gift from Volker 
Nickeleit (UNC-CH) was used to derive standard curves for viral DNA quantitation. 
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Determination of effective and cytotoxic concentrations 
Data for the extracellular BKV DNA load and BrdU incorporation in the presence of 
increasing drug concentrations were expressed as percent inhibition for both uninfected and 
infected HSG cells. Graphs were generated by applying the best-fitting curve using GraphPad 
Prism to calculate the EC50 and CC50. The respective selectivity index (SI) was obtained by 
determining the CC50/EC50 ratios. 
 
Results 
Effect of Cidofovir, Ciprofloxacin and Leflunomide on BKV early gene expression in salivary 
gland cells and in Vero cells 
To investigate the effect of cidofovir (CDV), ciprofloxacin (CPRO) and leflunomide 
(LEF) on BKV early gene expression, we measured T Ag RNA in triplicate at days 3 and 4 pi 
with VR-837 BKV (ATCC) by qRTPCR in 3 separate experiments (each symbol represents a 
distinct experiment) (Figure 1). The results were normalized to the levels of β-actin using the 2-
 method, and are presented as the changes (n-fold) in T Ag transcript levels relative to 
untreated BKV-infected cells at each time point. Compared to salivary glands cells infected with 
BKV only, a consistent decrease in mean T Ag expression was observed in the presence of 
CPRO and CDV. No significant change was detected in mean BKV levels with LEF at day 3, but 
a significant decrease with LEF treatment was detected at day 4.  Effect on gene expression was 
determined beginning on day 3 post infection because we have previously shown that BKV 
replication is delayed in salivary gland cells, such that a significant increase in extracellular viral 
load occurs at 3 dpi (28) compare to kidney (RPTE) cells which occurs after 2 dpi (28, 39) 
(Figure 1 supplemental). 
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In Vero cells, T Ag expression was measured in triplicate at 3, 4 and 5 days pi and post 
drug treatment by qRTPCR. RNA levels were compared to BKV only. With CDV treatment a 
variable trend of high T Ag expression was detected on day 3 pi followed by a decrease on day 4 
and a rebound on day 5.  LEF treatment resulted in low T Ag expression on day 3, followed by 
an increase on day 4 and a decrease on day 5. CPRO treatment however was consistently low at 
all time points post infection.   
Effect of Cidofovir, Ciprofloxacin and Leflunomide on BKV late gene transcription in salivary 
gland cells and in Vero cells 
To investigate the effect of cidofovir, ciprofloxacin and leflunomide on BKV late gene 
expression, VP1 RNA was measured by qRTPCR in triplicate at 3, 4 and 5 days pi and post 
treatment.  Four separate experiments were performed for days 3 and 4 and two separate 
experiments for day 5 (Each symbol denotes a separate experiment) (Figure 2).  The results were 
normalized to the levels of β-actin using the 2-  method, and are presented as the changes 
(n-fold) in VP1 transcript levels relative to untreated BKV-infected cells at each time point. A 
consistent increase in mean VP1 expression was detected in the presence of CDV at days 3, 4 
and 5.  This increase was also observed with LEF at days 3 and 4, with a decrease at day 5.  A 
consistent decrease in mean VP1 expression was detected with CPRO treatment during each time 
point post infection. 
Similarly in Vero cells, VP1 RNA was measured in triplicate at 3, 4 and 5 days pi/post 
drug treatment by qRTPCR. These studies were performed three times, Figure 2B is a 
representative experiment. A decrease in mean VP1 expression was observed in the presence of 
CDV at days 3 and 4pi but an increase in VP1 expression was detected on day 5 pi. LEF 
treatment on day 4pi resulted in a slight decrease in VP1 expression compared to day 3 followed 
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by a significant increase on day 5pi.  CPRO treatment showed consistently low levels of VP1 
expression at each time point post infection. 
Effect of Cidofovir, Ciprofloxacin and Leflunomide on protein expression in salivary gland cells  
To investigate the effect of cidofovir, ciprofloxacin and leflunomide on BKV T Ag 
protein expression, T Ag protein was measured at 3, 4 and 5 days pi/post drug treatment by 
immonoblot (Figure 3A). The results were normalized to the levels of β-actin using densitometry 
(Figure 3B), and are presented as T Ag protein relative to untreated BKV-infected cells at each 
time point. A consistent decrease in T Ag protein expression was detected in the presence of all 
three drugs at days 3, 4 and 5.  Interestingly, by day 5 LEF exhibited the most inhibition. 
Treatment with LEF may have had some effect on the infected cells as beta actin levels 
continued to decrease over the 3 day period.  Similar to what was seen by immunoblot, 
immunofloresence also detected the most profound decrease in T Ag protein expression with 
CPRO treatment.  T Ag expression was diminished by approximately the same amount in LEF 
and CDV treated cells. A representative panel is shown in Figure 3C. Similar results were 
detected for VP1 protein expression (data not shown).    
Effect of Cidofovir, Ciprofloxacin and Leflunomide on BKV genome replication in salivary 
gland cells 
To investigate whether BKV genome replication in salivary gland cells were affected by 
drug treatment, BKV DNA loads were measured at 3, 4 and 5 dpi/post drug treatment by qPCR 
(Figure 4). A standard curve was constructed using a plasmid encoding for the BKV genome to 
determine BKV copy number. The largest decrease of BKV genome replication occurred with 
CPRO-treated cells over the three day period 2.5-4 log decrease compared to untreated. LEF 
decreased BKV genome replication 0.5-1 log while CDV showed an intermediate phenotype 
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with a 2-3 log decrease over the three day period. Primers targeted toward both T Ag (Figure 4) 
and VP1 (supplemental Figure 4) regions of the genome provided similar results.  
Effect of Cidofovir, Ciprofloxacin and Leflunomide on encapsidated BK viral progeny release in 
salivary gland cells and in Vero cells 
To investigate how these treatments affected the release of encapsidated BK virions into 
the supernatant of HSG and Vero cells, DNase resistant particles were quantified by qPCR and 
BKV DNA loads measured at 3, 4 and 5 dpi/post drug treatment (Figure 5A). A standard curve 
was constructed using a plasmid encoding for BKV genome to determine BKV copy number. 
Amplification was performed with both T Ag (Figure 5A and 5C) and VP1 (5A suppl and 5C 
suppl) primer sets, both providing similar results. In media from both BKV only cell types, the 
virion release continued to increase from day 3 to day 5. In HSG media, treatment with all of the 
agents resulted in decrease of 1-1.5 logs at day 3 and 2-3 logs decrease at day 5 (Figure 5A). In 
Vero media, treatment with both CPRO and CDV resulted in 1.5-2 logs decrease while LEF 
showed an increase in encapsidated virion release over the 3 to 5 day post infection period 
(Figure 5C and 5C suppl). 
The efficacy of these agents on the treatment of wild type clinical isolate-derived virus 
was also assessed 5 days pi of HSG cells.  Across treatments a 0.5 to 1 log decrease was detected 
in two HIVSGD patient viruses (HIV SGD 18 and 19) and urine derived archetype virus (Lung 
transplant WW) while 0.5 log decrease was detected with treatment of the laboratory adapted 
strain (MM)  at 5 days post treatment (Figure 5B). Amplification was performed with both T Ag 
(Figure 5B) and VP1 (5B suppl) primer sets, both providing similar results. 
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Effect of Cidofovir, Ciprofloxacin and Leflunomide on salivary gland cell proliferation and 
viability 
To investigate metabolic activity of drug-treated HSG cells with or without BKV 
infection, WST-1 assays were used over 3 to 5 day period. Compared to uninfected untreated 
HSGs, BKV infection increased cellular metabolic activity at all time points, with the greatest 
increase occurring at 5 days pi to 105%. With the exception of CPRO at day 3, all drug-treated 
cells with BKV infection displayed increased metabolic activity compared to uninfected cells 
with drug at each time point (Figure 6A). The most significant increase occurred at day 4 pi, to 
103% for CPRO+BKV, CDV+BKV and LEF+BKV. Compared to uninfected untreated HSG 
cells, drug treatment only did not significantly change metabolic activity at any time point 
investigated. To investigate host cell DNA replication and metabolic activity with increasing 
concentrations of drug treatment both BrdU incorporation and WST-1 assays were used. Each 
drug reduced host cell DNA replication in a concentration-dependent manner (Figure 6B).  
 
 
 
 
 
 
 
 
Figure 1A. Effect of drug treatment on early BK viral gene expression in human salivary 
gland cells.   HSG cells were infected with BKV for 24h then treated with drug as described in 
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the materials and methods. At stated times post infection cells were collected, RNA isolated, 
cDNA generated and qRTPCR performed for T Ag viral transcripts. Gene expression values 
were normalized to the levels of β-actin transcripts, using 2-DDC(T) method and are represented as 
the changes (n-fold) in VP1transcript levels with the levels in non-drug treated (BKV only) 
samples arbitrarily set to 1. Each symbol represents a different experiment. 
 
 
Figure 1B. Effect of drug treatment on early BK viral gene expression in Vero cells.   Vero 
cells were infected with BKV for 24h then treated with drug as described in the materials and 
methods. At stated times post infection cells were collected, RNA isolated, cDNA generated and 
qRTPCR performed for Tag viral transcripts. Gene expression values were normalized to the 
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levels of β-actin transcripts, using 2-DDC(T) method and are represented as the changes (n-fold) in 
Tag transcript levels with the levels in non-drug treated (BKV only) samples arbitrarily set to 1. 
Figure 1 supplemental. Comparison of BKV replication trend over time in human 
kidney(RPTE) versus salivary gland (HSG) cells.  HSG cells show a significant increase in 
extracellular BKV load at 3dpi compared to RPTE cells which occurs earlier at 2dpi. RPTE trend 
was extracted from work performed by Li et al(47).  
 
Figure 2A. Effect of drug treatment on late BK viral gene expression in human salivary 
gland cells. HSG cells were infected with BKV for 24h then treated with drug as described in the 
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materials and methods. At stated times post infection cells were collected, RNA isolated, cDNA 
generated and qRTPCR performed for VP1 viral transcripts. Gene expression values were 
normalized to the levels of β-actin transcripts, using 2-DDC(T) method and are represented as the 
changes (n-fold) in VP1 transcript levels with the levels in non-drug treated (BKV only (-)) 
samples arbitrarily set to 1. Each dot represents a different experiment. 
 
Figure 2B. Effect of drug treatment on late BK viral gene expression in Vero cells. Vero 
cells were infected with BKV for 24h then treated with drug as described in the materials and 
methods. At stated times post infection cells were collected, RNA isolated, cDNA generated and 
qRTPCR performed for VP1 viral transcripts. Gene expression values were normalized to the 
levels of β-actin transcripts, using 2-DDC(T) method and are represented as the changes (n-fold) in 
VP1 transcript levels with the levels in non-drug treated (BKV only (-)) samples arbitrarily set to 
1. 
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Figure 3A. Effect of drug treatment on BK protein expression in human salivary gland 
cells.   At stated times post infection cell lysates were collected and used for immunoblotting as 
described in the materials and methods. Antibodies against T Ag (top panel) and β-actin (bottom 
panel) were used. Bottom panel shows relative L Tag protein expression compared to β-actin.  
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Figure 3B. Effect of drug treatment on BK protein expression in human salivary gland 
cells.   At 4 days post infection cells were fixed and stained for T Ag (green). DAPI (blue) was 
used to stain the cell nuclei. Representative photograph of BKV T Ag and nuclear staining are 
shown for BKV-infected cells treated with and without drugs (20X magnification). 
 
 
Figure 4. Effect of drug treatment 
on BKV genome replication in 
human salivary gland cells.   HSG 
cells were infected with BKV and 
treated with drug as described in the 
materials and methods. At stated 
times post infection cells were 
collected, DNA isolated, and qrtPCR 
performed for T Ag DNA copy no. A standard curve (data not shown) was constructed using a 
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plasmid coding for BKV whole genome. The error bars represent the SD  and the asterisk  
denotes a p-value <0.05 as determined by  the t-test.  
 
 
Figure 4 supplemental. Effect of drug treatment on BKV genome replication in human 
salivary gland cells.   HSG cells were infected with BKV and treated with drug as described in 
the materials and methods. At stated times post infection cells were collected, DNA isolated, and 
qrtPCR performed for VP1 DNA copy no. A standard curve (data not shown) was constructed 
using a plasmid coding for BKV whole genome. The error bars represent the SD and the asterisk 
denotes a p-value <0.05 as determined by the t-test.  
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Figure 5A. Effect of drug treatment on infectious BK virus progeny release from human 
salivary gland cells.   HSG cells were infected with BKV and treated with drug as described in 
the materials and methods. At stated times post infection supernatant was collected, Dnase-
treated and qrtPCR performed for T Ag DNA copy no. A standard curve (data not shown) was 
constructed using a plasmid coding for BKV whole genome. The error bars represent the SD  
and the asterisk  denotes a p-value <0.05 as determined by  the t-test.   
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Figure 5A supplemental. Effect of drug treatment on infectious BK virus progeny release in 
human salivary gland cells.   HSG cells were infected with BKV and treated with drug as 
described in the materials and methods. At stated times post infection supernatant was collected, 
Dnase-treated and qrtPCR performed for VP1 DNA copy no. A standard curve (data not shown) 
was constructed using a plasmid coding for BKV whole genome. . The error bars represent the 
SD  and the asterisk  denotes a p-value <0.05 as determined by  the t-test.   
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Figure 5B. Effect of drug treatment on patient-derived infectious BK virus progeny release 
in human salivary gland cells.   HSG cells were infected with BKV and treated with drug as 
described in the materials and methods. At 5 days post infection supernatant was collected, 
Dnase-treated and qrtPCR performed for T Ag DNA copy no. A standard curve (data not shown) 
was constructed using a plasmid coding for BKV whole genome.  Data is shown as fold relative 
to untreated, BKV-infected cells (BKV only), with BKV only set at 100%.  
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Figure 5B supplemental. Effect of drug treatment on patient-derived infectious BK virus 
progeny release in human salivary gland cells. HSG cells were infected with BKV and treated 
with drug as described in the materials and methods. At 5 days post infection supernatant was 
collected, Dnase-treated and qrtPCR performed for VP1 DNA copy no. A standard curve (data 
not shown) was constructed using a plasmid coding for BKV whole genome.  Data is shown as 
fold relative to untreated, BKV-infected cells (BKV only), with BKV only set at 100%.  
 
>%#' &1$RA$(' 88)14 1: 9+)?$$
 163 
Figure 5C. Effect of drug treatment on infectious BK virus progeny release from Vero cells.   
Vero cells were infected with BKV and treated with drug as described in the materials and 
methods. At stated times post infection supernatant was collected, Dnase-treated and qrtPCR 
performed for T Ag DNA copy no. A standard curve (data not shown) was constructed using a 
plasmid coding for BKV whole genome. The error bars represent the SD  and the asterisk  
denotes a p-value <0.05 as determined by  the t-test.  
 
Figure 5C supplemental. Effect of drug treatment on infectious BK virus progeny release 
from Vero cells.   Vero cells were infected with BKV and treated with drug as described in the 
materials and methods. At stated times post infection supernatant was collected, Dnase-treated 
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and qrtPCR performed for VP1DNA copy no. A standard curve (data not shown) was 
constructed using a plasmid coding for BKV whole genome. The error bars represent the SD  
and the asterisk  denotes a p-value <0.05 as determined by  the t-test.  
 
Figure 6A. Effect of drug treatment on total host cell DNA replication in BKV-infected and 
uninfected human salivary gland cells. Cellular DNA replication was examined with BrdU 
incorporation and metabolic activity as described in Materials and Methods. Medium with or 
without drug was added 24hpi and absorbance measured at indicated time points. Absorbance for 
untreated uninfected cells (mock) at each time point was set as 100%.  
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Figure 6B. Effect of drug treatment on metabolic activity in BKV-infected and uninfected 
human salivary gland cells. Medium with indicated drug concentrations was added 24hpi and 
absorbance measured at 72hpi. Absorbance for untreated uninfected cells was set as 100%. 
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Figure 7A. Determination of EC50 values by curve fitting. The effect of increasing  drug 
concentration on BKV supernatant loads at 72 hpi was analyzed by curve fitting using GraphPad 
Prism for EC50. The data display means of triplicate.  
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Figure 7B. Determination of CC50 values by curve fitting. The effect of increasing drug 
concentration on BrdU incorporation at 72 hpi was analyzed by curve fitting using GraphPad 
Prism for CC50. The data display means of triplicate 
 
Discussion 
HIV-SGD treatment thus far has been palliative due to the lack of an identified 
pharmacologic target. However, our group has recently shown that BK infection is associated 
with HIV-SGD (28, 29). All previous BKV anti-viral experiments have been performed in 
human or monkey kidney cells or lung fibroblasts (12, 34, 35). Based on our observation that 
BKV can also infect salivary gland cells and is associated with pathology both in vitro and in 
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vivo in humans (28, 29, 40, 41) we decided to test three antiviral drugs, CPRO, CDV and LEF 
on the BKV life cycle in salivary gland cells in vitro. The concentration of drugs used to treat 
cells were based on previous experiments performed by Bernhoff et al(14), Sharma et al(22)and 
Liacini et al(35). All of these drugs act by either inhibiting topoisomerase activity or are thought 
to disrupt DNA polymerases, effectively halting viral replication (42). 
CPRO has been shown to inhibit BKV activity in vitro in kidney cells (43) and reduce 
BK viremia when used in combination with immunosuppression reduction in kidney transplant 
patients (16). CPRO inhibits type II topoisomerase activity during bacterial DNA replication and 
is thought to inhibit BKV T Ag viral helicase activity (20). Our data has shown that CPRO is 
able to inhibit BKV early and late gene expression in both salivary gland and monkey kidney 
cells (Fig 1, 2 and 3). As well as inhibit DNA replication (Fig 4) and progeny release in salivary 
gland cells and monkey kidney cells (Fig 5A, 5B).  In addition, when BKV patient-derived 
clinical isolates were used to infect salivary gland cells, they were also inhibited by CPRO (Fig 
5B). CPRO had minimal effect on metabolic activity and host cell DNA replication at the 
concentration used for these experiments over the three to five day time period tested (Fig 6A).  
However, we did observe a gradual decrease in host cell DNA replication when the 
concentration of drug was over 150ug/ml (Fig 6B). The EC50 and CC50 of CPRO in salivary 
gland cells were calculated at 98.51ug/ml and 368.7ug/ml, respectively (Figure 7A, 7B). The SI 
was calculated at 3.74. A low selectivity index, defined as the ratio of the 50% reduction in host 
cell replication value to the 50% virus inhibitory concentration value, suggests a modest anti-
BKV effect.  
CDV treatment is currently approved for CMV-induced retinitis in HIV infected patients 
(44) and has been used at low doses to treat transplant patients resulting in decreased BK viremia 
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and viruria (24). There are also reports however, of the deleterious effects of reduced renal 
function and increased viral load in cidofovir-treated BKVN patients (23). CDV inhibits CMV 
viral DNA polymerase activity, however it's mode of action against BKV is currently unknown. 
In vitro, CDV has been shown to inhibit BKV activity in human kidney and lung fibroblast cells 
(12, 14) but has never been tested in human salivary gland cells. Our data has shown that CDV 
inhibits BKV early gene expression but not late gene expression in human salivary gland cells 
(Fig 1A, 2A). However, in monkey kidney cells, early gene expression inhibition is inconsistent 
while late gene expression is inhibited up until 5dpi. CDV inhibited DNA replication (Fig 4) and 
progeny release in both salivary gland and monkey kidney cells (Fig 5), but were not as effective 
as CPRO. In addition, CDV inhibited two HIVSGD patient-derived viruses (HIVSGD 18 and 
19) and the laboratory adapted strain (MM) more effectively than CPRO but not the urine 
derived archetype virus (lung transplant WW). CDV had minimal effect on metabolic activity 
and host cell DNA replication at the concentration used for these experiments over the three to 
five day time period tested (Fig 6). However, at 72hpi with increasing drug concentration we 
observed a seventy percent decrease in host cell DNA replication in the presence of viral 
infection with and without drug while cell metabolism decreased at lower drug concentrations 
(5- 40ug/ml) and increased at higher drug concentrations (50-150ug/ml) (Fig 6).  The EC50 and 
CC50 of CDV in salivary gland cells were calculated at 64.72ug/ml and 100.4ug/ml, 
respectively. The SI was calculated at 1.55 suggesting a low anti-BKV effect. Previous work 
calculated the SI of CDV in human embryonic lung fibroblasts (WI-38) and human renal 
proximal tubular epithelial cells as 2.3 (12) and 4.9 respectively(45).  Although CDV inhibited 
BKV replication in salivary gland cells, there are clinical limitations for its use due to its 
nephrotoxicity and limited oral bioavailability (23). 
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LEF is an anti-inflammatory drug approved to treat rheumatoid arthritis and other 
autoimmune conditions. LEF has been shown to inhibit pyrimidine synthesis, tyrosine kinase and 
dihydroorotate dyhydrogenase activity (12). Like CDV, there is conflicting data with regards to 
its activity against BKV in vitro (12, 13). In vivo studies have shown LEF activity against CMV 
and HSV and has been used in combination with immunosuppression reduction in treatment of 
BKVN (12, 26).  LEF’s antiviral activity against CMV has been shown via interference with 
viral assembly, specifically on the viral envelope (27), however BKV is a non-enveloped virus.  
At the level of transcription, our data showed that LEF inhibition was inconsistent over the three 
days tested in both salivary gland cells and in monkey kidney cells (Fig 1). It is possible that the 
observed variability in transcript levels in the presence of LEF may be due to drug toxicity. At 
the protein level, LEF consistently decreased T Ag expression, albeit beta actin levels were 
markedly lower with LEF treatment, suggesting cell toxicity. LEF appeared to be the least 
effective drug with regard to inhibiting BKV DNA replication (Fig 4) and progeny release in 
both Vero and salivary gland cells (Fig 5). LEF consistently inhibited patient-derived progeny 
release in salivary gland cells compared to the other drug types (Fig 5B). LEF had minimal effect 
on metabolic activity and host cell DNA replication at the concentration used for these 
experiments over the three to five day time period tested (Fig 6). However, at 72hpi we observed 
a decrease in host cell DNA replication at concentrations above 15ug/ml and an increase in cell 
metabolism at drug concentration between 10 and 40 ug/ml (Fig 6).  The EC50 and CC50 of LEF 
in salivary gland cells were calculated at 8.449ug/ml and 76.9ug/ml, respectively. The SI was 
calculated at 9.1 suggesting a strong anti-BKV effect. Serum steady-state levels of the principal 
metabolite of LEF are 8.8, 18.0, and 63.0 µg/mL after 24 days of therapy with a 5, 10, or 25 mg 
daily dose, respectively (12)(Physicians Desk Reference, accessed at 
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http://www.micromedex.com), therefore the concentrations used in our experiments are in the 
clinically relevant range. 
In conclusion, BKV genome replication in human salivary gland cells was decreased by 
all three drug types with CPRO being the most effective. The mechanism of these drugs against 
BKV are currently up for debate, however it is possible that BKV inhibition in salivary gland 
cells may be due to manipulation of a host intracellular signaling pathway that is altered by each 
drug that is important for BKV replication for example the Akt or mTOR pathway. With regards 
to patient treatment, CDV has been shown to be cytotoxic in kidney cells in vivo and is therefore 
not a favorable candidate for HIVSGD treatment in patients. Although LEF in our studies had a 
high SI in salivary gland cells, it was the most toxic based on the protein assay (Figure 3A). In 
kidney transplant patients however, LEF is used as an immunomodulatory agent to lower the 
incidence of organ rejection. Our data highlight the need for continued studies to discover more 
effective and less toxic drugs that can inhibit BKV replication in salivary gland cells. These 
studies are important because we have previously shown a causal relationship between BKV 
infection of the salivary gland and HIV-associated salivary gland disease (HIV-SGD)(29) which 
is AIDS defining in pediatric HIV infection and increasing in the adult HIV population(46). In 
addition, HIV-SGD is of particular interest because in 1-2% of patients malignant lymphomas 
have been described in association with glandular lesions making this disease a premalignant 
lesion(32, 33). Until better drugs become available and more in vitro and in vivo studies are 
performed, it would be reasonable to test CPRO in clinical trials to evaluate its efficacy in 
salivary gland disease in HIV patients.  
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APPENDIX 2:  
CORRELATION OF TRANSCRIPTION OF MALAT-1, A NOVEL NONCODING RNA, 
WITH DEREGULATED EXPRESSION OF TUMOR SUPPRESSOR p53 IN SMALL 
DNA TUMOR VIRUS MODELS
1
 
 
Overview 
Although metastasis-associated lung adenocarcinoma transcript (MALAT)-1 is known to 
be consistently upregulated in several epithelial malignancies, little is known about its function 
or regulation. We therefore examined the relationship between MALAT-1 expression and 
candidate modulators such as DNA tumor virus oncoproteins human papillomavirus (HPV)-16 
E6 and E7, BK virus T antigen (BKVTAg), mouse polyoma virus middle T antigen 
(MPVmTAg) and tumor suppressor genes p53 and pRb. Using suppressive subtractive 
hybridization (SSH) and real-time reverse transcriptase polymerase chain reaction (RT-PCR) 
assays, MALAT-1 was shown to be increased in viral oncongene-expressing salivary gland 
biopsies from humans and mice. The results also indicated that MALAT-1 transcripts and 
promoter activity were increased in vitro when viral oncongene-expressing plasmids were 
introduced into different cell types. These same viral oncogenes in addition to increasing 
MALAT-1 transcription have also been shown to inhibit p53 and/or pRb function. In p53 mutant 
or inactive cell lines MALAT-1 was also shown to be highly upregulated. We hypothesize that 
there is a correlation between MALAT-1 over-expression and p53 deregulation. In conclusion, 
we show that disruption of p53, by both polyoma and papilloma oncoproteins appear to play an 
important role in the up-regulation of MALAT-1. MALAT-1 therefore might represent a 
biomarker for p53 deregulation within malignancies.
                                                 
1
 This appendix previously appeared as an article in the Journal of Cancer Therapy. The original citation is as 
follows: Jeffers, LK et al. “Correlation of Transcription of MALAT-1, a Novel Noncoding RNA, with Deregulated 
Expression of Tumor Suppressor p53 in Small DNA Tumor Virus Models”, Journal of Cancer Therapy, 2013, 4, 
774-786. 
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Introduction  
Metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) is a novel large, 
noncoding RNA. The MALAT-1 gene, also known as the  gene, is found on chromosome 
11q13 and is well conserved among mammalian species (1). The MALAT-1 transcript is widely 
expressed in normal human and mouse tissue, has been shown to localize to the nucleus(2) and 
its 3' end can be processed to yield a tRNA-like cytoplasmic RNA(3). MALAT-1, has been 
shown to be a potentially generic marker for epithelial carcinomas(4-7)and is greatly up-
regulated in lung adenocarcinoma metastasis(1) endometrial stromal sarcoma of the uterus(7), 
nonhepatic human carcinomas(5) and recently was reported to be overexpressed in placenta 
previa and to play a role in trophoblast invasion regulation (8).  Up-regulation of MALAT-1 also 
has been shown to predict unfavorable outcomes of drug therapy in patients with 
osteosarcoma(4) and its 3' end is an important biological motif in the invasion and metastasis of 
colorectal cancer cells (9). These malignancies all have been associated with malfunction of 
p53(10, 11) a nuclear transcription factor that plays a role in cellular stress, including its 
accumulation during DNA damage and oncogene activation. P53 has been established as a 
key tumor suppressor, apoptosis inducer, and prognostic marker in cancer, with about 50% of 
human tumors encoding for a mutated p53 gene(12).   
Several small DNA tumor viruses affect p53 function, including the polyomaviruses, the 
adenoviruses, and the papillomaviruses. These viruses play a role in the development of cancer 
in humans by encoding for proteins that interact with tumor suppressor genes p53 and pRb(13). 
Polyomavirus large T antigen, for example, binds to and inhibits p53 and pRb(14-16).  The 
mouse polyoma virus middle T antigen (MPVmTAg) prevents p53-induced apoptosis through 
the phosphatidylinositol 3-kinase (PI3K) signal transduction pathway by way of PP2A 
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interactions(17). Adenovirus E1B(18) and high-risk human papillomavirus (HPV-16) E6(19) 
proteins both bind to and compromise p53 function, whereas HPV-16 E7 inhibits pRb 
function(20) 
The genomes of small DNA tumor viruses have consistently been detected in certain 
malignancies. HPV is consistently detected in cervical cancer(21) and in a subset of oral 
cancers(22), whereas BK virus (BKV) DNA has been isolated in several human tumors, both 
integrated into the genome and episomally, including in bone, pancreatic islet cells, the kidney, 
the urinary tract, the prostate, and various brain tissues(23-29). In addition, overexpression of 
polyoma virus mTAg has been shown to cause salivary gland enlargement in mice and pathology 
similar to that observed in human salivary gland disease(30, 31).   
We hypothesized that MALAT-1 expression is affected by dysregulation of tumor suppressor 
p53. We used viruses, viral gene products, and cell lines to test the modulation of a cloned 
MALAT-1 promoter and to determine the effect of p53 or p53 mutants on MALAT-1 
expression. We also conducted in vivo testing of MALAT-1 expression in a transgenic mouse 
model of salivary gland disease (SGD) and in 4 subjects with HIV-associated SGD (HIVSGD).  
 
Materials and Methods 
Subjects, animals and cell culture  
       Minor salivary glands (MSG) were dissected from the lower lips of 4 HIV positive patients 
with SGD and from 4 healthy control subjects (with or without ranula) in IRB approved protocol 
at either the UNC University Hospital dental clinic or UCSF Oral AIDS Center. Biopsy samples 
were snap-frozen and kept in liquid nitrogen or formalin-fixed and embedded in paraffin until the 
RNA extraction procedure. Four MMTV/PyV-mT transgenic mice and 4 wild type mice parotid 
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samples were kindly donated from Dr. Lesley Ellies.  
HSG cells are an epithelial cell line isolated by using tissue culture techniques from an 
irradiated human submandibular salivary gland which showed no neoplastic lesion(42). HSG 
cells were obtained as a gift from Dr. B. Baum (NIH) and cultured in McCoy’s 5A medium 
(Sigma).   African monkey kidney cells or Vero cells (American Type Culture Collection 
[ATCC]) were cultured in DMEM (Sigma). All cell types were grown in medium supplemented 
with 10% fetal bovine serum (FBS) (Sigma), and 1% penicillin-streptomycin (pen/strep)(Gibco) 
unless otherwise stated and maintained in a humidified 37
0
C, 5%CO2 chamber. 
Suppression Subtractive Hybridization (SSH)   
One to two µg of pooled biopsied salivary glands from HIV-SGD patients and pooled 
control (healthy persons) RNA was sent to Evrogen (Russian Republic) for SSH. In brief, 
SMART technology was used to synthesize cDNA, which was subsequently digested with RsaI 
in preparation for subtraction in both directions (HIV-SGD as driver/control as tester, and vice 
versa). Adaptors were ligated to the two cDNA populations, followed by two rounds of 
hybridization and amplification. The secondary PCR products from the two subtracted 
populations were then ligated into the pAL9 vector. 
Sequencing of subtracted cDNA library           
Two hundred and fifty positive clones from each of the subtractions were randomly 
selected and cultured in 1.5 mL LB-medium in duplicate 96-well plates at 37 °C overnight. 
Clones were selected by blue-white screening (Promega) and sequenced using a M13 forward 
promoter (-21) primer (5 -TGT AAA ACG ACG GCC AGT-3 ) and BigDye 3.0 sequencing mix 
(Applied Biosystems) before analysis by capillary electrophoresis on an ABI 3700 genetic 
analyser (Applied Biosystems). The sequences of the inserts of differentially expressed genes 
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were identified using NCBI Blast search (blastn).  
RNA extraction and cDNA synthesis 
Total RNA was extracted from pooled MSGs of HIV-SGD patients, pooled MSGs of 
healthy controls, mouse parotid frozen tissues and Vero cells using RNeasy MiniKit 
(Qiagen,USA). Total RNA isolation from formalin fixed tissue using the Optimum FFPE RNA 
Isolation Kit (Ambion Diagnostics, INC) according to manufacturer’s instructions. The RNA 
was suspended in nuclease-free water and quantitated by UV spectrophotometry, aliquoted and 
stored at -80ºC. One μg total RNA from the HIV-SGD and control tissues, mice parotid tissue 
and Vero cells were reverse transcribed to cDNA using random primers and the SuperScript
TM
 II 
Reverse Transcriptase (RT) Kit (Invitrogen) as described by the manufacturer. Contaminating 
DNAs were removed by use of RQ1 DNase kit (Promega) as described by the manufacturer. 
Northern Blot 
 Total RNA was isolated using TRizol (Invitrogen) as described by the manufacturer. 
Contaminating DNAs were removed by use of RQ1 DNase kit (Promega) as described by the 
manufacturer. 10 ug of RNA was subjected to electrophoresis and Northern blotting. MALAT-1 
was hybridized with a 
32
P-labeled oligonucleotide probe for MALAT-1 
Semi-quantitative and quantitative real-time RT-PCR 
 Semi-quantitative RT-PCR was performed using previously published primers for T 
Ag(43)and  Taq Polymerase (Qiagen, USA). The following program was used for amplification: 
95˚C for 2 min (1x); 94˚C for 45 sec, 56˚C for 45 sec, 72˚C for 30 sec with 2 sec increase per 
cycle (35x), 72˚C for 10 min (1x). Amplified cDNA was electrophoresed on 2% agarose gel 
(Sigma).   
Real time RT-PCR was performed with LightCycler 480 Syber Green I Master Mix in the 
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presence of transcribed cDNA and 0.25mM of gene specific primers. Experiments were 
performed in duplicate and β-actin was used as an internal control.  Duplicate or triplicate Ct 
values were averaged, normalized to an average β-actin Ct value, and fold activation in healthy 
vs diseased tissue was calculated using the 2-ΔΔCt method. For Vero cells, gene expression 
values are presented as
 
the changes (n-fold) in T Ag transcript levels, with the levels
 
in non-
transfected/mock samples arbitrarily set to 1. 
Immunofluorescence/Immunohistochemistry 
Frozen sections were cut from minor salivary glands (HIV-SGD and control glands) and 
from mouse parotid glands (transgenic and wild type) for immunofluorescent analysis. Tissue 
sections were fixed, blocked, then stained with either PAb416 (Genetex) antibody specific for 
SV40 T antigen or IgG isotype control. PAb416 has been shown to cross react with BKV Tag 
and is commonly used for BKV Tag detection. Both antibodies were incubated with fixed cells 
for 1 hr at 37
0
C followed by a fluorescencein-conjugated anti-mouse (Sigma) antibody (1:20). 
Slides were overlaid with Vectashield (Vector Laboratories) then subjected to 
immunofluorescence microscopy.  
Formalin fixed sections were deparaffinized, and washed.  Slides were incubated in 3% 
hydrogen peroxide and blocked and incubated with PAb416 (Genetex). DAKO LSAB+ 
peroxidase kit (DAKO Corporation) was used according to manufacturer's specifications.   
Plasmid cloning, transfection and infection 
A 5.5 kb region upstream of MALAT-1 transcription site was amplified using primers 
5’GGGACGCGTAAAGAGGATTCTATCTAACAAGGA3’ and 
5’GGGCTCGAGGAAACGTGAAAACCCACTCT3’ and inserted into pSeap2-Basic expression 
cloning vector (Clontech) using restriction sites MluI and XhoI. To determine MALAT-1 
 183 
promoter activity, Vero cells were first infected with BKV as previously described(39) with 64 
HAUs of virus for 24 h. At 24 h post infection (hpi), virus was removed from the culture media, 
cells were washed with 1X PBS and replaced with fresh medium containing the MALAT-1 
promoter plasmid and β-gal construct plus transfection reagent. At stated times post transfection 
the cell monolayers or supernatant were collected for immunoblot assays, beta-galactosidase 
enzyme assay (Promega) or secreted alkaline phophatase enzyme assay (Promega) according to 
manufacturers instructions.  
Immunoblotting 
Total cell protein was extracted using 1% SDS lysis buffer (1% (w/v) SDS, 0.05M 
Tris.Cl pH8, 1mM DTT). Protein concentrations were determined using the BioRad protein 
assay, and equal amounts of protein were electrophoresed on a 10% Bis-Tris polyacrylamide 
minigel (Invitrogen). PAb416 (1:200) (Genetex) in 5% non-fat dry milk in 0.1% Tween-20 PBS 
(PBS-T) was used to detect T Ag expression and Actin (C-11)-R sc-1615-R (1:1000)(Santa Cruz 
Biotechnology) in 1% BSA/TBS-T for actin expression. After washing in PBS-T/TBS-T, blots 
were probed with a horseradish peroxidase-conjugated secondary antibody (1:10,000) 
(Promega). Antibody complexes were detected using SuperSignal West Pico Chemiluminescent 
substrate (Thermo scientific) and exposed to film (Kodak). 
Beta galactosidase enzyme assay 
 β-Galactosidase Enzyme Assay System with Reporter Lysis Buffer (Promega) was 
performed according to manufacturer’s instructions. Briefly, cells were collected, centrifuged 
and resuspended in1X lysis buffer and transferred in triplicate to 96 well plates. Diluted sample 
was added to an equal volume of Assay 2X Buffer, which contained the substrate ONPG (o-
nitrophenyl-beta-D-galactopyranoside). Samples were incubated for 30 minutes, terminated by 
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addition of sodium carbonate, and the absorbance read at 420nm with a spectrophotometer.   
Secreted alkaline phosphatase reporter gene assay, chemiluminescent 
 SEAP assay was performed according to manufacturer’s instructions. Briefly, culture 
supernatant from transfected or mock (untreated) cells were collected at stated times post-
transfection. Collected sample was diluted 1:4 in Dilution buffer, heated at 65
0
C for 30 min then 
centrifuged at maximum speed to 30 s. Heat-treated samples were then transferred to a 
microplate (black or white), inactivated with Inactivation Buffer then treated with Substrate 
Reagent. Chemiluminescence was measured using a luminometer.  
Statistical Analysis 
  One-way ANOVA tests were performed to determine statistically significant differences 
in MALAT-1 promoter activation and expression using Graph pad software. 
miRNA Prediction  
The entire MALAT-1 sequence was imported into an online program mfold 
(http://www.bioinfo.rpi.edu/applications/mfold) to predict the presence of micro RNAs within 
the genome.  
 
Results 
Differential gene expression in HIV-SGD by SSH  
Differential gene expression in minor salivary glands from patients with HIV-SGD and 
healthy control subjects were examined with the use of SSH. Pooled RNA from four HIV-SGD 
positive subjects and from four HIV negative subjects was utilized to diminish individual 
variation. Two SSH libraries were constructed, disease (plus) and healthy library (minus).  The 
minus library was enriched for genes whose expression was suppressed in HIV-SGD and the 
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plus library was enriched for genes whose expression was induced by disease development. 250 
randomly selected clones were sequenced from the minus SSH library and 250 clones from the 
plus library; of those 232 and 208 contained cDNA inserts, respectively.  The SSH library was 
automatically processed using a specifically created software tool. This processing included 3 
basic steps: finding adaptor sequences on the 5’ and 3’ ends of a clone as markers and extracting 
a fragment from the clone, blasting the batch of fragments, clustering alignments and linking 
with unique gene identification. We were able to align 436 sequences with known or predicted 
human genes.  Our total number of alignments reached 502 due to 57 chimeric clones which had 
2 or three clones from different RNA’s linked together during SSH.  Of the 436 cDNAs 73 
sequences were identified that did not match to any known or predicted mRNAs but aligned with 
the human genomic DNA and with EST databases. These were considered novel.  
 A non-redundant set of the genes was created which excluded highly expressed clones 
present in both disease and healthy genes in the plus library.  There were 6 genes found more 
than once among sequenced SSH clones in each of the libraries (Table 1). It was shown 
previously that a number of cDNA fragments corresponding to a gene in the SSH library 
correlates with a degree of differential expression of the gene(32). Considering all of the 
differentially expressed clones detected by SSH analysis, major functional classes of 
transcriptionally regulated genes in minus library included signal transduction (9%), cell 
cycle(8%), immune/defense(8%), synthesis/ development/ differentiation (8%)  and transport 
(8%).  Transcriptionally regulated genes in the plus expression library included those involved in 
signal transduction (15%), synthesis/development/differentiation(13%), apoptosis(8%), 
metabolism(8%) and transport. The largest category of de-regulated genes were unknown, 
among these was the metastasis associated lung adenocarcinoma transcript-1 (MALAT-1).  
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MALAT-1 transcript and promoter activity is deregulated in the absence of p53 expression, in 
vitro 
A reporter assay was developed to assess activation of MALAT-1’s enhancer/promoter 
region. First, we examined the MALAT-1 enhancer/promoter region 5.5 kb upstream of the ATG 
start site by means of open-source software (PROMO 3.0; available at 
http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgidirDB=TF_8.3)(33). This 
program identifies putative transcription factor binding sites in DNA sequences from the species 
(or group of species) of interest. The similarity between the sequence examined and the 
transcription binding site is > 98% (or dissimilarity is < 2%). Figure 1A shows the transcription 
sites found in the enhancer/promoter region of MALAT-1.We then quantified the MALAT-1–
secreted embryonic alkaline phosphatase (SEAP) by chemiluminescent assay (Roche Diagnostic) 
and transiently cotransfected the reporter construct into p53-negative, sarcoma osteogenic 
(SAOS) cells with or without plasmids encoding wild-type p53 or p53 mutants R273H (a contact 
mutation), R175H (a structural mutation), H178Y, and L22QW23S(34-36). The first two 
mutants are considered hot-spot mutations; that is, they abolish the wild-type tumor suppression 
function of p53 (37, 38). The H178Y mutant has been shown to rescue the loss of function 
G245S phenotype when coexpressed in vitro. The L22QW23S mutant maintains its ability to 
bind to p53-specific DNA elements but lacks transactivation activity(34). Cotransfections were 
performed using p53 expression plasmids and MALAT-1 promoter in pSEAP vector and 
supernatant collected at 72 hours post transfection. Higher MALAT-1 expression levels were 
detected in cells that did not express p53 or that contained p53 mutations (Figure 1B). We also 
examined MALAT-1 expression profiles in cell lines containing p53 mutations (C33A, HSG), 
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those containing DNA tumor viruses that sequester p53 (CaSki, SiHa), p53-negative cells 
(SAOS), and cells containing wild-type p53 (OKF6-Tert).  Only the cell types expressing wild-
type p53 showed low MALAT-1 levels (Figure 1C). These differences were statistically 
significant (P < 0.001).   
To further investigate the role of p53 in deregulating MALAT-1 expression, we over-
expressed HPV16 oncogenes E6 and E7 which inhibit p53 and pRb respectively. Our results 
showed that over expression of HPV-16 E6 in oral keratinocytes significantly enhanced 
MALAT-1 expression while HPV-16 E7 did not. Coexpression of both E6 and E7 resulted in a 
net increase in MALAT-1 transcription (Figure 2A).  
To confirm that viral oncogenes that inhibit p53 may play a role in MALAT-1 deregulation, 
we infected or transfected BK virus or viral genome into HSG or Vero cells. BKV T ag binds to 
and inhibits p53 and pRb function(16). Both human parotid salivary gland (HSG) and African 
monkey kidney (Vero) cells were used for in vitro studies because BKV has been shown to 
replicate in both cell types(39).  MALAT-1 transcript levels were 1.6-fold higher in BKV-
infected salivary gland cells versus uninfected/mock cells 4 days after infection (Figure 2B). 
MALAT-1 transcription was also consistently increased in Vero cells that overexpressed BKV 
whole genome compared to empty vector and nontransfected according to Northern blot testing 
(Figure 2B). Semi-quantitative real-time reverse transcriptase polymerase chain reaction (RT-
PCR; Figure 2C), and quantitative real-time RT-PCR (Figure 2D) for MALAT-1 in T antigen 
transfected Vero cells also showed an increase in MALAT-1 transcripts. A 2.3 and 5.5 fold 
increase in MALAT-1 at 24 and 48 hours post transfection was detected by qRT-PCR in Vero 
cells. 
To assess the correlation between p53 and T ag oncogene expression, we measured T ag and 
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p21 transcript levels in BKV infected Vero cells. T antigen is known to bind to and inhibit p53 
activity, while p21 is a downstream effector of p53 and would be expected to decrease in the 
absence of p53 expression. The results as expected indicated that p21 transcripts were low with 
high levels of BKV T ag expression, and high with low levels of T ag expression (Figure 2E). To 
determine whether BKV T ag expression regulates MALAT-1 promoter activity, we transfected 
Vero cells with the MALAT-1 promoter followed by BKV infection. MALAT-1 promoter 
activity was up-regulated 7-fold at 72 hours post BKV infection in comparison to uninfected. 
BKV T ag expression within these cells was confirmed in the immunoblot assay (Figure 2F).    
BKV T ag comprises of several transcription binding sites including p53 and pRb. To 
determine whether p53 or pRb plays a role in MALAT-1 regulation, we co-transfected both Vero 
(wild-type p53) and HSG (mutated p53) cells with either BKV T ag or BKV T ag pRb-binding 
mutant and the MALAT-1 promoter expression plasmid. The results showed that MALAT-1 
promoter activity was increased compared to vector only in Vero cells regardless of T ag 
phenotype (Figure 2G). Whereas, in HSG cells containing mutant p53, neither wild-type TAg 
nor Rb further enhanced MALAT-1 transcription above vector alone (Figure 2H) 
Next, we investigated MALAT-1 levels in an in vivo model of BK T antigen-expressing 
salivary gland premalignant lesion (HIVSGD). Among all of the differentially expressed clones 
detected by SSH analysis, the most common category of deregulated genes was the “unknown” 
category, which included MALAT-1 (Table 1). Quantitative real-time RT-PCR detected a 2.6-
fold increase in MALAT-1 expression in pooled DNA analysis from patients with HIVSGD 
versus healthy controls (Figure 3A). Semi-quantitative real-time RT-PCR likewise detected up-
regulation of MALAT-1 in individual DNA samples from four patients with SGD (A-D) versus 
four healthy controls (A-D) (Figure 3A).  
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Immunohistochemical  analysis of salivary gland biopsy samples from three patients with 
HIVSGD detected BKV T ag protein within the tissues as well as in a BKV positive kidney 
control with BKV nephropathy (BKVN) (Figure 3B, top). In addition, p53 was colocalized with 
BKV T ag within biopsied salivary glands from the patients with SGD (representative figure, 
Figure 3B, bottom). Downstream effectors of p53 (p21, PIGP-1, and WIG-1) were consistently 
down-regulated in semi-quantitative (left) and quantitative real-time (right) RT-PCR, whereas 
ING-3, negatively regulated by p53 expression and T ag was overexpressed, in both pooled 
cDNA (data not shown) and individual samples from patients with HIVSGD compared with 
healthy controls (Figure 3C).   
In the murine model of polyomavirus-associated SGD, semi-quantitative real-time RT-PCR 
detected greater amplification of MALAT-1 cDNA from four transgenic mice with SGD, 
whereas transcripts were consistently reduced in four wild-type mice (Figure 3D, middle). 
Immunofluorescence studies detected T ag within biopsied salivary glands of transgenic mice but 
not in the wild-type mice (Figure 3D, top). Both ING-3 and MALAT-1 were greatly upregulated 
in transgenic mice versus wild-type mice in quantitative real-time RT-PCR assay (Figure 3D, 
bottom). 
 
 
 
 
 
Table 1. Genes up-regulated in polyomavirus-associated salivary gland disease as assessed 
by suppressive subtractive hybridization. 
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Table 1
Genes up-regulated in polyomavirus-associated salivary gland disease as assessed by suppressive subtractive
hybridization
Gene Description Category No. of clones
MALAT-1 metastasis-associated lung adenocarcinoma transcript 1 (noncoding RNA) Unknown 4
PIGR polymeric immunoglobulin receptor Immunity 3
CYTB Cytochrome B Transport, Mitochondria 3
HLA-B major histocompatibility complex, class I, B Immunity 2
PIP prolactin-induced protein Immunity 2
RPLP0 ribosomal subunit protein L16 Protein synthesis 2
J Cancer Ther. Author manuscript; available in PMC 2013 October 25.
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Figure 1.
MALAT-1 promoter activity and transcript levels correlate with p53 activity. A. Several
consensus binding sites were detected upstream of the MALAT-1 start site, including five
p53 binding sites (green), three T antigen binding sites (red), two TCF-2 binding sites
(purple), and two E2F-1 binding sites (blue). B. Representative data showing significantly
increased MALAT-1 promoter activity in p53-deficient SAOS cells 72 hours after
transfection with p53-expressing constructs. C. Representative levels of MALAT-1
expression in different cell types with or without p53 gene expression, presented as the
change (n-fold) in MALAT-1 transcript levels (level in OKF6 cells arbitrarily set to 1).
Jeffers et al. Page 12
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Figure 2. MALAT-1 promoter activity and transcript levels correlate with DNA tumor 
virus oncogene expression. (a) Representative data showing increased MALAT-1 promoter 
activity 48 hours after HPV16 E6 transfection and not with HPV16 E7. (b) Higher levels of 
MALAT-1 transcription, expressed as n-fold change in BK polyomavirus-infected human 
parotid gland (HSG) cells. Levels in mock samples were arbitrarily set to 1. Left. Northern blot 
showing a four-fold increase in MALAT-1 transcript levels in Vero cells transfected with BKV 
DNA. Right. (c) Semi-quantitative real-time RT-PCR shows amplified MALAT-1 cDNA bands 
from BKV-transfected Vero cells at stated times after transfection. (d) Quantitative real-time RT-
PCR shows increased MALAT-1 transcript levels in BKV-transfected Vero cells at stated times 
Figure 2.
MALAT-1 promoter activity and transcript levels correlate with DNA tumor virus oncogene
expression. A. Representative data showing increased MALAT-1 promoter activity 48 hours
after HPV16 E6 transfection and not with HPV16 E7. B. Higher levels of MALAT-1
transcription, expressed as n-fold change in BK polyomavirus-infected human parotid gland
(HSG) cell . Levels in mock samples were arbitrarily set to 1. Left. North rn blot showing a
four-fold increase in MALAT-1 transcript levels in Vero cells transfected with BKV DNA.
Right C. Semi-quantitative real-time RT-PCR shows amplified MALAT-1 cDNA bands
from BKV-transfected Vero cells at stated times after transfection. D. Quantitative real-time
RT-PCR shows increased MALAT-1 transcript levels in BKV-transfected Vero cells at
stated times aft r transfection. Expression values presented as the change (n-fold) i
MALAT-1 transcript levels, with levels at time 0 arbitrarily set to 1. E. Quantitative real-
time RT-PCR showing BKV Tag and p21 transcript levels over stated times after BKV
infection. F. MALAT-1 promoter activity in BKV-infected and uninfected Vero cells at 48
and 72 hours after transfection. Top. BKV T ag protein (top) detected in Vero cells infected
with BK virus and transfected with the MALAT-1 promoter plasmid. G. BKV T ag up-
regulated MALAT-1 promoter activity regardless of T ag pRb binding status in Vero cells
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after transfection. Ex- pression values presented as the change (n-fold) in MALAT-1 transcript 
levels, with levels at time 0 arbitrarily set to 1. (e) Quantitative real-time RT-PCR showing BKV 
Tag and p21 transcript levels over stated times after BKV infection. (f) MALAT-1 promoter 
activity in BKV-infected and uninfected Vero cells at 48 and 72 hours after transfection. Top. 
BKV T ag protein (top) detected in Vero cells infected with BK virus and transfected with the 
MALAT-1 promoter plasmid. (g) BKV T ag up-regulated MALAT-1 promoter activity 
regardless of T ag pRb binding status in Vero cells containing wild-type p53 compare to positive 
and negative controls, pSEAPc and pSEAPb, respectively. (h) Neither wild-type BKV T ag nor 
T ag pRb binding mutant enhanced MALAT-1 transcript levels in human salivary gland cells 
containing mutant p53 expression. 
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Figure 3.
MALAT-1 transcript levels correlate with DNA tumor virus oncogene expression in vivo.
A. Quantitative real-time RT-PCR showing up-regulation of MALAT-1 in pooled DNA
from four patients with HIV associated salivary gland disease (HIV SGD) compared with
healthy control subjects, Top. Semi-quantitative real-time RT-PCR showing up-regulation of
MALAT-1 in DNA from four patients with HIV SGD versus healthy control subjects,
Bottom. B. Nuclear BKVT ag (red arrows) detected via immunohistochemical analysis of
representative biopsy samples from three patients with HIV-related SGD (Patient A 20X, B
40X, C 20X with inset at 40X) and in BKV-infected kidney cells from an individual with
BKV nephropathy (positive control at 10X), Top. BKV T ag protein (red) and p53 protein
(green) colocalized within salivary gland biopsy tissue from patients with HIV SGD (at 40X
Jeffers et al. Page 18
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Figure 3. MALAT-1 transcript levels correlate with DNA tumor virus oncogene expression 
in vivo. (a) Quantitative real-time RT-PCR showing up-regulation of MALAT-1 in pooled DNA 
from four patients with HIV associated salivary gland disease (HIV SGD) compared with 
healthy control subjects, Top. Semi-quantitative real-time RT-PCR showing up-regulation of 
MALAT-1 in DNA from four patients with HIV SGD versus healthy control subjects, Bottom. 
(b) Nuclear BKVT ag (red arrows) detected via immunohistochemical analysis of representative 
biopsy samples from three patients with HIV-related SGD (Patient A 20×, B 40×, C 20× with 
inset at 40×) and in BKV-infected kidney cells from an individual with BKV neph- ropathy 
(positive control at 10×), Top. BKV T ag protein (red) and p53 protein (green) colocalized 
within salivary gland bi- opsy tissue from patients with HIV SGD (at 40× magnification). (c) 
Semi-quantitative (left) and quantitative real-time RT-PCR (right) showing detection of BKV T 
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ag in HIV SGD and not in healthy controls, down-regulation of p53-regulated genes p21, PIGP1 
and WIG1 and up-regulation of ING3 in salivary gland tissue from patients with HIV SGD 
versus healthy controls. Healthy cDNA levels were arbitrarily set at 1. (d) BKV T ag protein 
(red) detected via immunofluorescence in three middle T ag-expressing transgenic mice with 
SGD (left) compared with wild-type mice without the disease (20× and 40× mag- nification) 
(right), Top. Semi-quantitative real-time RT-PCR showing up-regulation of MALAT-1 transcript 
levels in trans- genic mice salivary gland biopsies compared with wild-type mice, Middle. 
Quantitative real-time RT-PCR showing up-regulation of MALAT-1 and ING3 in transgenic 
mice with SGD versus wild-type mice. Wild-type cDNA levels arbitrarily set at 1, Bottom. 
 
 
 
 
 
 
 
 
 
 
Table 2. Correlation among cancers that express high MALAT1 transcripts, involve p53 
deregulation and are associated with DNA tumor virus infection.  
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Table 2
Correlation among cancers that express high MALAT1 transcripts, involve p53 deregulation and are
associated with DNA tumor virus infection.
Human carcinomas p53 status MALAT-1 over-expressed
Endometrial Stromal Sarcoma[7] P53 nuclear accumulation[44] Yes
Hepatocellular Carcinoma[5] P53 mutation[5] Yes
Non Small Cell Lung Cancer[1] P53 mutation[12] Yes
HIV-Salivary Gland Disease (premalignant) N/D Yes
Osteosarcoma[4] P53 mutation[45] Yes
Breast[5] P53 nuclear accumulation[46] Yes
Pancreas[5] P53 mutation[47] Yes
Colon[5] P53 mutation[48] Yes
Late-Stage Prostate Cancer[5] P53 mutation[49] Yes
Cervical (CaSki cell line) [41] HPV inhibits P53 activity[50] Yes
Endometrial Stromal Sarcoma [7] P53 nuclear accumulation[44] Yes
Hepatocellular Carcinoma[5] P53 mutation[5; 45] Yes
Non Small Cell Lung Cancer[1] P53 mutation[12] Yes
HIV-Salivary Gland Disease (premalignant) N/D Yes
Osteosarcoma[4] P53 mutation[46] Yes
Breast[5] P53 nuclear accumulation [47] Yes
Pancreas [5] P53 mutation[48] Yes
Colon[5] P53 mutation[49] Yes
Late-Stage Prostate Cancer[5; 45] P53 mutation[50; 51] Yes
Cervical (CaSki cell line)[43] HPV inhibits P53 activity[52] Yes
J Cancer Ther. Author manuscript; available in PMC 2013 October 25.
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Figure 4. Model of MALAT-1 regulation including predicted miRNA at the 3’ end of the 
MALAT-1 RNA.  
 
Discussion 
MALAT-1 is known to be up-regulated in several epithelial malignancies, including non-
small cell lung tumors, stromal sarcomas, and nonhepatic carcinomas(4-7, 40).  In this series of 
in vitro and in vivo experiments, we noted substantial MALAT-1 up-regulation in the presence 
of polyoma and papilloma oncoproteins that disrupt or negate p53 expression/function. In 
contrast, the pRb pathway did not appear to be critical to MALAT-1 regulation. Regardless of 
the mechanism of p53 deregulation—expression of frequently mutated p53 sites (Figure 1) or 
expression of tumorvirus oncoproteins targeting p53 (Figure 2 and 3)—MALAT-1 was 
consistently overexpressed. Thus MALAT-1 might represent a biomarker for p53 dysregulation 
within malignancies. 
MALAT-1 expression in CaSki cells has been shown to be involved in cervical cancer cell 
growth, cell cycle progression, and invasion(41). CaSki cells harbor HPV-16, a small DNA 
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tumor virus that encodes for the E6 protein. This protein is known to form complexes with p53 
and target it for degradation(41) . In contrast, the HPV-16 E7 protein is known to sequester pRb 
and inhibit its normal function in the cell cycle. The enhanced expression of MALAT-1 in the 
presence of HPV-16 E6, and its downregulation in the presence of HPV-16 E7, lend support to 
the hypothesis that p53, but not the pRb pathway, appears to be critical to MALAT-1 modulation 
(Figure 3).  
In normal tissues, MALAT-1 is expressed in numerous cell types, with the highest relative 
expression found in the normal pancreas and lung (~2.0- and 1.6-fold relative increases in 
expression, respectively)(1). Its expression is also associated with epithelial cell malignancies 
such as non-small cell lung cancer(1) endometrial stromal sarcoma(7) and nonhepatic 
carcinomas(5).  Of interest, all of these cancers are associated with p53 mutation (Table 2). 
However, normal salivary gland cells appear to express negligible MALAT-1(1). Our study 
shows, for the first time, that the presence of a polyoma virus (BKV) is linked to up-regulation of 
MALAT-1 in patients with HIVSGD. Interestingly, the perinuclear BKV Tag staining pattern in 
HIVSGD is very similar to that detected by the Imperiale group in prostate dysplasia(2, 3).   
Moreover, oncoprotein expression from three distinct DNA tumor viruses - HPV-16, BKV, and 
mouse polyoma virus -are capable of upregulating MALAT-1 potentially via p53 deregulation.   
Interestingly, using an mRNA folding prediction program it appears that the 3’ end of the 
MALAT-1 gene may encode a microRNA (miRNA) (Figure 4).  miRNAs are single-stranded 
RNA molecules of 21-23 nucleotides in length, which regulate gene expression. miRNAs are 
encoded by genes from whose DNA they are transcribed but miRNA are not translated into 
protein, that is they are non-coding RNA; instead each primary transcript (a pri-miRNA) is 
processed into a short stem-loop structure called a pre-miRNA and finally into a functional 
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miRNA. Mature miRNA molecules are partially complementary to one or more messenger RNA 
(mRNA) molecules, and their main function is to down-regulate gene expression. Like known 
miRNAs, MALAT-1 is a non-coding transcript, folds into a short stem loop structure at the 3’ 
end and is conserved across mammalian species. Modulation of MALAT-1 expression by p53, 
perhaps by miRNA regulation, is intriguing and opens the door toward understanding the 
regulation of this important malignancy-associated gene. Investigation of MALAT-1 as a 
miRNA is currently being explored and potential targets in SGD will be determined. In the 
meantime, MALAT-1 might represent a biomarker for p53 deregulation within malignancies.  
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